# EDGAR Filing Document

**Accession Number:** 0001829280
**File Stem:** 0001140361-23-006194
**Filing Date:** 2023-2
**Character Count:** 307951
**Document Hash:** b6dea5686b69e4642169957b7047460d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-006194.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001140361-23-006194

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 19

**CONFORMED PERIOD OF REPORT**: 20230210

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Completion of Acquisition or Disposition of Assets

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Forian Inc.
- **CENTRAL INDEX KEY:** 0001829280
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **IRS NUMBER:** 853467693
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40146
- **FILM NUMBER:** 23615099

**BUSINESS ADDRESS:**
- **STREET 1:** 41 UNIVERSITY DRIVE
- **STREET 2:** SUITE 400
- **CITY:** NEWTOWN
- **STATE:** PA
- **ZIP:** 18940
- **BUSINESS PHONE:** 267-757-8707

**MAIL ADDRESS:**
- **STREET 1:** 41 UNIVERSITY DRIVE
- **STREET 2:** SUITE 400
- **CITY:** NEWTOWN
- **STATE:** PA
- **ZIP:** 18940

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

#### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d) OF THE

#### SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): **February 10, 2023**

## FORIAN INC.
(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br>| **001-40146**<br>| **85-3467693**<br>|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **41 University Drive, Suite 400, Newtown, PA** | **18940**<br>|
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: (267**) 225-6263**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value<br>| FORA<br>| The Nasdaq Stock Market LLC<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement** |

---

#### Stock Purchase Agreement
On February 10, 2023, Helix Technologies, Inc., a Delaware corporation ("Helix") and a wholly owned subsidiary of Forian Inc. (the "Company"), completed the sale of 100% of the outstanding capital stock of its wholly owned subsidiary, Bio-Tech Medical Software, Inc., a Florida corporation ("BioTrack"), to BT Assets Group Inc., a Delaware corporation ("Buyer") and a wholly owned subsidiary of Alleaves Inc., a Delaware corporation ("Alleaves"), pursuant to that certain Stock Purchase Agreement (the "Purchase Agreement"), dated February 10, 2023, by and among Helix, BioTrack and the Buyer (the "Transaction"). Through the Transaction, the Company exited the cannabis software business.

The total consideration paid by the Buyer under the Purchase Agreement is $30 million, subject to any working capital adjustments. The Buyer paid $20 million in cash at closing and is required to make twelve equal monthly payments totaling $10 million commencing March 2023, which subsequent payments are guaranteed by certain affiliates of the Buyer.

The Purchase Agreement contains customary representations, warranties and covenants. The Buyer has obtained representation and warranty insurance, subject to certain exclusions, deductibles, policy limits and other terms and conditions set forth therein.

The foregoing description of the Purchase Agreement is qualified in its entirety by reference to the text of the Purchase Agreement. The Purchase Agreement is attached as Exhibit 2.1 hereto and incorporated herein by reference.

#### License Agreement
The Company, Helix, BioTrack and the Buyer also entered into that certain License Agreement, dated February 10, 2023 (the "License Agreement"), pursuant to which the Company and its affiliates have been granted a perpetual (subject to certain conditions described below), world-wide, exclusive (subject to certain conditions as described in the License Agreement), royalty-free, transferrable and sublicensable license to certain U.S. transactional data processed by the point of sale software systems owned, licensed or operated by the Buyer and its affiliates.

Upon the consummation of a Qualified Transaction (as defined in the License Agreement), the license transitions from a perpetual term to a term expiring on the later to occur of (a) the five-year anniversary of the consummation of such Qualified Transaction and (b) the seven-year anniversary of the effective date of the License Agreement.

The foregoing description of the License Agreement is qualified in its entirety by reference to the text of the License Agreement. The License Agreement is attached as Exhibit 10.1 hereto and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 2.01** | **Completion of Acquisition or Disposition of Assets** |

---

The information set forth in Item 1.01 above relating to the closing of the Transaction is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers** |

---

#### Departure of Dan Barton as Chief Executive Officer and President and Class II Director
On February 13, 2023, the Company announced that Daniel Barton resigned as the Company's Chief Executive Officer and President and as a Class II member of the Board of Directors (the "Board") effective February 10, 2023. Mr. Barton's resignation was not the result of any disagreement relating to the Company's strategy, operations, policies or practices or any issues regarding the Company's accounting policies, procedures, estimates or judgements.

------

In connection with Mr. Barton's resignation, the Company and Mr. Barton entered into a separation agreement containing a general release of claims (the "Separation Agreement"). Mr. Barton will be eligible to receive the following, subject to continued compliance with the Separation Agreement: (i) continuation of Mr. Barton's salary of $250,000 for twelve (12) months; (ii) $87,500, representing Mr. Barton's annual bonus for the year ended December 31, 2022; (iii) acceleration of Mr. Barton's remaining 106,656 unvested restricted shares of Company common stock; and (iv) a maximum of twelve (12) months of continued COBRA coverage. The foregoing summary of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the complete agreement, which is attached as Exhibit 10.2 hereto and incorporated herein by reference.

#### Appointment of Interim Chief Executive Officer and President
Effective as of February 10, 2023, the Board appointed Max C. Wygod as interim Chief Executive Officer and President.

Mr. Wygod, age 36, serves as Executive Chairman of the Company, a role he has held since the Company's inception in 2021. Mr. Wygod co-founded Medical Outcomes Research Analytics, LLC ("MOR") in 2019 and served as a Manager of MOR until February 2021. Mr. Wygod is a healthcare executive and investor with experience investing, acquiring, and divesting public and private growth companies at the intersection of healthcare and information technology. Previously, Mr. Wygod served as a Vice President of Business Development at WebMD Health, where he participated in facilitating its sale to Internet Brands, a KKR portfolio company in 2017. A seven-year veteran at WebMD, Mr. Wygod had various business development and operating roles that included WebMD's strategic growth objectives through capital allocation, acquisitions, partnerships, joint ventures, commercial relationships, investments and divestitures. Mr. Wygod received a B.A. from Duke University and an M.B.A. in Finance and Entrepreneurship from The Stern School at New York University.

Mr. Wygod will not receive any additional compensation in consideration for serving as interim Chief Executive Officer and President.

Other than as disclosed herein, there are no arrangements or understandings between Mr. Wygod and any other person and Mr. Wygod has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Wygod is the son of Class I director Martin J. Wygod.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events** |

---

#### Press Releases
On February 13, 2023, the Company and Alleaves issued a joint press release announcing the Transaction and the License Agreement, which release also announced the resignation of Mr. Barton and the appointment of Mr. Wygod. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

#### Reduction in Board Size
On February 10, 2023, following the resignation of Mr. Barton, and as permitted by the Bylaws of the Company, the Board reduced the size of the Board from eleven (11) to ten (10) members by eliminating the existing Class II vacancy on the Board resulting from the resignation of Mr. Barton.

------

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statement and Exhibits** |

---

(b) The unaudited pro forma consolidated financial information of the Company giving effect to the Transaction, and the related notes thereto, have been derived from its historical consolidated financial statements and are attached as Exhibit 99.3 hereto.

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [2.1](brhc10047564_ex2-1.htm) | Stock Purchase Agreement, dated February 10, 2023, by and among Helix Technologies, Inc., Bio-Tech Medical Software, Inc. and BT Assets Group, Inc. |
| [10.1](brhc10047564_ex10-1.htm) | License Agreement, dated February 10, 2023, by and among Forian Inc., Helix Technologies, Inc., BT Assets Group, Inc. and Bio-Tech Medical Software, Inc. |
| [10.2](brhc10047564_ex10-2.htm) | Separation Agreement, dated February 10, 2023, by and between Forian Inc. and Daniel Barton |
| [99.1](brhc10047564_ex99-1.htm) | Joint Press Release, dated February 13, 2023 |
| [99.2](brhc10047564_ex99-2.htm) | Unaudited pro forma condensed consolidated financial information |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: February 13, 2023 | **FORIAN INC.** | **FORIAN INC.** |
|  | By: | /s/ Edward Spaniel, Jr. |
|  | Name: | Edward Spaniel, Jr. |
|  | Title: | Executive Vice President, General Counsel and Secretary |

---

------

## Exhibit 2.1

<u> </u>

------

<u>Exhibit 2.1</u>

#### STOCK PURCHASE AGREEMENT

#### BY AND AMONG

#### BIO-TECH MEDICAL SOFTWARE, INC.,

#### HELIX TECHNOLOGIES, INC.

#### AND

#### BT ASSETS GROUP, INC.

#### DATED AS OF

#### FEBRUARY 10, 2023

------

#### **TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **<u>Page</u>** |
| SECTION 1 DEFINITIONS | SECTION 1 DEFINITIONS | 1 |
| 1.1 | Definitions | 1 |
| SECTION 2 THE TRANSACTIONS | SECTION 2 THE TRANSACTIONS | 12 |
| 2.1 | Purchase and Sale of Company Common Stock | 12 |
| 2.2 | Time and Place of Closing | 12 |
| 2.3 | Closing Payments | 12 |
| 2.4 | Subsequent Cash Payments | 12 |
| 2.5 | Withholding Taxes | 13 |
| 2.6 | Adjustment to Purchase Price | 13 |
| SECTION 3 REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY | SECTION 3 REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY | 14 |
| 3.1 | Organization, Standing and Power | 14 |
| 3.2 | Capital Structure | 14 |
| 3.3 | Authority; Execution and Delivery; Enforceability | 15 |
| 3.4 | No Conflicts; Consents | 15 |
| 3.5 | Financial Statements | 16 |
| 3.6 | Absence of Certain Changes or Events | 16 |
| 3.7 | Taxes | 17 |
| 3.8 | Employee Benefits | 18 |
| 3.9 | Employment and Labor Matters | 19 |
| 3.10 | Legal Proceedings | 21 |
| 3.11 | Compliance with Applicable Laws | 21 |
| 3.12 | Environmental Matters | 22 |
| 3.13 | Contracts | 22 |
| 3.14 | Real Property; Personal Property | 24 |
| 3.15 | Intellectual Property | 25 |
| 3.16 | Certain Payments and Practices | 29 |
| 3.17 | Product Warranty and Liability | 29 |
| 3.18 | Suppliers and Customers | 30<br>|
| 3.19 | Brokers' Fees and Expenses | 30 |
| 3.20 | Insurance | 30 |
| 3.21 | Related Party Transactions | 30 |
| 3.22 | Accounts Receivable | 31 |
| 3.23 | Bank Accounts | 31 |
| 3.24 | EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES | 31 |
| SECTION 4 REPRESENTATIONS AND WARRANTIES OF SELLER | SECTION 4 REPRESENTATIONS AND WARRANTIES OF SELLER | 31 |
| 4.1 | Organization | 31 |
| 4.2 | Power and Authorization | 31 |
| 4.3 | Consents and Approvals; No Violations | 32 |
| 4.4 | Noncontravention | 32 |
| 4.5 | Title | 32 |
| 4.6 | No Brokers | 32 |
| 4.7 | Taxes | 32 |

---

i

------

---

| | | |
|:---|:---|:---|
| SECTION 5 REPRESENTATIONS AND WARRANTIES OF BUYER | SECTION 5 REPRESENTATIONS AND WARRANTIES OF BUYER | 32 |
| 5.1 | Organization | 32 |
| 5.2 | Power and Authorization | 33 |
| 5.3 | Consents and Approvals; No Violations | 33 |
| 5.4 | Solvency | 33 |
| 5.5 | Investment Representation | 33 |
| 5.6 | Financial Ability | 33 |
| 5.7 | No Brokers | 33 |
| 5.8 | Acknowledgment and Representations by Buyer | 34 |
| SECTION 6 COVENANTS | SECTION 6 COVENANTS | 34 |
| 6.1 | Confidentiality | 34 |
| 6.2 | Tax Matters | 34 |
| 6.3 | Employee and Related Matters | 36 |
| 6.4 | Florida Performance Bond | 37 |
| 6.5 | Further Assurances | 37 |
| SECTION 7 CLOSING DELIVERABLES | SECTION 7 CLOSING DELIVERABLES | 37 |
| 7.1 | Company and Seller Deliveries | 37 |
| 7.2 | Buyer Closing Deliveries | 38 |
| 7.3 | Frustration of Closing Conditions | 39 |
| SECTION 8 R&W INSURANCE; SURVIVAL AND PARTIAL RELEASE | SECTION 8 R&W INSURANCE; SURVIVAL AND PARTIAL RELEASE | 39 |
| 8.1 | R&W Insurance | 39 |
| 8.2 | Survival and Partial Release | 39 |
| SECTION 9 MISCELLANEOUS | SECTION 9 MISCELLANEOUS | 40 |
| 9.1 | [RESERVED] | 40 |
| 9.2 | Amendment | 40 |
| 9.3 | Waiver | 40 |
| 9.4 | Specific Performance | 40 |
| 9.5 | Expenses | 40 |
| 9.6 | Notices | 40 |
| 9.7 | Binding Agreement; Assignment | 41 |
| 9.8 | Severability | 41 |
| 9.9 | Construction | 41 |
| 9.10 | Captions | 41 |
| 9.11 | Entire Agreement | 42 |
| 9.12 | Counterparts | 42 |
| 9.13 | Choice of Law; Consent to Jurisdiction | 42 |
| 9.14 | WAIVER OF JURY TRIAL | 42 |
| 9.15 | Parties in Interest | 42 |
| 9.16 | Press Releases and Announcements; Confidentiality | 42 |
| 9.17 | No Representations Regarding Projections or Forecasts; Acknowledgment | 43 |
| 9.18 | Disclosure Schedule | 43 |

---

ii

------

#### INDEX OF EXHIBITS

---

| | |
|:---|:---|
| Exhibit A | Form of Interim Services Agreement |
| Exhibit B | Form of Stock Power |
| Exhibit C | Form of License Agreement |
| Exhibit D-1 | Form of Guaranty Agreement |
| Exhibit D-2 | Form of Secured Guaranty Agreement |
| Exhibit E-1 | Form of Pledge Agreement |
| Exhibit E-2 | Form of Security Agreement |
| Exhibit F | Form of Indemnification Side Letter |

---

iii

------

#### STOCK PURCHASE AGREEMENT
THIS STOCK PURCHASE AGREEMENT (this "<u>Agreement</u>") is made as of February 10, 2023, by and among BT Assets Group, Inc., a Delaware corporation ("<u>Buyer</u>"), on the one hand, and each of Helix Technologies, Inc., a Delaware corporation ("<u>Seller</u>"), and Bio-Tech Medical Software, Inc. (d/b/a BioTrack), a Florida corporation and a wholly owned subsidiary of Seller (the "<u>Company</u>"), on the other hand.

WHEREAS, Seller owns all of the issued and outstanding shares of capital stock of the Company;

WHEREAS, the Company provides software products and services within the cannabis industry, including products and services marketed under the trade and product names BioTrack and Cannalytics<sup>®</sup>;

WHEREAS, subject to the terms and conditions set forth in this Agreement, the parties desire to enter into and perform the transactions contemplated by the Transaction Agreements (the "<u>Transactions</u>"); and

WHEREAS, subject to the conditions to Closing being fulfilled by all parties to this Agreement, immediately following the Closing, the Buyer will own all of the issued and outstanding capital stock of the Company.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

#### SECTION 1

#### DEFINITIONS
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Definitions</u>. For purposes of this Agreement, the following terms shall have the meanings set forth below:

"<u>2020 Merger Agreement</u>" means that certain Agreement & Plan of Merger dated as of December 16, 2020 (as amended to date) between and among Seller, Parent and DNA Merger Sub, Inc.

"<u>Accounting Principles</u>" shall mean GAAP as in effect at the date of the financial statement to which it refers, or if there is no such financial statement, then as of the Closing, using and applying the same accounting principles, practices, procedures, policies and methods (with consistent classifications, judgments, elections, inclusions, exclusions and valuation and estimation methodologies) used and applied by the Company in the preparation of the Interim Financial Statements as set forth in <u>Section 3.5</u> of the Disclosure Schedule; *provided* that Accounting Principles (a) shall not include any purchase accounting or other adjustment arising out of the consummation of the Transactions, (b) shall be based on facts and circumstances as they exist prior to the Closing and shall exclude the effect of any act, decision or event occurring at or after the Closing, and (c) shall follow the defined terms contained in this Agreement.

"<u>Affiliate</u>" means, with respect to any Person, any other Person controlling, controlled by or under common control with such particular Person, where "control" means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person whether through the ownership of voting securities, as trustee, personal representative or executor, by contract, credit arrangement or otherwise.

"<u>Agreement</u>" has the meaning given to such term in the Preamble.

------

"<u>Allocation Schedule</u>" has the meaning given to such term in <u>Section 6.2(d)(ii)</u>.

"<u>Anti-Corruption Laws</u>" has the meaning given to such term in <u>Section 3.16(a)</u>.

"<u>Blue Sky Laws</u>" has the meaning given to such term in <u>Section 3.4(b)</u>.

"<u>Business Day</u>" means any day that is not a Saturday, Sunday or other day on which banks are required or authorized by Law to be closed in the State of Delaware.

"<u>Business Systems</u>" means, with respect to a Person, all Software, information technology and computer systems (including the computers, computer software, databases, firmware, middleware, servers, workstations, routers, hubs, switches, interfaces, data communications lines, websites, applications and all other information technology equipment and software, and all associated documentation).

"<u>Buyer</u>" has the meaning given to such term in the Preamble.

"<u>Buyer Parties</u>" has the meaning given to such term in <u>Section 8.2</u>.

"<u>Buyer's Benefit Programs</u>" has the meaning given to such term in <u>Section 6.3(a)</u>.

"<u>Cash</u>" means the unrestricted cash and cash equivalents required to be reflected as cash and cash equivalents on the balance sheet of the Company prepared in accordance with GAAP applied on a basis consistent with the Accounting Principles, but excluding, for the avoidance of doubt, any Restricted Cash. For the avoidance of doubt, Cash shall be calculated net of issued but uncleared checks, wire transfers and drafts, but shall include checks, wire transfers and drafts deposited for the account of the Company.

"<u>CERCLA</u>" means the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended from time to time prior to the Closing Date, and any rules or regulations promulgated thereunder.

"<u>Closing</u>" has the meaning given to such term in <u>Section 2.2</u>.

"<u>Closing Date</u>" has the meaning given to such term in <u>Section 2.2</u>.

"<u>Closing Cash Amount</u>" means the aggregate amount of Cash of the Company as of the Closing.

"<u>Closing Cash Payment</u>" means the cash payment in the amount equal to $20,030,179, which amount equals the sum of (i) Twenty Million Dollars ($20,000,000) *plus* (ii) the estimated Working Capital Overage, based on the Estimated Working Capital, *less* (iv) the Estimated Transaction Expenses.

"<u>Closing Date Indebtedness</u>" means the aggregate amount of Indebtedness of the Company as of immediately prior to the Closing.

"<u>Closing Working Capital</u>" means the aggregate amount of Working Capital of the Company as January 31, 2023.

"<u>Code</u>" means the Internal Revenue Code of 1986, as amended from time to time.

"<u>Company</u>" has the meaning given to such tern in the Preamble.

------

"<u>Company Benefit Plan</u>" means (i) an employee benefit plan within the meaning of Section 3(3) of ERISA whether or not subject to ERISA; (ii) stock option plans, stock purchase plans, bonus or incentive plans, severance pay plans, programs, agreements or arrangements, deferred compensation arrangements or agreements, employment agreements, compensation plans, programs, agreements or arrangements, change in control plans, programs, agreements or arrangements, supplemental income arrangements, vacation plans, fringe benefits and all other employee benefit plans, agreements, and arrangements, not described in (i) above; and (iii) plans or arrangements providing compensation to employee and non-employee directors, in each case in which the Company sponsors, contributes to, or provides benefits under or through such plan, or has any obligation to contribute to or provide benefits under or through such plan, or if such plan provides benefits to or otherwise covers any current or former employee, officer or director of the Company (or their spouses, dependents, or beneficiaries) or with respect to which the Company has or may have any Liability (contingent or otherwise, including be reason of being an ERISA Affiliate).

"<u>Company Bonuses</u>" means all Liabilities of the Company in relation to "stay" or other similar retention bonuses, change-in-control bonuses or other bonuses or compensation due or arising as a result of the execution, delivery or performance of the Transaction Agreements, whether or not vested as of Closing, to any of the Company's employees, former employees, consultants, former consultants or retirees and any retention bonuses, in each case, based on or arising under employment or engagement with the Company.

"<u>Company Business Data</u>" has the meaning given to such term in <u>Section 3.15(h)</u>.

"<u>Company Business Systems</u>" has the meaning given to such term in <u>Section 3.15(f)</u>.

"<u>Company Common Stock</u>" means the Company's common stock, par value $0.001 per share.

"<u>Company Employee</u>" has the meaning given to such term in <u>Section 3.9(a)</u>.

"<u>Company Governmental Contract</u>" has the meaning given to such term in <u>Section 13.13(a)(xiv)</u>.

"<u>Company Inbound IP Contract</u>" has the meaning given to such term in <u>Section 3.13(a)(vi)</u>.

"<u>Company IP</u>" shall mean any Intellectual Property Rights used or held for use in the business as currently conducted by the Company.

"<u>Company IP Contract</u>" has the meaning given to such term in <u>Section 3.13(a)(vii)</u>.

"<u>Company Leased Real Property</u>" has the meaning given to such term in <u>Section 3.14(b)</u>.

------

"<u>Company Material Adverse Effect</u>" means, with respect to the Company or the business of the Company, any fact, event, change, development, circumstance or effect that (i) is or would, with the passage of time, be reasonably likely to be materially adverse to the financial condition, business, results of operations, assets, Liabilities or operations of the Company other than any fact, event, change, development, circumstance or effect, directly or indirectly arising out of or attributable to any of the following (or results thereof): (A) changes in general economic conditions; (B) general changes or developments in the industries in which the Company operates (including the cannabis and healthcare information technology services industries); (C) any fire, flood, hurricane, earthquake, tornado, windstorm or other similar calamity or act of God or man-made disaster; (D) any national or international political or social conditions, including the engagement by any country in hostilities, whether commenced before or after the Closing Date, and whether or not pursuant to the declaration of a national emergency or war, or the occurrence or threatened occurrence of any military action, terrorism, civil unrest, riots, curfews, public disorders or cyberattack; (E) changes in GAAP or any applicable Law or other binding directives issued by any Governmental Authority or the interpretation thereof; (F) any actions taken (or omitted to be taken) at the prior written request of Buyer or required to be taken (or omitted) by the express terms of this Agreement; (G) any epidemics, pandemics, disease outbreaks, or other public health emergencies (including COVID-19); (H) the implementation of any COVID-19 Measures by any national, state, regional or local government or governing authority; (I) any failure by the Company to achieve any earnings, budgets or other financial projections, forecasts, performance or results of operations for any period ending on or after the Closing Date (it being understood and agreed that the facts and circumstances giving rise to such failure may be taken into account in determining whether there has been a Company Material Adverse Effect, except to the extent such facts and circumstances are excluded from being taken into account by clauses (A) through (H) above); (J) the announcement or pendency of this Agreement; (K) any action taken or refrained from being taken (1) as expressly contemplated by the Transaction Agreements, in each case according to the terms hereof or thereof, or (2) to which Buyer has consented to in writing (or in accordance with this Agreement is deemed to have consented); except in the case of clauses (A) through (H) above to the extent such fact, event, change, development, circumstance or effect has had or reasonably would be expected to have a disproportionate effect on the Company relative to the other similarly situated Persons engaged in the same or substantially similar business as the Company, or (ii) materially impairs or materially delays or would, with the passage of time, be reasonably likely to materially impair or materially delay the ability of the Company to consummate the Transactions and/or to perform its obligations under the Transaction Agreements.

"<u>Company Material Contract</u>" has the meaning given to such term in <u>Section 3.13(a)</u>.

"<u>Company Material Customers</u>" has the meaning given to such term in <u>Section 3.18</u>.

"<u>Company Material Suppliers</u>" has the meaning given to such term in <u>Section 3.18</u>.

"<u>Company Outbound IP Contract</u>" has the meaning given to such term in <u>Section 3.13(a)(vii)</u>.

"<u>Company Owned Software</u>" has the meaning given to such term in <u>Section 3.15(k)</u>.

"<u>Company Products and Services</u>" has the meaning given to such term in <u>Section 3.15(c)</u>.

"<u>Company Real Property Leases</u>" has the meaning given to such term in <u>Section 3.14(b)</u>.

"<u>Company Registered IP</u>" has the meaning given to such term in <u>Section 3.15(a)</u>.

"<u>Company Related Party</u>" has the meaning given to such term in <u>Section 3.21(a).</u>

"<u>Company Related Party Transaction</u>" has the meaning given to such term in <u>Section 3.21(a).</u>

"<u>Company Transaction Expenses</u>" means, to the extent not paid as of immediately prior to the Closing, without duplication, (i) the fees and disbursements payable to legal counsel, bankers and accountants of the Company, and/or Seller in connection with the negotiation, documentation and consummation of the Transactions, (ii) all other fees and expenses, in each case, incurred by the Company and/or Seller in connection with the Transactions as determined on the Closing Date, including Seller's apportioned share of the R&W Insurance Policy as provided in <u>Section 8.1</u>, and (iii) all Company Bonuses except as set forth in the Estimated Closing Statement other than, for the avoidance of doubt, any severance payments as a result of any terminations effected by Buyer or the Company after the Closing.

------

"<u>Confidentiality Agreement</u>" means that certain Mutual Non-Disclosure Agreement by and between Parent and Buyer's Affiliate dated as of January 4, 2022.

"<u>Contract</u>" means any written or oral legally binding contract, license, sublicense, mortgage, purchase order, indenture, loan agreement, lease, sublease, agreement or instrument or any legally binding commitment to enter into any of the foregoing to which the Company is a party or by which any of the Company's assets are bound.

"<u>COVID-19 Measures</u>" means any quarantine, "shelter in place," "stay at home," workforce reduction, social distancing, "personal protective equipment," shut down, closure, sequester, "return to work," "reopening," safety or similar law, regulation, policy, directive, guidance, rule or order promulgated by any Governmental Authority, including but not limited to the Centers for Disease Control and Prevention and the World Health Organization, in each case, related to the COVID-19 Pandemic.

"<u>COVID-19 Pandemic</u>" means the SARS-Cov2 or COVID-19 pandemic, including any future resurgence or evolutions or variants or mutations thereof and/or any related or associated disease outbreaks, epidemics and/or pandemics resulting therefrom.

"<u>Data Protection and Security Requirements</u>" means (i) all Laws relating to the processing of Personal Data, data privacy, data or cyber security, breach notification, or data localization, including the Federal Trade Commission Act, the California Consumer Privacy Act (CCPA), HIPAA and the GDPR; (ii) all regulatory and self-regulatory guidelines and published interpretations by Governmental Authorities of such Laws; (iii) industry standards applicable to the industry in which the Company operates; (iv) all provisions of Contracts to which the Company is a party or by which the Company is bound that relate to the processing of Personal Data; and (v) all policies and notices of the Company relating to the processing of Personal Data.

"<u>Disclosure Schedule</u>" means the Disclosure Schedule attached hereto, dated as of the date hereof, delivered by the Company to Buyer in connection with this Agreement.

"<u>Environmental Laws</u>" means all Laws concerning protection of human health or the environment in connection with the presence, use, production, generation, handling, transport, treatment, storage, disposal, distribution, labeling, testing, processing, discharge, Release, threatened Release, control or cleanup of any Hazardous Materials, as the foregoing are enacted and in effect prior to or on the Closing Date.

"<u>Environmental Permits</u>" has the meaning given to such term in <u>Section 3.12</u>.

"<u>ERISA</u>" means the Employee Retirement Income Security Act of 1974, as amended from time to time.

"<u>ERISA Affiliate</u>" means any entity that would have ever been considered a single employer with the Company under Section 4001(b) of ERISA or part of the same "controlled group" as the Company for purposes of Section 302(d)(3) of ERISA.

"<u>Estimated Closing Statement</u>" has the meaning given to such term in <u>Section 2.6(a)</u>.

"<u>Estimated Transaction Expenses</u>" has the meaning given to such term in <u>Section 2.6(a)</u>.

"<u>Estimated Working Capital</u>" has the meaning given to such term in <u>Section 2.6(a)</u>.

------

"<u>Excess</u>" has the meaning given to such term in <u>Section 2.6(d)</u>.

"<u>Exchange Act</u>" means the Securities Exchange Act of 1934, as amended.

"<u>Federal Consolidated Income Tax Return</u>" has the meaning given to such term in <u>Section 6.2(c)(i)</u>.

"<u>Final Closing Cash Payment</u>" has the meaning given to such term in <u>Section 2.6(b)</u>.

"<u>Financial Statements</u>" has the meaning given to such term in <u>Section 3.5</u>.

"<u>Florida Performance Bond</u>" has the meaning given to such term in <u>Section 6.4</u>.

"<u>Florida Surety</u>" has the meaning given to such term in <u>Section 6.4</u>.

"<u>Fraud</u>" means common law fraud under the Laws of the State of Delaware with respect to the making of any representation or warranty in connection with this Agreement or the Transactions, including those representations and warranties set forth in <u>Section 3</u> (Representations and Warranties of the Company) or <u>Section 4</u> (Representations and Warranties of the Seller) of this Agreement (as applicable) or in any certificate delivered pursuant to this Agreement or in the representations and warranties in any other Transaction Document. For the avoidance of doubt, the term "Fraud" does not include any claim for equitable fraud, promissory fraud, unfair dealing and any other fraud-based claim.

"<u>GAAP</u>" means United States generally accepted accounting principles, consistently applied throughout the periods involved.

"<u>Governmental Authority</u>" means any federal, national, state, provincial or local, whether transnational, domestic, foreign or supranational, government or any court of competent jurisdiction, administrative agency, applicable self-regulatory organization, tribunal or commission or other governmental or regulatory authority, department, agency or instrumentality, including any political subdivision thereof, whether transnational, domestic, foreign or supranational.

"<u>Guaranty Agreements</u>" means those certain guaranty agreements by and among the Seller and (i) the guarantor Affiliates of Buyer party thereto, in the form attached hereto as <u>Exhibit D-1</u> and (ii) the Company, in the form of <u>Exhibit D-2</u>.

"<u>Hazardous Materials</u>" means any hazardous or toxic materials, substances or wastes regulated under Environmental Laws, including toxic chemicals, petroleum products or byproducts, friable asbestos and polychlorinated biphenyls.

"<u>Indebtedness</u>" means, without duplication, (i) any indebtedness for borrowed money, (ii) any indebtedness evidenced by any note, bond, debenture or other debt securities, (iii) any indebtedness for the deferred purchase price of property or services with respect to which a Person is liable, contingently or otherwise, as obligor or otherwise, (iv) any commitment by which a Person assures a creditor against loss (including contingent reimbursement liability with respect to letters of credit), (v) any liabilities under leases that would be considered capitalized leases under GAAP, (vi) any indebtedness secured by a Lien on a Person's assets (other than a Permitted Lien), (vi) unpaid income Taxes of the Company for Pre-Closing Tax Periods beginning on or after January 1, 2022 (and, in the case of a Straddle Period, determined in accordance with <u>Section 6.2(c)(iii))</u> that are first due to be paid after the Closing Date (taking into account any applicable extensions) solely in jurisdictions where the Company filed a Tax Return for the immediately preceding taxable period (*provided* that, such unpaid income Taxes shall be calculated (A) in accordance with past practices of the Company and (B) as of the end of the day on the Closing Date taking into account any Transaction Tax Deductions, net operating losses and other Tax attributes of the Company to the extent permitted by applicable Law at a "more likely than not" (or higher) level of comfort and any applicable prepayments of Tax or payments of estimated Taxes), but excluding any Taxes imposed on the Company due to Buyer's action after Closing outside the Ordinary Course of Business, and (vii) any accrued and unpaid interest on, and any prepayment premiums, penalties or similar contractual charges in respect of, any of the foregoing obligations computed as though payment is being made in respect thereof on the Closing Date. Notwithstanding the foregoing, "<u>Indebtedness</u>" shall not include any deferred revenue, trade payables and accrued expenses arising in the Ordinary Course of Business or obligations under the Florida Performance Bond.

------

"<u>Independent Accountant</u>" shall mean a certified public accountant satisfactory to Buyer and Seller; *provided*, that if Buyer and Seller do not appoint an Independent Accountant within ten (10) days after either Buyer or Seller gives notice to the other of a request therefor, either of them may request the American Arbitration Association to appoint as the Independent Accountant a partner in the New York office of a nationally recognized independent registered public accounting firm based on its determination that the partner has had no material relationships with the parties or their respective Affiliates within the preceding two years and taking into account such firm's material relationships during the preceding two years with the parties and their respective Affiliates, and such appointment shall be final, binding and conclusive on Buyer and Seller.

"<u>Intellectual Property Rights</u>" means any and all of the following, as they exist in any jurisdiction throughout the world: (i) patents, patent applications of any kind, patent rights, inventions, discoveries and invention disclosures (whether or not patented) (collectively, "<u>Patents</u>"); (ii) rights in registered and unregistered trademarks, service marks, trade names, trade dress, corporate names, logos, packaging designs, slogans and Internet domain names, rights to social media accounts, and other indicia of source, origin or quality, together with all goodwill associated with any of the foregoing, and registrations and applications for registration of any of the foregoing (collectively, "<u>Marks</u>"); (iii) copyrights in both published and unpublished works (including all compilations, databases and computer programs, manuals and other documentation and all derivatives, translations, adaptations and combinations of the above) and registrations and applications for registration of any of the foregoing (collectively, "<u>Copyrights</u>"); (iv) know-how, trade secrets, confidential or proprietary information (including customer and supplier lists, customer and supplier records, pricing and cost information, reports, software development methodologies, technical information, proprietary business information, process technology, plans, drawings, blue prints, know-how, inventions and invention disclosures (whether or not patented or patentable and whether or not reduced to practice), ideas, research in progress, algorithms, data, databases, data collections, designs, processes, drawings, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, source code, source code documentation, testing procedures and testing results and business, financial, sales and marketing plans) and rights under applicable trade secret Law in the foregoing (collectively, "<u>Trade Secrets</u>"); (v) rights of publicity and privacy and data protection rights; and (vi) any and all other intellectual property rights and/or proprietary rights relating to any of the foregoing.

"<u>Interim Financial Statements</u>" has the meaning given to such term in <u>Section 3.5</u>.

"<u>Interim Services Agreement</u>" means that certain Interim Services Agreement by and among Buyer, the Company, Seller and Parent, substantially in the form attached hereto as <u>Exhibit A</u>.

"<u>Key Employee</u>," means, with respect to the Company, any Company employee set forth in <u>Section 1.1(a)</u> of the Disclosure Schedule.

"<u>Knowledge</u>," means, with respect to the Company, the actual knowledge of the individuals set forth in <u>Section 1.1(b)</u> of the Disclosure Schedule, in each case after reasonable inquiry of the employees, consultants or independent contractors of the applicable Person with the administrative or operational responsibility for such matter in question.

------

"<u>Law</u>" Means any transnational, domestic or foreign federal, provincial, state or local law, statute, treaty, convention, code, ordinance, rule, regulation (including of self-regulatory organizations), interpretations, resolutions, Order or other similar requirement enacted, adopted, promulgated or applied by a Governmental Authority.

"<u>Liability</u>" means any material liability, debt, obligation, deficiency, penalty, assessment, fine or other loss, fee, cost or expense of any kind or nature whatsoever, whether asserted or unasserted, absolute or contingent, known or unknown, accrued or unaccrued, liquidated or unliquidated, and whether due or to become due and regardless of when asserted.

"<u>License Agreement</u>" means that certain license agreement by and between Buyer, the Company and their respective Affiliates, on the one hand, and Seller and Parent and their respective Affiliates, on the other hand, in the form attached hereto as <u>Exhibit C</u>.

"<u>Licensed Company IP</u>" has the meaning given to such term in <u>Section 3.15(b)</u>.

"<u>Licensed Software</u>" has the meaning given to such term in <u>Section 3.15(k)</u>.

"<u>Lien</u>" means any lien, pledge, charge, mortgage, security interest, deed of trust, judgment, adverse right or other encumbrance of any sort.

"<u>Malicious Code</u>" has the meaning given to such term in <u>Section 3.15(m)</u>.

"<u>Misconduct Claim</u>" means, without limitation, unlawful harassment and or discrimination, or any other unlawful act of a similar nature, if made to an employee, independent contractor or customer who has not invited such conduct, and any unlawful retaliatory act for refusing or opposing any of the foregoing.

"<u>Multiemployer Plan</u>" means a plan defined in Section 3(37) of ERISA.

"<u>Non-Party Affiliates</u>" has the meaning given to such term in <u>Section 8.2</u>.

"<u>Non-Released Claims</u>" has the meaning given to such term in <u>Section 8.2</u>.

"<u>Off-the-Shelf Software</u>" means any commercially available Software that the Company licenses (including under shrink-wrap, click-through, or other standard licensing terms) for use in the business of the Company, in any individual case, under a license with a maximum annual payment obligation on the part of the Company of less than twenty-five thousand dollars ($25,000).

"<u>Open Source Technology</u>" means any Software or other Intellectual Property Rights that are distributed as or that contain, or are derived in any manner (in whole or in part) from, any Software or other Intellectual Property Rights that are distributed as free software, open source or similar licensing or distribution models, or requires as a condition of use, modification or distribution that any Intellectual Property Rights (1) be disclosed or distributed in source code form, (2) be licensed for the purpose of making derivative works, (3) be redistributable at no charge, or (4) grants to any third party any license, non-assertion covenant or other rights or immunities to or under any Intellectual Property Rights. Open Source Technology includes Intellectual Property Rights licensed or distributed under any of the following licenses or distribution models, or licenses or distribution models similar to any of the following: Apache License, MIT License, BSD 3-Clause "New" or "Revised" License or BSD 2-Clause "Simplified" or "FreeBSD" License, GNU's General Public License (GPL), Lesser/Library GPL (LGPL), or Affero GPL, Mozilla Public License, Common Development and Distribution License (CDDL), Eclipse Public License, Artistic License, Netscape Public License, Sun Community Source License (SCSL), Sun Industry Standards License (SISL), the Common Public License, Creative Commons License, or any license or distribution agreement or arrangement listed on www.opensource.org/licenses/index.php or any successor website thereof or that is considered "free" or "open source" by the Open Source Foundation or the Free Software Foundation.

------

"<u>Order</u>" means any order, judgment, injunction, award, decree, ruling or writ of any Governmental Authority.

"<u>Ordinary Course of Business</u>" means with respect to a Person, any action taken, or omitted to be taken, by such a Person in the ordinary course of such Person's business that is materially consistent with the past practices of such Person; *provided, however*, that actions taken or omitted to be taken in response to a condition or conditions arising from the COVID-19 Pandemic, including COVID-19 Measures, in accordance with the Law shall be deemed Ordinary Course of Business of such Person.

"<u>Owned Company IP</u>" has the meaning given to such term in <u>Section 3.15(b)</u>.

"<u>Parent</u>" means Forian Inc., a Delaware corporation and the parent of Seller.

"<u>Parent Insurance Policies</u>" has the meaning given to such term in <u>Section 3.20</u>.

"<u>Parties</u>" (collectively) or "<u>Party</u>" (individually) shall refer to the Company, Seller and Buyer.

"<u>Permitted Liens</u>" means (i) any Lien for Taxes or other governmental charges, assessments or levies that are not yet delinquent or that are being contested in good faith by appropriate proceedings, (ii) any statutory landlord's, mechanic's, carrier's, workmen's, repairmen's or other similar Lien arising or incurred in the Ordinary Course of Business, (iii) any covenants, conditions, restrictions, declarations, easements, rights-of-way, roads, highways or reservation of rights, including easements and/or rights of way, for sanitary and storm sewers, storm water discharge pipes, conduits and swales, water mains and pipes, electric lines, cable lines, telephone lines and lines for other similar purposes (whether overhead or underground), and affecting the leasehold estate in any Company Leased Real Property and being transferred to Buyer at the Closing that are in existence and recorded as of the Closing Date, (iv) with respect to Company Leased Real Property only, any Lien (including Indebtedness) encumbering the fee interest title in any Company Leased Real Property and not attributable to the Company and any statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements, and (v) nonexclusive licenses to Intellectual Property Rights granted in the Ordinary Course of Business.

"<u>Person</u>" means any individual, partnership, limited liability company, corporation, cooperative, association, joint stock company, trust, joint venture, unincorporated organization or Governmental Authority, body or entity or any department, agency or political subdivision thereof.

"<u>Personal Data</u>" means any data or information in any medium relating to an identified or identifiable individual, browser or device and any other data or information that constitutes personal information or personally identifiable information under any applicable Law, and includes, but is not limited to, a natural person's first and last name, home or other physical address, telephone number, e-mail address, photograph, social security number, driver's license number, passport number or other government-issued identification number, biometric information, credit card or other financial information, or customer or account number, IP address, cookie information, or other unique identifiers. An identifiable individual is one who can be identified, directly or indirectly, in particular by reference to an identification number or to one or more factors specific to his/her physical, physiological, mental, economic, cultural or social identity.

------

"<u>Pledge Agreement</u>" means that certain pledge agreement by and between Buyer and Seller in the form attached hereto as <u>Exhibit E-1</u>.

"<u>Post-Closing Statement</u>" has the meaning given to such term in <u>Section 2.6(b)</u>.

"<u>Pre-Closing Tax Period</u>" means any taxable period ending on or before the Closing Date and the portion through the end of the Closing Date for any Straddle Period.

"<u>Pre-Closing Tax Returns</u>" has the meaning given to such term in <u>Section 6.2(c)(ii)</u>.

"<u>Purchase Price</u>" means Thirty Million Dollars ($30,000,000).

"<u>R&W Insurance Policy</u>" means the buyer side representations and warranties indemnity policy with policy number US00126040BL23A to be issued by AXA XL to Buyer (as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time) pursuant to the binder agreement, dated as of the date hereof, between AXA XL and Buyer.

"<u>Release</u>" shall have the meaning set forth in CERCLA.

"<u>Released Claims</u>" has the meaning given to such term in <u>Section 8.2</u>.

"<u>Restricted Cash</u>" means all cash and cash equivalents not freely usable by and available to Seller or the Company because it is subject to restrictions, limitations or Taxes on use or distribution by applicable Law, contract or otherwise, including third-party deposits.

"<u>Securities Act</u>" means the Securities Act of 1933, as amended.

"<u>Security Agreement</u>" means that certain security agreement by and between Buyer and Seller in the form attached hereto as <u>Exhibit E-2</u>.

"<u>Section 338(h)(10) Election</u>" has the meaning given to such term in <u>Section 6.2(d)(i)</u>.

"<u>Section 338(h)(10) Forms</u>" has the meaning given to such term in <u>Section 6.2(d)(iii)</u>.

"<u>Seller</u>" has the meaning given to such term in the Preamble.

"<u>Shortfall</u>" has the meaning given to such term in <u>Section 2.6(d)</u>.

"<u>Software</u>" means any and all computer programs, software and code, including all versions, translations, updates, revisions, improvements and modifications thereof, whether in source code, object code, or executable code format, including systems software, application software (including mobile apps), firmware, middleware, programming tools, scripts, routines, interfaces, input and output formats, libraries, data, data models and databases, and all related specifications and documentation, including developer notes, comments and annotations, flow charts, outlines, narrative descriptions, operating instructions, user manuals, training materials and tangible media relating to any of the foregoing.

"<u>Straddle Period</u>" means any taxable period beginning on or prior to and ending after the Closing Date.

------

"<u>Subsequent Cash Payments</u>" shall mean such payments in the aggregate amount of Ten Million Dollars ($10,000,000) to be paid by Buyer in accordance with <u>Section 2.4</u>.

"<u>Subsidiary</u>" means, with respect to any person, any corporation or other organization or Person, whether incorporated or unincorporated, of which (i) such party or any other subsidiary of such party is a general partner (excluding such partnerships where such party or any subsidiary of such party does not have a majority of the voting interest in such partnership), or (ii) at least fifty percent (50%) of the securities or other interests having by their terms ordinary voting power to elect at least fifty percent (50%) of the board of directors or others performing similar functions with respect to such corporation or other organization is directly or indirectly owned or controlled by such party or by any one or more of its subsidiaries or Affiliates.

"<u>Target Working Capital</u>" means Zero Dollars ($0).

"<u>Tax</u>" or "<u>Taxes</u>" means any federal, state, local or foreign income, gross receipts, capital gains, profits, franchise, alternative or add-on minimum, sales, use, transfer, excise, severance, stamp, premium, customs, duties, withholding, real property, ad valorem, personal property, capital stock, social security, unemployment, employment, disability or any other assessment or charge in the nature of a tax imposed by any Governmental Authority, including any interest, penalties or additions to tax or additional amounts in respect of the foregoing.

"<u>Tax Returns</u>" means returns, declarations, reports, claims for refund, information returns or other documents filed or required to be filed in connection with the determination, assessment or collection of any Taxes.

"<u>Taxing Authority</u>" means any Governmental Authority responsible for the imposition, assessment, reassessment or collection of any Taxes.

"<u>Transactions</u>" has the meaning given to such term in the Recitals.

"<u>Transaction Agreements</u>" means this Agreement, the Interim Services Agreement, the Stock Power, the License Agreement, the Guaranty Agreements, the Indemnification Side Letter and the Security and Pledge Agreement.

"<u>Transaction Tax Deductions</u>" means (i) all fees, costs and expenses incurred by the Company in connection with or incident to the Transaction Agreements and the Transactions, including Company Transaction Expenses and any other legal, accounting and investment banking fees, costs and expenses, and (ii) any applicable expenses or other amounts not otherwise described in clause (ii) of this definition that are paid by or on behalf of the Company in connection with the Transactions to the extent that such expenses or amounts are paid prior to the Closing or reduce the Consideration. The amount of the Transaction Tax Deductions shall be computed assuming that an election was made under Revenue Procedure 2011-29 to deduct seventy percent (70%) of any Transaction Tax Deductions that are success-based fees (as described in Revenue Procedure 2011-29).

"<u>Transfer</u>" means, with respect to any security, to sell, offer, pledge, contract to sell, grant any option or contract to purchase, purchase any option or contract to sell, grant any right or warrant to purchase, lend or otherwise transfer (including by gift or operation of law), dispose of, hypothecate or encumber, directly or indirectly, such security, or to enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such security.

"<u>Transfer Taxes</u>" has the meaning given to such term in <u>Section 6.2(a)</u>.

------

"<u>UCC-1 Financing Statements</u>" means the Uniform Commercial Code Financing Statements (Form UCC 1), naming Buyer as the debtor and Seller as the secured party, or other similar instruments or documents, filed or to be filed under the Uniform Commercial Code of all jurisdictions as may be necessary or, in the opinion of Seller, desirable to perfect the security interest of the Seller pursuant to the Security and Pledge Agreement.

"<u>Unaudited Financial Statements</u>" has the meaning given to such term in <u>Section 3.5</u>.

"<u>WARN Act</u>" means the Worker Adjustment and Retraining Notification Act, 29 U.S.C. §§ 2101 et seq., and the regulations promulgated thereunder.

"<u>Working Capital</u>" means the difference, whether positive or negative, between (i) the current assets of the Company and (ii) the current liabilities of the Company, in each case (i) for only those line items as set forth on the Estimated Closing Statement, (ii) calculated as of the Closing and (iii) determined in accordance with the Accounting Principles.

"<u>Working Capital Overage</u>" means the amount, if any, by which the Closing Working Capital is greater than the Target Working Capital; *provided* that such amount is at least Fifty Thousand Dollars ($50,000).

"<u>Working Capital Underage</u>" means the amount, if any, by which the Closing Working Capital is less than the Target Working Capital; *provided* that such amount is at least negative Fifty Thousand Dollars ($(50,000)).

#### SECTION 2

#### THE TRANSACTIONS
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Purchase and Sale of Company Common Stock</u>. Upon the terms of and subject to the conditions set forth in this Agreement, and in reliance upon the representations, warranties and covenants set forth herein, at the Closing, Seller shall sell, transfer and deliver to Buyer, free and clear of any and all Liens, all of the issued and outstanding capital stock of the Company for the Purchase Price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Time and Place of Closing</u>. The closing of the Transactions (the "Closing") shall be held remotely by exchange of documents and signatures (or their electronic counterparts) simultaneously with the execution of the Transaction Agreements effective at 11:59 p.m. Eastern Time on the date hereof (the "Closing Date"). Except as otherwise set forth herein, all actions to be taken and all documents to be executed and delivered at the Closing will be deemed to have been taken, executed and delivered simultaneously, and no proceedings will be deemed taken nor any documents deemed executed or delivered until all such proceedings have been taken, and all such documents executed and delivered.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Closing Payment</u><u>s</u>. In consideration of the sale of the Company Common Stock, on the Closing Date, Buyer shall pay or deliver, or cause to be paid or delivered, to Seller, the Closing Cash Payment, by wire transfer of immediately available funds in accordance with the wiring instructions provided by Seller on the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4&nbsp;&nbsp;&nbsp;&nbsp; <u>Subsequent Cash Payments</u>. On or before the tenth (10<sup>th</sup>) day of each month (or the next immediately succeeding Business Day if not a Business Day) commencing on March 10, 2023 and ending on February 8, 2024, Buyer shall remit to Seller by wire transfer of immediately available funds the sum of Eight Hundred Thirty-Three Thousand Three Hundred Thirty-Three Dollars and Thirty-Three Cents ($833,333.33); *provided* that the payment made on or before February 8, 2024, shall be made in the amount of Eight Hundred Thirty-Three Thousand Three Hundred Thirty-Three Dollars and Thirty-Seven Cents ($833,333.37).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5&nbsp;&nbsp;&nbsp;&nbsp; <u>Withholding Taxes</u>. Each of Buyer and Seller shall be entitled to deduct and withhold from any consideration otherwise payable to any Person pursuant to this Agreement such amounts as it is required to deduct and withhold with respect to the making of such payment under the Code, or any provision of applicable Tax Law; *provided*, that if Buyer or Seller determine that any payment to any Person hereunder is subject to deduction or withholding, then Buyer or Seller, as the case may be, shall (i) provide notice to such Person at least five (5) Business Days prior to making any such deduction or withholding, and (ii) use commercially reasonable efforts to cooperate with the applicable Person to reduce or eliminate any such deduction or withholding to the extent permitted by Law. To the extent that such amounts are so deducted or withheld or paid over to or deposited with the relevant Governmental Authority by Buyer or Seller, such deducted or withheld amounts shall be treated for all purposes of this Agreement as having been paid to the applicable Person in respect to which such deduction or withholding was made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Adjustment to Purchase Price</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Closing Purchase Price</u>. On or prior to the Closing, Seller shall prepare and deliver to Buyer an estimated closing statement of the Company as of the Closing Date, which is included in <u>Section 1.1(d)</u> of the Disclosure Schedule (the "<u>Estimated Closing Statement</u>"), which Estimated Closing Statement sets forth Seller's good faith calculation, together with all schedules and data as may be appropriate to support such calculation of its good faith estimate of: (i) the Closing Working Capital (the "<u>Estimated Working Capital</u>"), prepared in accordance with the Accounting Principles, and (ii) the Company Transaction Expenses (the "<u>Estimated Transaction Expenses</u>"); and, based on such estimates, a calculation of the Closing Cash Payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Post-Closing Adjustment Amount</u>. Within sixty (60) days after the Closing Date, the Company shall prepare and deliver to Seller a statement (the "<u>Post-Closing Statement</u>") setting forth the Company's good faith calculation of the (i) the actual Closing Net Working Capital and the Working Capital Underage or Working Capital Overage (if any), (ii) actual Company Transaction Expenses, (iii) the actual Closing Cash Payment (the "<u>Final Closing Cash Payment</u>") and (iii) a certificate of the Chief Financial Officer of the Company that the Post-Closing Statement was prepared in accordance with the Accounting Principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp; If Buyer notifies Seller in writing that Buyer objects to one or more items reflected in the Post-Closing Statement, Buyer and Seller shall negotiate in good faith to resolve such dispute; *provided*, *however*, that if Buyer and Seller are unable to resolve any dispute with respect to the Post-Closing Statement within ninety (90) days following the Closing Date, such dispute shall be resolved by the Independent Accountant. The fees and expenses of the Independent Accountant shall be borne equally by Seller and Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If, after the final determination of all of the items set forth in the Post-Closing Statement pursuant to the terms of this <u>Section 2.6</u>, the Final Closing Cash Payment as so finally determined is less than the Closing Cash Payment (the amount equal to such difference, the "<u>Shortfall</u>"), then Buyer shall be entitled to a payment from Seller in an amount equal to the Shortfall within five (5) business days of such final determination. If, after the final determination pursuant to the foregoing, the Final Closing Cash Payment as so finally determined is greater than or equal to the Closing Cash Payment (the amount equal to such difference, the "<u>Excess</u>"), then Seller shall be entitled to a payment from Buyer in an amount equal to the Excess within five (5) business days of such final determination.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Adjustments for Tax Purposes</u>. Any payments made pursuant to this <u>Section 2.6</u> shall be treated as an adjustment to the Purchase Price by the parties for Tax purposes, unless otherwise required by Law.

#### SECTION 3

#### REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY
Subject to such exceptions as are set forth in the Disclosure Schedule and delivered herewith by the Company to Buyer, the Company hereby represents and warrants to Buyer that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1&nbsp;&nbsp;&nbsp;&nbsp; <u>Organization, Standing and Power</u>. The Company is a duly organized, validly existing corporation and in good standing under the laws of the State of Florida. The Company has all requisite power and authority to own, lease and operate its properties and conduct its businesses as and where presently conducted. The Company is duly qualified or licensed to do business and in good standing in each jurisdiction (in the case of good standing, to the extent such jurisdiction recognizes such concept) where the nature of its business or the ownership or leasing of its properties make such qualification necessary, other than in such jurisdictions where the failure to be so qualified or licensed, individually or in the aggregate, has not had and would not reasonably be expected to have, a Company Material Adverse Effect. The Company has made available to Buyer true, correct and complete copies of the Company's Certificate of Incorporation and Bylaws (and all amendments thereto) as currently in full force and effect. The Company is not in violation of any of the provisions of its Certificate of Incorporation or Bylaws or similar organizational documents (and all amendments thereto).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Capital Structure</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; The authorized capital stock of the Company consists of 1,000 shares of Company Common Stock, all of which are issued and outstanding and owned by Seller. All of the issued and outstanding shares of Company Common Stock have been duly authorized, validly issued and are fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Other than the Company Common Stock owned by Seller, there are no outstanding (i) equity securities of the Company, (ii) no securities of the Company convertible into or exchangeable or exercisable for equity securities of the Company, (iii) no subscriptions, calls, options, warrants or other rights to acquire from the Company and no obligations of the Company to issue or sell, any shares of capital stock of, equity securities in or debt securities of, the Company, and (iv) no equity equivalents, stock appreciation rights, phantom stock ownership interests or similar rights in the Company. All outstanding options held by employees of the Company under any Company Benefit Plan or similar programs sponsored by Seller or Parent are exercisable solely for shares of common stock of Parent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are not outstanding obligations of the Company to repurchase, redeem or otherwise acquire any securities or equity interests in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has no Subsidiaries and does not own, directly or indirectly, any capital stock or voting securities of, or other equity interests in, or any interest convertible into or exchangeable or exercisable for, any capital stock or voting securities of, or other equity interests in, any Person.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Authority; Execution and Delivery; Enforceability</u>. The Company has all requisite corporate power and authority to execute and deliver each of the Transaction Agreements to which it is a party, to perform its obligations thereunder and to consummate the Transactions. The sole director of the Company has adopted resolutions (a) determining that the terms of the Transaction Agreements and the Transactions are fair to and in the best interests of the Company and (b) approving and declaring advisable the execution, delivery and performance of the Transaction Agreements and the Transactions. Such resolutions have not been amended or withdrawn. No other corporate or other organizational proceedings on the part of the Company are necessary to authorize or adopt this Agreement or to consummate the Transactions. The Company has duly executed and delivered each Transaction Agreement to which it is a party and, assuming the due authorization, execution and delivery by Seller and Buyer, such Transaction Agreements constitute its legal, valid and binding obligation, enforceable against it in accordance with its terms except, in each case, as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent transfer, moratorium or similar Laws affecting creditors' rights generally and by general principles of equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Conflicts; Consents</u><u>.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No Permit, consent, approval, clearance, waiver or order of or from, or registration, declaration, notice or filing made to or with, or any action by, any Governmental Authority is required to be obtained, taken or made by or with respect to the Company in connection with the execution and delivery of the Transaction Agreements or its performance of its obligations thereunder or the consummation of the Transactions, other than (i) in compliance with applicable requirements of the Exchange Act, Securities Act and U.S. state securities laws ("<u>Blue Sky Laws</u>") and (ii) such Permits, consents, approvals, clearances, waivers, orders, registrations, declarations, notices, filings or actions that, individually or in the aggregate, (x) have not had and would not reasonably be expected to have a Company Material Adverse Effect or (y) prevent or materially delay consummation of the Transactions.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Financial Statements</u>. Section 3.5 of the Disclosure Schedule sets forth true and correct copies of the Company's unaudited financial statements consisting of the balance sheet of the Company as at December 31, 2021 and the related statements of income and retained earnings for the period commencing March 2, 2021 and ended December 31, 2021 (the "<u>Unaudited Financial Statements</u>"), and unaudited financial statements consisting of the balance sheet of the Company as at November 30, 2022, and the related statements of income and retained earnings for the eleven-month period then ended (the "<u>Interim Financial Statements</u>" and together with the Unaudited Financial Statements, the "<u>Financial Statements</u>") have been delivered to Buyer. The Financial Statements comply as to form in all material respects with applicable accounting requirements with respect thereto as of their respective dates, have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved, subject, in the case of the Interim Financial Statements, to normal and recurring year-end adjustments and the absence of notes, none of which individually or in the aggregate would reasonably be expected to be material to the Company, taken as a whole. The Financial Statements fairly present in all material respects the financial condition of the Company as of the respective dates they were prepared and the results of the operations of the Company for the periods indicated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6&nbsp;&nbsp;&nbsp;&nbsp; <u>Absence of Certain Changes or Events</u>. Since January 1, 2022, there has not occurred any fact, circumstance, occurrence, effect, event or development or change that, individually or in the aggregate, has had or would reasonably be expected to have a Company Material Adverse Effect. Since January 1, 2022, the Company has conducted and operated its businesses in the Ordinary Course of Business, except for the execution and delivery of this Agreement, and has not taken any of the following actions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, stock or property or any combination thereof) in respect of, any of its capital stock, other equity interests or voting securities; (ii) split, combine, subdivide, recapitalize or reclassify any of its capital stock, other equity interests or voting securities or securities convertible into or exchangeable or exercisable for capital stock or other equity interests or voting securities, or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for its capital stock, other equity interests or voting securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; make or adopt any change or election in its accounting methods, principles or practices, except insofar as may be required by a change (whether occurring before or after the date of this Agreement) in GAAP or Law (or interpretations thereof);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; except as required by applicable Law or GAAP, (i) write off as uncollectible, or establish any extraordinary reserve with respect to, any account or note receivable or other Indebtedness, (ii) delay, accelerate or cancel any account or note receivable or other Indebtedness, or (iii) sell or assign any account or note receivable or other Indebtedness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other than with respect to customers for payment terms not in excess of sixty (60) days, make, amend, renew, extend or renegotiate any extension of credit or loan to any Person, or enter into any commitment to do any of the foregoing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; except for the filing of the 2021 federal Tax Return as a consolidated entity, make, change or revoke any material election with respect to Taxes, file any amended Tax Return, settle or compromise any material Tax liability, consent to or request any extension or waiver of any limitation period with respect to any material claim or assessment for Taxes, incur any material Tax liability outside of the Ordinary Course of Business (other than as a result of the Transactions), prepare or file any Tax Return in a manner inconsistent in any material respect with past practice, enter into any closing agreement with respect to any material Tax, surrender any right to claim a material Tax refund or fail to pay any material Taxes as they become due and payable (including estimated Taxes);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adopt or enter into a plan or agreement of complete or partial liquidation, dissolution, merger, consolidation or other reorganization of the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acquire or enter into any agreement to acquire any real property.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Taxes</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has timely filed or has caused to be timely filed all income, franchise and other material Tax Returns required to be filed by or with respect to it (taking into account any valid extension of time within which to file), and all such Tax Returns are accurate and complete and in compliance with applicable Tax Law. The Company has fully and timely paid or caused to be fully and timely paid all material Taxes required to be paid by it (including any Taxes due and payable to the extent required by Company Real Property Leases), other than Taxes that are not yet due and payable or that are being contested in good faith in appropriate proceedings and for which adequate reserves have been established in accordance with GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No deficiency for any Tax has been asserted or assessed by a Taxing Authority against the Company which deficiency has not been paid or is not being contested in good faith in appropriate proceedings and adequately reserved under GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has complied in all material respects with applicable Tax Law with respect to the withholding of Taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is not pending or, to the Knowledge of the Company, threatened in writing any audit, examination, claim, or notice of deficiency in respect of any Taxes of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no Liens for Taxes on any of the assets, rights or properties of the Company other than Company Permitted Liens.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has not waived any statute of limitations with respect to Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No written claim has been received by the Company from a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that it is or may be subject to taxation by that jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company will not be required to include any item of income in, or to exclude any item of deduction from, taxable income for any taxable period (or portion thereof) beginning after the Closing Date as a result of any (A) change in method of accounting or improper method of accounting with respect to a taxable period (or portion thereof) on or prior to the Closing Date; (B) "closing agreement" as described in Section 1721 of the Code (or similar provision of state, local or foreign Law), entered into on or prior to the Closing Date; (C) installment sale or open transaction made on or prior to the Closing Date; (D) prepaid amount received or deferred revenue accrued on or prior to the Closing Date; or (E) election under Section 965 or Section 108(i) of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has not (i) been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code; (ii) been a stockholder of a "controlled foreign corporation" as defined in Section 957 of the Code (or any similar provision of state, local or foreign law); (iii) been a "personal holding company" as defined in Section 542 of the Code (or any similar provision of state, local or foreign law); (iv) been a stockholder of a "passive foreign investment company" within the meaning of Section 1297 of the Code; or (v) engaged in a trade or business, had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise become subject to Tax jurisdiction in a country other than the country of its formation.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is not, nor has it been, a partner for Tax purposes with respect to any joint venture, partnership, or other arrangement or Contract which is treated as a partnership for Tax purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is, as of the Tax period ending on the Closing Date, a member of the Seller's affiliated group filing a consolidated federal income Tax Return, within the meaning of Code Section 338(h)(10)(A)(i).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp; The Company does not maintain, contribute to or sponsor any "nonqualified deferred compensation plan" (as defined in Section 409A(d)(1) of the Code).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)Neither the execution and delivery of this Agreement nor the consummation of the Transactions (either alone or in combination with any other event, whether contingent or otherwise), will, or could reasonably be expected to, give rise directly or indirectly to the payment of any amount that could be characterized as a "parachute payment" within the meaning of Section 280G(b)(2) of the Code. There is no Contract, agreement, plan or arrangement to which the Company is party or by which the Company is bound which requires the Company to pay a Tax gross-up or reimbursement payment to any Person, including with respect to Taxes imposed under Section 409A or Section 4999 of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is not party to nor is bound by any Tax sharing, allocation or indemnification agreement or arrangement, other than such an agreement or arrangement entered into in the Ordinary Course of Business the primary purpose of which is not related to Taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During any tax period for which the statute of limitations has not expired, the Company has not been a "distributing corporation" or a "controlled corporation" in a distribution intended to qualify for tax-free treatment under Section 355 of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has not participated in any "reportable transaction" within the meaning of Treasury Regulation Section 1.6011-4 (or a similar provision of local, state or foreign Law).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;&nbsp;&nbsp;&nbsp; The Company has properly (i) collected and remitted sales, use, value added and similar Taxes with respect to sales made to its customers or services provided to its customers and (ii) for all sales or services that are exempt from sales, use, value added and similar Taxes and that were made without charging or remitting such Taxes, received and retained any appropriate Tax exemption certificates and other documentation qualifying such sale or service as exempt.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;&nbsp;&nbsp;&nbsp; The Company has not (i) filed, or has pending, any ruling requests with any Taxing Authority relating to Taxes, including any request to change any accounting method which is still in effect, or (ii) granted to any Person any power of attorney that is in force with respect to any income Tax matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notwithstanding any other representations and warranties in this Agreement, the representations and warranties in <u>Section 3.8</u> (to the extent expressly related to Taxes) and this <u>Section 3.7</u> constitute the sole representations and warranties in this Agreement with respect to Tax matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Employee Benefits</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 3.8(a)</u> of the Disclosure Schedule sets forth a complete list of all material Company Benefit Plans.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; (i) Each Company Benefit Plan has been established, operated, invested, funded and administered in accordance, in all material respects, with its terms, any applicable labor, collective bargaining or other agreement with any Union and any applicable Law (including ERISA and the Code) and (ii) to the Knowledge of the Company, the Company has not engaged in any transaction with respect to any Company Benefit Plan that would be reasonably likely to subject any Company Benefit Plan or the Company to any material Tax or penalty (civil or otherwise) imposed by ERISA, the Code or other applicable Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Company Benefit Plan intended to be qualified under Section 401(a) of the Code and has received or may otherwise reasonably rely upon a favorable determination or opinion letter from the IRS as to its tax-qualification under the Code, and each trust maintained thereunder is exempt from federal income taxation under the provisions of Section 501(a) of the Code, and, to the Knowledge of the Company, nothing has occurred since the date of any such determination that could reasonably be expected to adversely affect the qualification of such Company Benefit Plan or its related trust.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other than routine claims for benefits, there are no suits, claims, proceedings, actions or governmental audits or investigations that are pending or, to the Knowledge of the Company, threatened, against or involving any Company Benefit Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp; Neither the Company nor any ERISA Affiliate currently has, or within the six-year period immediately prior to the Closing Date, maintained, participated in, contributed to, or had an obligation to contribute to (i) a "defined benefit plan" as defined in Section 3(35) of ERISA, (ii) a Pension Plan, (iii) a "multiple employer welfare arrangement" as defined in Section 3(40) of ERISA or (iv) a "multiemployer plan" as defined in Section 3(37) of ERISA or Section 414(f) of the Code. No liability under Title IV or Section 302 of ERISA has been incurred by the Company or any ERISA Affiliate that has not been satisfied in full, and, to the Knowledge of the Company, no condition exists that would reasonably be expected to present a material risk to the Company of incurring any such liability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No Company Benefit Plan provides for post-retirement or other post-employment welfare benefits (other than health care continuation coverage (i) as required by Section 4980B of the Code or similar state or local Law or (ii) health care coverage through the end of the calendar month in which a termination of employment occurs).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp; Notwithstanding any other representations and warranties in this Agreement, the representations and warranties in this <u>Section 3.8</u> constitute the sole representations and warranties in this Agreement with respect to employee benefits matters of any kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Employment and Labor Matters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 3.9(a)</u> of the Disclosure Schedule contains a list, as of a date within the ten (10) Business Day period immediately preceding the Closing Date, of all individuals employed by the Company (including those on a leave of absence or on layoff status) (collectively, "<u>Company Employees</u>"), in alphabetical order (last name first) and sets forth for each such Company Employee the following: (i) name; (ii) title or position (including whether full or part time); (iii) department; (iv) whether regular, temporary or leased; (v) hire date; (vi) current wages/compensation (e.g., salary, hourly) rate; (vii) any and all Company Bonuses or other compensation and contingent arrangements (including commission, bonus, severance, or other incentive-based compensation); (viii) exempt or non-exempt status, (ix) accrued but unused paid time off (including vacation, personal and/or sick days); and (x) whether the individual is active or on a leave of absence or layoff if subject to recall (and if so, the nature and length of the leave or layoff status and expected date of return to work). The Company is not delinquent in material payments to any employee or former employee for any services or amounts required to be reimbursed or otherwise paid. The Company is and at all times since March 2, 2021, has been in compliance in all material respects with any and all agreements between the Company and any employee of the Company.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is not party to, nor bound by, any labor or collective bargaining agreement with any Union.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp; The consent or consultation of, or the rendering of formal advice by, any Union is not required for the Company to enter into this Agreement or to consummate any of the Transactions or to terminate or layoff any employees of the Company in the event any of the Transactions are consummated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp; The Company has not had at any time since March 2, 2021, any duty to bargain with any labor organization. The Company is not currently negotiating any labor, collective bargaining or other agreement with any Union, and there is not, and has not been, any Union representing or purporting to represent any employee of the Company. No employee or Union is making or has made a demand for recognition or has filed a petition seeking representation with the National Labor Relations Board with respect to employees of the Company, and, to the Knowledge of Company, no Union, employee or group of employees is seeking or has sought to organize employees of the Company for the purpose of collective bargaining. The Company has no Knowledge of any facts to suggest that any demand for recognition or effort or attempt to organize employees of the Company is imminent, likely or expected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Since March 2, 2021, there has been no actual or, to the Knowledge of the Company, threatened in writing, labor strike, dispute, walkout, work stoppage, picketing, hand billing, slowdown or lockout against the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp; The Company is and, at all times since March 2, 2021, has been, in compliance in all material respects with all applicable Laws pertaining to employment, labor relations and employment, wage and hour, workers' compensation, health and safety, and labor relations practices, collective bargaining and employee benefits. All individuals characterized and treated by the Company as independent contractors or consultants are properly classified and utilized as independent contractors under all applicable Laws, and are not employees of the Company. All individuals classified and utilized by the Company as leased employees are properly classified as employees of the applicable leasing company, and are not employees of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)Since March 2, 2021, there have been no, material grievances, complaints, citations, charges, actions, claims, suits, litigation, arbitrations, mediations, investigations, hearings or other proceedings against the Company pending, or, to the Knowledge of the Company, threatened to be brought or filed, by or with any court or arbitrator or any other Governmental Authority, or any Orders or settlement agreements, in connection with the employment of any current, former or prospective employee of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All employees of the Company are currently properly classified and compensated by the Company in accordance with the Fair Labor Standards Act and state and local wage and hour Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is and at all times since March 2, 2021, has been in compliance in all material respects with any and all Laws related to mass layoff and plant closings, including the WARN Act, and the Company has no plans to undertake any action that would trigger any notice or payment or other obligation under the WARN Act. Since March 2, 2021, the Company has not incurred any material liability or obligation under the WARN Act or comparable state or local law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp; To the Knowledge of the Company, no current employee or independent contractor of the Company is in any material respect in violation of any term of any employment agreement, nondisclosure agreement, common law nondisclosure obligation, fiduciary duty, noncompetition agreement, restrictive covenant or other obligation to the Company.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To the Knowledge of the Company, no Key Employee is in any material respect in violation of any term of any employment agreement, nondisclosure agreement, common law nondisclosure obligation, fiduciary duty, non-competition agreement, non-solicitation agreement, restrictive covenant, Company policy or other obligation to any third-party as related to their employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp; To the Knowledge of the Company, no Key Employee has notified the Company or otherwise expressed that he/she intends to terminate his/her employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)To the Knowledge of the Company, since March 2, 2021, no current or former management or executive-level employee of the Company has engaged in or been alleged to have engaged in any act or conduct that constitutes a Misconduct Claim, and to the Knowledge of the Company, no such allegation is pending or threatened, or has been investigated, litigated or become the subject of administrative proceedings. Since March 2, 2021, the Company has not terminated any current or any former employee related to any Misconduct Claim, or entered into any settlement or settlement discussions with any person regarding a Misconduct Claim. Since March 2, 2021, the Company has established and made available to its employees a policy or policies against harassment and a complaint procedure, and has required all officers, managers and staff employees to undergo anti-harassment training.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10&nbsp;&nbsp;&nbsp;&nbsp; <u>Legal Proceedings</u>. There is no, and since March 2, 2021, there has been no, suit, action, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, audit, examination, inquiry, investigation or similar proceeding pending or, to the Knowledge of the Company, threatened against the Company or any of their respective former or current officers, directors or employees or properties (including any properties owned, operated, leased or licensed by the Company) or assets. There is no suit, action, litigation, arbitration or proceeding (including any civil, criminal, administrative or appellate proceeding) pending or threatened by the Company against any other Person. There is no, and since March 2, 2021, there has been no, Order against or, to the Knowledge of the Company, threatened or pending by any Governmental Authority involving the Company or any of their respective former or current officers, directors or employees or properties (including any properties owned, operated, leased or licensed by the Company) or assets. The Company has no current obligation under any settlement agreement, consent decree, waiver of rights or similar agreement or arrangement with respect to any suit, action, litigation, arbitration, proceeding, hearing, audit, examination, inquiry, investigation or similar proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11&nbsp;&nbsp;&nbsp;&nbsp; <u>Compliance with Applicable Laws</u>. At all times since March 2, 2021, the business of the Company has been conducted in accordance with all Laws applicable thereto (save and except for applicable U.S. marijuana-related federal laws and laws implicated by the violation of U.S. marijuana-related federal laws) and, to the Knowledge of the Company, the Company, nor any of its respective former or current officers, directors or employees, is or has been subject of or been requested to provide information in connection with any hearing, audit, examination, inquiry, investigation, notice, claim, charge or assertion with respect to any alleged failure to comply with any provision of applicable Law or been given any notice of any of the foregoing. At all times since March 2, 2021, except where any failure with respect to such Permits, individually or in the aggregate, has not had and would not reasonably be expected to have, a Company Material Adverse Effect, (a) the Company has been in possession of all Permits required by all applicable Laws to be held by it for the operation of the business of the Company or that are necessary to occupy the Company Leased Real Property or for the lawful ownership of its properties and assets and all fees and other amounts due with respect to such Permits have been paid; (b) the business of the Company has at all such times maintained and been in compliance in all material respects with all such Permits; and (c) all such Permits are in full force and effect and are not limited in duration or subject to conditions. There are no proceedings, actions or claims pending or threatened in writing (or, to the Knowledge of the Company, threatened orally) that would reasonably be expected to result in the termination, revocation, cancellation, suspension or modification of any such Permit, or any failure to comply in any respect with any term or requirement of such Permit. The Company has not been informed in writing or, to the Knowledge of the Company, orally by any applicable Governmental Authority of any actual or possible violation of any such Permit, or any failure to comply in any respect with any term or requirement of any such Permit. No event or condition has occurred or exists which would result in a violation of, breach, default or loss of a benefit under, or acceleration of an obligation of the Company under, or variation, suspension, revocation or non-renewal or non-variation by request of, any Permit (in each case, with or without notice or lapse of time or both). The Company has not, since March 2, 2021, conducted any internal investigation concerning any alleged violation of any applicable Law by the Company or any of its respective Representatives (regardless of the outcome of such investigation).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12&nbsp;&nbsp;&nbsp;&nbsp; <u>Environmental Matters</u>. (a) The Company is, and at all times since March 2, 2021, has been, in compliance in all material respects with all applicable Environmental Laws and all Permits required by Environmental Law ("<u>Environmental Permits</u>") required to own and operate the business and assets of the Company; (b) the Company, except as would not be reasonably expected to be material, has timely filed applications for, or for renewal of, all such Environmental Permits, and no action or proceeding is pending or, to the Knowledge of the Company, threatened to revoke, modify, suspend or terminate any such Environmental Permit; (c) the Company has not received any written notice or claim from any Person that alleges that the Company is in violation of, or has liability or responsibility under, any applicable Environmental Law; (d) there are no unresolved legal or administrative proceedings pending (x) alleging that the Company is liable for response actions to address a Release of a Hazardous Material, or (y) requesting information under the authority of any Environmental Law (including information requests under Section 104 of CERCLA or Section 114 of the Clean Air Act, 42 U.S.C. § 7401, et seq.); (e) to the Knowledge of the Company, there has been no Release of Hazardous Materials, nor are any Hazardous Materials present at any Company Leased Real Property, that would reasonably be expected to result in any responsibility or liability on the part of the Company; (f) to the Knowledge of the Company, there are no underground storage tanks present at any Company Leased Real Property, and (g) the Company has not assumed or provided indemnity against any liability under any Environmental Law, except with respect to any of the foregoing under (a), (b) or (c) as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. The representations and warranties set forth in this <u>Section 3.12</u> are the Company's sole and exclusive representations relating to environmental matters of any kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13&nbsp;&nbsp;&nbsp;&nbsp; <u>Contracts</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 3.13(a)</u> of the Disclosure Schedule sets forth, as of the Closing Date, a true and complete list, and the Company has made available to Buyer true and complete copies, of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each Contract to which the Company is a party that (A) restricts the ability of the Company or would, after the Closing, restrict in any material respect the ability of Buyer to compete in any business or with any Person or in any geographic area, (B) prohibits the Company from engaging in any business with any Person or levying a fine, charge or other payment for doing so, (C) contains "most favored nation," "exclusivity" or similar provisions, (D) grants any right of first refusal or right of first offer or similar right or (E) requires the purchase of all of the Company's requirements for a product or service from a third party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp; each Contract (A) related to Indebtedness of the Company other than any such agreement solely between the Company and one or more of its Affiliates or (B) that grants a Lien, other than a Company Permitted Lien, with respect to any material asset or property of the Company;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp; each Contract to which the Company is a party relating to (A) the formation, creation, operation, management or control of any partnership, joint venture, strategic alliance, collaboration or similar arrangement or (B) the ownership of any equity interest in any Person;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;&nbsp;&nbsp; each Contract between the Company, on the one hand, and on the other hand (A) any Key Employee of the Company or (B) to the Knowledge of the Company, any Affiliate of any such Key Employee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;&nbsp;&nbsp; each Contract relating to the disposition or acquisition by the Company of any Person, business organization, division or business of any Person (including through merger or consolidation or the purchase of a controlling equity interest in or substantially all of the assets of such Person or by any other manner), or of any assets (other than acquisitions or dispositions of assets in the Ordinary Course of Business), in each case, (A) with obligations (contingent or otherwise) remaining to be performed as of June 30, 2022, including any indemnification obligations, purchase price adjustment, any earn-out, backend payment or similar obligation, (B) with liabilities continuing after the Closing Date or (C) involving amounts in excess of $50,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;&nbsp;&nbsp; each Contract containing a grant of license, sublicense or any other right to the Company of any Company IP (other than Off-the-Shelf Software and Contracts concerning generally commercially available hardware or software pursuant to shrink-wrap, click-through or other standard licensing terms with annual license fees or similar payments not exceeding $25,000) (collectively, "<u>Company Inbound IP Contracts</u>");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)each Contract containing a grant of license, sublicense or any other right by the Company of any Company IP to any third party (other than as ancillary to the Company's receipt of services or equipment or in conjunction with a sale of products or services to customers in the Ordinary Course of Business) (collectively, "<u>Company Outbound IP Contracts</u>" and, together with the Company Inbound IP Contracts, the "<u>Company IP Contracts</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;&nbsp;&nbsp;&nbsp; each Contract to which the Company is a party that involves a Company Material Customer or a Company Material Supplier;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each Contract that is a settlement agreement that imposes obligations on the Company after the date of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each Contract obligating the Company to provide indemnification (other than arising in the Ordinary Course of Business of the Company or pursuant to any Company Material Contract;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)&nbsp;&nbsp;&nbsp;&nbsp; any Contract relating to any loan or other extension of credit made by the Company, other than accounts receivable in the Ordinary Course of Business of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii)&nbsp;&nbsp;&nbsp;&nbsp; each Contract providing for the development or construction of, or additions or expansions to, any real property, under which the Company has, or expects to incur, an obligation in excess of $50,000 in the aggregate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii)&nbsp;&nbsp;&nbsp;&nbsp; any Contract, including any joint venture, product development, research and development or limited partnership agreement, involving a sharing of profits, losses, costs or liabilities by the Company with any other Person; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv)any Contract to which the Company is a party that is with a Governmental Authority (each, a "<u>Company Governmental Contract</u>").

Each Contract described in this <u>Section 3.13(a)</u> and is referred to herein as a "<u>Company Material Contract</u>." There are no active or outstanding offers, bids, quotations or proposals to sell products made or services provided by the Company that, if accepted or awarded, would lead to any Contract or subcontract of the type described by any of the foregoing items in this <u>Section 3.13(a)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) Each Company Material Contract is a valid, binding and legally enforceable obligation of the Company, as the case may be, and, to the Knowledge of the Company, of the other parties thereto, except, in each case, as enforceability may be limited by bankruptcy, insolvency, reorganization or similar Laws affecting creditors' rights generally and by general principles of equity, (ii) each such Company Material Contract is in full force and effect, and (iii) the Company is not (with or without notice or lapse of time, or both) in breach or default under any such Company Material Contract and, to the Knowledge of the Company, no other party to any such Company Material Contract is (with or without notice or lapse of time, or both) in breach or default thereunder, except, in the case of clauses (i) or (ii), with respect to any Company Material Contract which expires by its terms (as in effect as of the Closing Date) or which is terminated in accordance with the terms thereof by the Company in the Ordinary Course of Business. The Company has not received any written notice regarding any actual or possible violation or breach of or default under, or intention to cancel or modify or intention not to renew, any Company Material Contract. The Company does not have any obligation (contingent or otherwise) to pay any amounts in respect of any indemnification obligations, purchase price adjustment, any earn-out, backend payment or similar obligation, in connection with any acquisition or disposition by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14&nbsp;&nbsp;&nbsp;&nbsp; <u>Real Property; Personal Property</u>.

 

<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company does not own nor has it ever owned any real property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 3.14(b)</u> of the Disclosure Schedule sets forth a true, correct and complete list of all existing leases, subleases and other agreements (the "<u>Company Real Property Leases</u>") under which the Company uses or occupies or has the right to use or occupy, now or in the future, any real property ("<u>Company Leased Real Property</u>"). The Company has made available to Buyer true, correct and complete copies of all Company Real Property Leases (including all modifications, amendments, supplements, waivers and side letters thereto). Each Company Real Property Lease is valid, binding and in full force and effect and enforceable against the Company, as applicable, and, to the Knowledge of the Company, each other party thereto in accordance with its terms, except to the extent such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or other similar Laws nor or hereafter in effect relating to creditors' rights generally, and (ii) general principles of equity (regardless of whether enforceability is considered in a proceeding at Law or in equity). Each Company Real Property Lease has sufficient remaining term thereunder (taking into account any available unexercised renewal or extension options for additional term) to allow the Company to continue operations without interruption in the normal course of business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is not (with or without notice or lapse of time, or both) in breach or default under any Company Real Property Lease in any material respect. To the Knowledge of the Company, no landlord under any Company Real Property Lease is (with or without notice or lapse of time, or both) in breach or default thereunder. The Company has not received any notice of default under any Company Real Property Lease which has not been fully cured and corrected. The Company has a good and valid leasehold interest in the Company Leased Real Property free and clear of all Liens, except for (A) those reflected or reserved against in the balance sheet of the Company as of June 30, 2022 and (B) Company Permitted Liens. The Company has not subleased, assigned, licensed or permitted the use or occupancy of all or any part of the Company Leased Real Property by any other party.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)There are no condemnation proceedings pending, or to the Knowledge of the Company, threatened affecting any portion of the Company Leased Real Property. To the Knowledge of the Company, there are (i) no material defaults under any easements, covenants, restrictions or similar matters affecting any portion of the Company Leased Real Property, (ii) no lawsuits or administrative actions or proceedings alleging violations of any Laws by any Company Leased Real Property, and (iii) no actual or threatened special assessments or reassessments of the Company Leased Real Property, and, in each case, the Company has not received any written notice thereof. The Company has not granted to any Person any option or right of first refusal to purchase or acquire or lease any portion of the Company Leased Real Property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has legal title to, or a valid and enforceable right to use, all equipment and other tangible personal property that is used or held for use in the operation of the business of the Company in the Ordinary Course of Business, in each case, free and clear of any and all Liens except Company Permitted Liens. Such equipment and other tangible personal property are all of the equipment and other tangible personal property that is necessary and sufficient for the operation of the business of the Company in the Ordinary Course of Business as presently conducted or as presently expected to be conducted. All of such equipment and other tangible personal property has been maintained in accordance with normal industry practice, is in good operating condition and repair (normal wear and tear excepted), and is suitable for the purposes for which it presently is used. <u>Section 3.14(e)</u> of the Disclosure Schedule sets forth a list of all laptops used by the Company Employees, which equipment, together with all equipment and other tangible property owned by either of Parent or Seller that is located within the Company Leased Real Property or within the remote locations of Company Employees and is used or held for use in the operation of the business of the Company shall be deemed owned by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.15<u>Intellectual Property</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Section 3.15(a)</u> of the Disclosure Schedule sets forth a true and complete list of all non-expired registrations and applications for Intellectual Property Rights that are owned by the Company ("<u>Company Registered IP</u>"), including the applicable (i) jurisdiction of application/registration, (ii) application or registration number, (iii) date of filing or issuance, and (iv) owner. The Company is the sole and exclusive owner of all of the Company Registered IP. All required filings and fees related to the Company Registered IP have been timely filed with and paid to the relevant Governmental Authority and authorized registrars, and all Company Registered IP is otherwise in good standing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 3.15(b)</u> of the Disclosure Schedule sets forth a true and complete list of all Company IP that is not Company Registered IP. The Company exclusively owns or has the right to use all Company IP, free and clear of all Liens (other than Permitted Liens). All Company IP owned by the Company ("<u>Owned Company IP</u>") and, to the Knowledge of the Company, all Company IP licensed to the Company by a third party ("<u>Licensed Company IP</u>") is subsisting, enforceable and valid, and has not expired or been canceled or abandoned. The consummation of the Transactions will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent of any other Person in respect of, the Company's right to own, use or hold for use any Intellectual Property Rights as owned, used or held for use in the conduct of the Company's operations. The Company is not bound by, and no Owned Company IP and, to the Knowledge of the Company, no Licensed Company IP is subject to, any Contract containing any covenant or other provision that limits or restricts, in any material respect, the ability of the Company to use, exploit, assert, or enforce any of the Company IP. The Company will continue to own or have immediately after the Closing valid rights or licenses as are sufficient to use all of the Company IP to the same extent as prior to the Closing. The consummation of the Transactions will not result in the loss or impairment of the Company's rights in any Company IP and will not result in the breach of, or create on behalf of any third party, the right to terminate or modify any agreement as to which the Company is a party and pursuant to which the Company is authorized or licensed to use any third party Intellectual Property Right.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; None of: (i) the Owned Company IP, (ii) to the Knowledge of the Company, the Licensed Company IP, (iii) the products or services of the Company (the "<u>Company Products and Services</u>"), or (iv) the operation of the business of the Company, in each case (i)-(iv), infringes, misappropriates or otherwise violates, or has formerly infringed, misappropriated, or otherwise violated, any Intellectual Property Rights owned by another Person. There are, and have been formerly, no threats, claims, suits, actions or other proceedings (including any oppositions, interferences, reviews, or re-examinations) settled or pending or, to the Knowledge of the Company, threatened in writing that allege any such infringement, misappropriation or violation or challenging the validity, enforceability, registrability, or ownership of any Owned Company IP or, to the Knowledge of the Company, the Licensed Company IP. None of the Owned Company IP or, to the Knowledge of the Company, the Licensed Company IP is subject to any outstanding Order or stipulation restricting or limiting in any material respect the ownership, use or licensing thereof by the Company as currently or contemplated to be used or licensed, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To the Knowledge of the Company, no Person is infringing, misappropriating or otherwise violating any Company IP, and no such claims are pending or threatened in writing against any Person by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has taken commercially reasonable steps to maintain and protect, and to provide for the continuity, integrity, and security of, trade secrets and other confidential information of or held by the Company, including requiring all Persons having access thereto to execute written non-disclosure agreements. The Company has used commercially reasonable efforts to enter into written agreements with current and former employees of the Company, and with current and former independent contractors, who are or were involved in or have contributed to the invention, creation, or development of any Intellectual Property Rights during the course of employment or engagement with the Company, whereby the employee or independent contractor (1) acknowledges the Company's exclusive ownership of all Intellectual Property Rights invented, created, or developed by such employee or independent contractor within the scope of his or her employment or engagement with the Company; (2) grants to the Company a present, irrevocable assignment of any ownership interest such employee or independent contractor may have in or to such Intellectual Property Rights, to the extent such Intellectual Property Rights do not constitute a "work made for hire" under applicable Law; and (3) irrevocably waives any right or interest, including any moral rights, regarding any such Intellectual Property Rights, to the extent permitted by applicable Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Business Systems of the Company (collectively, "<u>Company Business Systems</u>") are reasonably sufficient for the immediate and anticipated needs of the business and operations of the Company, including as to capacity, scalability, and ability to process current and anticipated peak volumes in a timely manner. The Company Business Systems are in sufficiently good working condition to perform all information technology operations and include sufficient licensed capacity (whether in terms of authorized sites, units, users, seats or otherwise) for all software, in each case as necessary for the conduct of the business and operations of the Company as currently conducted and as currently contemplated to be conducted. The Company maintains commercially reasonable back-up and data recovery, disaster recovery and business continuity plans, procedures and facilities, acts in compliance therewith, and tests such plans and procedures on a regular basis, and such plans and procedures have been proven effective in all material respects upon such testing.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company's data, privacy and security practices comply, and at all times have complied, in all material respects, with applicable Data Protection and Security Requirements. The Company has provided all notices and obtained all consents required by Data Protection and Security Requirements and satisfied all other requirements under Data Protection and Security Requirements for the processing of Personal Data and that are necessary for the conduct of business as currently conducted, as proposed to be conducted, and in connection with the consummation of the Transactions. The Transactions as of the Closing Date will comply with all Data Protection and Security Requirements applicable to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has implemented and at all times has maintained reasonable and appropriate organizational, physical, administrative and technical measures consistent with the state of the art for the industry in which the Company operates to protect the operation, confidentiality, integrity and security of all of the Company's confidential and other data and information, in any format, generated or used in the conduct of the business of the Company ("<u>Company Business Data</u>") and the Company Business Systems, against misuse. Without limiting the generality of the foregoing, the Company has implemented a comprehensive written information security program that complies with 45 C.F.R. Part 164, Subpart C and (i) identifies internal and external risks to the security of the Company Business Data or Company Business Systems and (ii) implements, monitors and improves adequate and effective safeguards to control those risks. The Company has not (nor has any Person acting on the Company's behalf) experienced any actual or alleged Security Incident, including, without limitation, any "breach" (as defined in 45 C.F.R. Part 164, Subpart D) of unsecured Protected Health Information or of EU Personal Data. The Company has not (nor has any Person acting on the Company's behalf) notified, and the Company has not experienced any event resulting in any requirement that the Company notify, any Person or Data Protection Authority of any Security Incident, including any loss or unauthorized access, use or disclosure, of EU Personal Data or of Protected Health Information that would constitute a breach for which notification to individuals, the media, or the HHS is required under 45 C.F.R. Part 164, Subpart D. In addition, the Company has not any material data security, information security or other technological vulnerabilities that could adversely impact the operation of relevant Company Business Systems or cause a Security Incident. The Company Business Systems have not materially malfunctioned or failed since March 2, 2021, and are free from material bugs and other defects and do not contain any "virus," "worm," "spyware" or other malicious software.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp; The Company has obligated all third party service providers, outsourcers, and processors of confidential information on their behalf and all third parties managing Company Business Systems on their behalf to appropriate contractual terms relating to the processing of Company Business Data (as applicable and as required by Data Protection and Security Requirements) and information security and have taken reasonable measures to ensure that such third parties have complied with their contractual obligations. Without limiting the generality of the foregoing, the Company has entered into business associate agreements with vendors and customers in all situations where required by 45 C.F.R. §§ 164.502(e) and 164.504(e) or Article 28 of the GDPR. The Company has taken reasonable measures to ensure that all third parties acting on its behalf have complied with their contractual obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has not received any notice of any claims, investigations (including investigations by any Governmental Entity, including the HHS Office for Civil Rights and any other Data Protection Authority), for alleged violations of Data Protection and Security Requirements with respect to Personal Data subject to Processing by, or under the control of, Company, and, to the Knowledge of the Company, there are no facts or circumstances that are likely to form the basis for any such claims, investigations or allegations.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 3.15(k)</u> of the Disclosure Schedule contains a complete and accurate list of all Software (i) that is used by the Company and for which the Company is the licensee or which the Company has otherwise obtained the right to use, other than Off-the-Shelf Software ("<u>Licensed Software</u>") and (ii) developed by the Company and that is used in the business of the Company ("<u>Company Owned Software</u>"). <u>Section 3.15(k)</u> of the Disclosure Schedule also sets forth a list of all license fees, rents, royalties or other charges that the Company has paid with respect to the Licensed Software in 2022. The Company is in compliance with all material provisions of any Contract pursuant to which the Company has the right to use the Licensed Software.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Section 3.15(l)</u> of the Disclosure Schedule identifies all Open Source Technology that is or has been used by the Company in the development of or incorporated into, combined with, linked with, distributed with, provided to any Person as a service, provided via a network as a service or application, or otherwise made available with, any Company Owned Software. The Company has not used any Open Source Technology in a manner that requires, or would reasonably be expected to require, the (i) disclosure or distribution of any Company Owned Software in source code form, (ii) license or other provision of any Company Owned Software on a royalty-free basis, or (iii) grant of any license, non-assertion covenant or other rights or immunities under any Company Owned Software or rights to modify, make derivative works based on, decompile, disassemble or reverse engineer any Company Owned Software, including any "copyleft" license. The Company has complied with all notice, attribution and other requirements of each license applicable to the Open Source Technology disclosed in <u>Section 3.15(l)</u> of the Disclosure Schedule.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp; No Company Owned Software (or, to the Knowledge of the Company, other Software) used in the business or operations of the Company or provision of any Company Product and Service contains any "time bomb," "Trojan horse," "back door," "worm," virus, malware, spyware, or other device or code ("<u>Malicious Code</u>") designed or intended to, or that would reasonably be expected to, (1) disrupt, disable, harm or otherwise impair in any material respect the normal and authorized operation of, or provide unauthorized access to, any computer system, hardware, firmware, network or device on which any such Software is installed, stored or used, or (2) damage, destroy or prevent the access to or use of any data or file without the user's consent. The Company has taken reasonable steps to prevent the introduction of Malicious Code into Company Owned Software used in the provision of any Company Products and Services, or otherwise in the business or operations of the Company. The Company (A) has provided to Buyer all of the Open Source Technology and all software containing, relying on, or derived from Open Source Technology, and (B) have not added or removed any portion of the Open Source Technology, or any portion of software containing, relying on, or derived from Open Source Technology, prior to or after March 2, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is in actual possession of and has exclusive control over all source code for all Company Owned Software. The Company possesses all source code and other documentation and materials necessary or useful to compile, maintain and operate all Company Owned Software. Except for application programming interfaces and other interface code that is generally available to customers, the Company has not disclosed, delivered, licensed or otherwise made available, and do not have a duty or obligation (whether present, contingent or otherwise) to disclose, deliver, license or otherwise make available, any source code for any Company Owned Software to any escrow agent or any other Person, other than (i) an employee, independent contractor or consultant of the Company pursuant to a valid and enforceable written agreement prohibiting use or disclosure except in the performance of services for the Company, or (ii) an independent third-party escrow agent pursuant to a valid and enforceable written source code escrow agreement providing for limited release only upon the occurrence of specified release events, and no such release event has occurred, and no circumstance or condition exists that would reasonably be expected to result in the occurrence of any such release event. Without limiting the foregoing, neither the execution of this Agreement nor the consummation of any of the Transactions will, or would reasonably be expected to, result in the release from escrow or other delivery to any Person of any source code for any Company Owned Software.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has provided a true and complete list of all known bugs, errors and defects and any other problem or issue with respect to any Software included in the Company products and services that materially adversely affect, or would reasonably be expected to materially adversely affect, the value, functionality, or performance of any of the Company products or services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.16&nbsp;&nbsp;&nbsp;&nbsp; <u>Certain Payments and Practices</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Since March 2, 2021, neither the Company nor any of their respective directors, officers or employees, or, to the Knowledge of the Company, any agent or other third party representative, has, in the course of his actions for, or on behalf of, any of them (i) made any unlawful payment, contribution, gift, entertainment or other unlawful expense relating to political activity, (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee, or (iii) violated any provision of any of the U.S. Foreign Corrupt Practices Act of 1977 or any similar applicable Law of any other jurisdiction (collectively, the "<u>Anti-Corruption Laws</u>"). Since March 2, 2021, the Company has not received any communication that alleges that the Company, or any of their respective Representatives, is, or may be, in violation of, or has, or may have, any liability under, any Anti-Corruption Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; None of the Company or any of its respective directors, officers or employees, or to the Knowledge of the Company, any agent or other third party representative acting on behalf of the Company are, or have been, since March 2, 2021, targets of U.S. economic sanctions or trade controls, including but not limited to being identified on the SDN List. Without limitation to the foregoing, neither the Company nor any of its respective directors, officers, or employees, nor to the Knowledge of the Company, any agent or other third party representative acting on behalf of the Company are, or have been since March 2, 2021, conducting any business with any Person, directly or indirectly, identified on the SDN List.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is and at all times since March 2, 2021, has been in compliance in all material respects with all applicable export control and sanctions requirements, including compliance with the Office of Foreign Assets Control of the Treasury Department, the Department of Commerce, and the Department of State for the export or re-export of any item, service, industry, product, article, commodity or technical data.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.17&nbsp;&nbsp;&nbsp;&nbsp; <u>Product Warranty and Liability</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Company has delivered to Buyer true, accurate and complete forms of the Company's customer agreements which contain customary customer warranties with respect to the Company Products and Services. To the Knowledge of the Company, all such Company Products and Services have been in conformity in all material respects with all applicable contractual commitments and all express and implied warranties, and, to the Knowledge of the Company, there are no situations, events, facts or circumstances that would reasonably be expected to give rise to any material liability for replacement or repair thereof or other damages in connection therewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; Since March 2, 2021 the Company has not made any other written material warranties (which remain in effect) with regard to its Company Products and Services. To the Knowledge of the Company, there are no inherent design defects or systemic or chronic problems in any Company Products and Services.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.18&nbsp;&nbsp;&nbsp;&nbsp; <u>Suppliers and Customers</u>. <u>Section 3.18</u> of the Disclosure Schedule sets forth a complete and accurate list of (a) the top twenty (20) trade vendors/suppliers of the Company based on payments made to the applicable trade vendor/supplier by the Company for each of the years ended December 31, 2021 and 2022 (the "<u>Company Material Suppliers</u>"); (b) the top twenty (20) customers of the Company based on revenue provided by the applicable customer to the Company for each of the years ended December 31, 2021 and 2022; and (c) each Governmental Authority that is a party to a Company Governmental Contract as of the Closing Date (clauses (b) and (c), the "<u>Company Material Customers</u>"). The relationships of the Company with each Company Material Supplier and Company Material Customer are good commercial working relationships. Since March 2, 2021, no Company Material Supplier or Company Material Customer has canceled or otherwise terminated or not renewed, or to the Knowledge of the Company threatened to, cancel or otherwise terminate or not renew, its relationship with the Company. Since March 2, 2021, the Company has not received any written notice that any Company Material Supplier or Company Material Customer may cancel or not continue its relationship with the Company or limit its services, supplies or materials to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19&nbsp;&nbsp;&nbsp;&nbsp; <u>Brokers' Fees and Expenses</u>. No broker, investment banker, financial advisor or other Person, is entitled to any broker's, finder's, financial advisor's or other similar fee or commission in connection with the Merger or any of the other Transactions based upon arrangements made by or on behalf of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.20&nbsp;&nbsp;&nbsp;&nbsp; <u>Insurance</u>. Parent maintains insurance coverage with reputable insurers in such amounts and covering such risks as Parent reasonably believes, based on past experience, is adequate for the businesses and operations of the Company (taking into account the cost and availability of such insurance) ("<u>Parent Insurance Policies</u>"). The Company does not maintain any separate insurance policies that cover its operations. All Parent Insurance Policies (a) are in full force and effect; (b) are sufficient for compliance by the Company with all Company Material Contracts and (c) provide insurance in such amounts and against such risks as Parent reasonably has determined to be prudent, taking into account the industries in which the Company operates, and as is sufficient to comply with applicable Law. None of the Parent Insurance Policies will terminate or lapse by its terms by reason of the consummation of the Transactions; *provided, however*, that all coverage with respect to the Company under the Parent Insurance Policies will terminate upon the consummation of the Transactions. There is no claim by the Company pending under any of the Parent Insurance Policies as to which coverage has been questioned, denied or disputed by the underwriters of such policies or bonds or in respect of which such underwriters have reserved their rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.21&nbsp;&nbsp;&nbsp;&nbsp; <u>Related Party Transactions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; Since March 2, 2021, there have not been, nor are there currently, any transactions, Contracts, arrangements, understandings, undertakings, obligations, liabilities or claims between the Company, on the one hand, and any Person (i) that is Affiliate of the Company, (ii) that is a stockholder, member, partner, manager, director or officer of the Company, (iii) that is a Family Member of any stockholder, member, partner, manager, director or officer of the Company, or (iv) with respect to which any of the Persons described in clauses (i), (ii) or (iii) of this <u>Section 3.21(a)</u> owns more than ten percent (10%) of the voting equity of such Person (each, a "<u>Company Related Party</u>"), on the other hand (each, a "<u>Company Related Party Transaction</u>"). Any such Company Related Party Transactions were entered into in the Ordinary Course of Business and on commercially reasonable terms and conditions. Any accounts due and payable by the Company to any Company Related Party are recorded on the Company's books and records, as the case may be, at their fair market value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No Company Related Party has or has had, directly or indirectly, (i) an economic interest in any Person that purchases from or sells or furnishes to, the Company, any goods or services, (ii) a beneficial interest in any Contract to which the Company is a party or by which it or its properties or assets are bound or directly or indirectly owns, or otherwise has any right, title or interest in, to or under, any material property or right, tangible or intangible, that is or is currently contemplated to be used by the Company, (iii) an ownership interest in any assets or rights of, or used by, the Company; provided, however, that ownership of no more than two percent (2%) of the outstanding voting stock of a publicly traded corporation shall not be deemed an "economic interest in any Person" for purposes of this <u>Section 3.21(b)</u> or (iv) is indebted to or, at any time since March 2, 2021, has borrowed money from or lent money to the Company.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.22&nbsp;&nbsp;&nbsp;&nbsp; <u>Accounts Receivable</u>. Subject to a reserve for bad debts shown on the balance sheet contained in the Interim Financial Statements, each account receivable that has been billed is (a) valid and existing and represents monies due (or believed in good faith to be due) for goods sold and delivered and services performed in the Ordinary Course of Business and (b) a legally binding obligation of the account debtor enforceable in accordance with its terms not subject to refunds, discounts (other than trade discounts provided in the Ordinary Course of Business), setoffs, adverse claims, counterclaims, assessments, defaults, prepayments, defenses or conditions precedent, subject to the effect of any Laws relating to bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance or preferential transfers, or similar Laws relating to or affecting creditors' rights generally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.23&nbsp;&nbsp;&nbsp;&nbsp; <u>Bank Accounts</u><u>. Section 3.23</u> of the Disclosure Schedule sets forth a true, complete and correct list of each of the bank accounts in the name of the Company, including the title and number of the account, the individuals with signatory authority over such account and the financial institution at which such account is located.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.24&nbsp;&nbsp;&nbsp;&nbsp; <u>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</u>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN <u>SECTION 3</u>, THE COMPANY EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, INCLUDING AS TO THE CONDITION, VALUE OR QUALITY OF ITS BUSINESS OR ASSETS, AND THE COMPANY SPECIFICALLY DISCLAIMS ANY AND ALL REPRESENTATIONS OR WARRANTIES OF ANY KIND, INCLUDING AS TO MERCHANTABILITY, USAGE, SUITABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WITH RESPECT TO ITS ASSETS, ANY PART THEREOF, THE WORKMANSHIP THEREOF, AND THE ABSENCE OF ANY DEFECTS THEREIN, WHETHER LATENT OR PATENT, IT BEING UNDERSTOOD THAT SUCH SUBJECT ASSETS ARE BEING ACQUIRED "AS IS, WHERE IS" AND "WITH ALL FAULTS" ON THE CLOSING DATE, AND IN THEIR PRESENT CONDITION, AND BUYER SHALL RELY SOLELY ON ITS OWN EXAMINATION AND INVESTIGATION THEREOF AS WELL AS THE REPRESENTATIONS AND WARRANTIES OF THE COMPANY SET FORTH IN <u>SECTION 3</u> OF THIS AGREEMENT.

#### SECTION 4

#### REPRESENTATIONS AND WARRANTIES OF SELLER
In order to induce Buyer to enter into and perform this Agreement and to consummate the Transactions, Seller hereby represents and warrants to Buyer that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1<u>Organization</u>. Seller is duly organized, validly existing and in good standing (to the extent such concept exists in the applicable jurisdiction) under the Law of its jurisdiction of incorporation or formation, as applicable, and has the requisite corporate power and authority to own, lease and operate its assets and properties and to carry on its business as it is now being conducted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Power and Authorization</u>. Seller has the power and authority to execute and deliver each Transaction Agreement to which it is a party and each other document, instrument and/or certificate contemplated thereby and to consummate the Transactions. The execution and delivery of the Transaction Agreements to which it is a party and the consummation of Transactions have been duly authorized by all necessary action on the part of Seller. Each of the Transaction Agreements that Seller is a party to has been duly executed and delivered by Seller and constitute a valid, legal and binding agreement of Seller (assuming that the Transaction Agreements have been duly and validly authorized, executed and delivered by the other Persons party thereto), enforceable against Seller in accordance with its terms, except (a) to the extent that enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting the enforcement of creditors' rights generally and (b) that the availability of equitable remedies, including specific performance, is subject to the discretion of the court before which any claim thereof may be brought.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3&nbsp;&nbsp;&nbsp;&nbsp; <u>Consents and Approvals; No Violations</u>. No action by (including any authorization, consent or approval), or in respect of, or filing with, any Governmental Authority is required for, or in connection with, the valid and lawful (a) authorization, execution, delivery and performance by Seller of the Transaction Agreements to which it is a party or (b) consummation of the Transactions by Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4&nbsp;&nbsp;&nbsp;&nbsp; <u>Noncontravention</u>. Neither the execution, delivery and performance by Seller of the Transaction Agreements to which it is a party nor the consummation of the Transactions will: (a) violate any provision of any Order applicable to Seller; (b) result in a breach or violation of, or default under, any Contract of Seller related to the Company; (c) require any action by (including any authorization, consent or approval) or in respect of (including notice to), any Person under any Contract related to the Company or Seller; or (d) result in a breach or violation of, or default under, (1) Seller's organization documents; or (2) the 2020 Merger Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Title</u>. Seller is the record and beneficial owner of all outstanding shares of Company Common Stock, and has good and marketable title to such shares, free and clear of all Liens except as are imposed by applicable securities laws. Seller has full right, power and authority to transfer and deliver to Buyer valid title to such shares of Company Common Stock, free and clear of all Liens. The assignment and other instruments of transfer delivered by Seller to Buyer at the Closing will be sufficient to transfer Seller's entire interest, legal and beneficial, in such shares and, immediately following the Closing, Buyer will be the record and beneficial owners of such shares, and have good and marketable title to such shares, free and clear of all Liens except as are imposed by applicable securities laws. Except as pursuant to this Agreement, there is no contract pursuant to which Seller has, directly or indirectly, granted any option, warrant or other right to any Person to acquire or vote any equity interests in Seller or the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Brokers</u>. Seller has no Liability of any kind to any broker, finder or agent in connection with the Transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Taxes</u>. Seller is eligible to make an election under Section 338(h)(10) of the Code with respect to the sale of the Company.

#### SECTION 5

#### REPRESENTATIONS AND WARRANTIES OF BUYER
As a material inducement to the Company to enter into this Agreement, Buyer hereby represents and warrants to Seller that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1&nbsp;&nbsp;&nbsp;&nbsp; <u>Organization</u>. Buyer is duly organized, validly existing and in good standing (to the extent such concept exists in the applicable jurisdiction) under the Law of its jurisdiction of incorporation or formation, as applicable, and has the requisite corporate power and authority to own, lease and operate its assets and properties and to carry on its business as it is now being conducted.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2&nbsp;&nbsp;&nbsp;&nbsp; <u>Power and Authorization</u>. Buyer has the power and authority to execute and deliver the Transaction Agreements and each other document, instrument and/or certificate contemplated by the Transaction Agreements and to consummate the Transactions. The execution and delivery of the Transaction Agreements and the consummation of Transactions have been duly authorized by all necessary action on the part of Buyer. Each of the Transaction Agreements have been duly executed and delivered by Buyer and constitute a valid, legal and binding agreement of Buyer (assuming that the Transaction Agreements have been duly and validly authorized, executed and delivered by the other Persons party thereto), enforceable against Buyer in accordance with its terms, except (a) to the extent that enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting the enforcement of creditors' rights generally and (b) that the availability of equitable remedies, including specific performance, is subject to the discretion of the court before which any claim thereof may be brought.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3&nbsp;&nbsp;&nbsp;&nbsp; <u>Consents and Approvals; No Violations</u>. Assuming the truth and accuracy of the representations and warranties of the Company set forth in <u>Section 3.4</u>, no action by (including any authorization, consent or approval), or in respect of, or filing with, any Governmental Authority is required for, or in connection with, the valid and lawful (a) authorization, execution, delivery and performance by Buyer of the Transaction Agreements to which it is a party or (b) consummation of the Transactions by Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4<u>Solvency</u>. Assuming the representations and warranties of the Company contained in <u>Section 3</u> are true in all material respects, at and immediately after the Closing Date, and after giving effect to the Transactions, the Company (a) will be solvent (in that both the fair value of its assets will not be less than the sum of its debts and that the present fair saleable value of its assets will not be less than the amount required to pay its probable liability on its debts as they become absolute and matured), (b) will have adequate capital with which to engage in its business, and (c) will not have incurred and does not immediately plan to incur debts beyond its ability to pay as they become absolute and matured.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5&nbsp;&nbsp;&nbsp;&nbsp; <u>Investment Representation</u>. The Buyer is purchasing the shares of Company Common Stock for its own account with the present intention of holding such shares for investment purposes and not with a view to or for sale in connection with any public distribution of such shares of Company Common Stock in violation of any Federal or state securities Laws. The Buyer is an "accredited investor" as defined in Rule 501 of Regulation D promulgated under the Securities Act. The Buyer acknowledges that it is informed as to the risks of the Transactions and of ownership of the shares of Company Common Stock. The Buyer acknowledges that the shares have not been registered under the Securities Act or any state or foreign securities Laws and that the shares of Company Common Stock may not be sold, transferred, offered for sale, pledges, hypothecated or otherwise disposed of unless such sale, transfer, offer, pledge, hypothecation or other disposition is pursuant to the terms of an effective registration under the Securities Act and are registered under any applicable state or foreign securities Laws or pursuant to an exemption from registration under the Securities Act and any applicable state or foreign securities Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Financial Ability</u>. Buyer has or will have sufficient Cash to enable Buyer to pay each Subsequent Cash Payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>No Brokers</u>. No broker, finder or agent is entitled to any brokerage fees, finder's fees or commissions in connection with the Transactions based upon arrangements made by or on behalf of the Buyer.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8&nbsp;&nbsp;&nbsp;&nbsp; <u>Acknowledgment and Representations by Buyer</u>. Buyer acknowledges and agrees that it (a) has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of the Company and (b) has been furnished with or given full access to such information about the Company and its business and operations as it has requested. In entering into this Agreement, Buyer has relied solely upon its own investigation and analysis and the representations and warranties of the Company expressly set forth in <u>Section 3</u> and the representations and warranties of Seller expressly set forth in <u>Section 4</u>, and Buyer acknowledges that, other than as expressly set forth in <u>Section 3</u> and <u>Section 4</u>, neither the Company or any of its directors, officers, employees, Affiliates, stockholders, agents or representatives makes or has made any representation or warranty, either express or implied, (a) as to the accuracy or completeness of any of the information (whether in any "data room" or otherwise) provided or made available to Buyer, or any of its agents, representatives, lenders or Affiliates prior to the Closing Date, or (b) with respect to any projections, forecasts, estimates, plans or budgets of future revenues, expenses or expenditures, future results of operations (or any component thereof), future cash flows (or any component thereof) or future financial condition (or any component thereof) of the Company heretofore or hereafter delivered to or made available to Buyer, or any of its agents, representatives, lenders or Affiliates.

#### SECTION 6

#### COVENANTS
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Confidentiality</u>. The Parties hereto acknowledge that Buyer and Parent previously executed the Confidentiality Agreement, which shall continue in full force and effect in accordance with its terms and regarding which each of Buyer and its Representatives (as defined in the Confidentiality Agreement) shall be deemed to be a Disclosing Party and Recipient thereunder, as applicable (each as defined in the Confidentiality Agreement). Each of Buyer and the Company agrees that it and its representatives shall, except as otherwise permitted by and subject to compliance with <u>Section</u> <u>9.16</u>, hold the terms of this Agreement, and the fact of this Agreement's existence, in strict confidence both prior to and following the Closing. At no time, whether prior to or following the Closing, shall any of the Parties hereto disclose any of the terms of this Agreement (including the economic terms) or any non-public information about a Party to any other Person without the prior written consent of the Party about which such non-public information relates (which, after the Closing, shall require the consent of the Seller with respect to information of the Company). Notwithstanding anything to the contrary in the foregoing, a Party and its representatives shall be permitted to disclose any and all terms of this Agreement to (a) its financial, tax and legal advisors and other representatives or (b) any other Person for whom consent, notice, waiver or approval is required in connection with the Transactions, solely for the purpose of satisfying such consent, notice, waiver or approval requirement, in each case specified in the foregoing clauses (a) and (b), each of whom is subject to a similar obligation of confidentiality; (c) any Governmental Authority or administrative agency (including the Securities and Exchange Commission and any national securities exchange) to the extent necessary or advisable in compliance with applicable Law; (d) the courts or arbitrator involved in dispute resolution proceedings; (e) any Taxing Authority in connection with any Tax audit, examinations or other similar Tax proceeding involving any Tax Return or Tax matters and (f) Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Tax Matters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Transfer Taxes</u>. Notwithstanding anything in this Agreement to the contrary, all transfer, documentary, sales, use, value added, goods and services, excise, stock transfer, stamp, recording, registration and any similar Taxes and fees, including any penalties and interest thereon, that become payable in connection with the Transactions ("<u>Transfer Taxes</u>") shall be paid fifty percent (50%) by Seller and fifty percent (50%) by Buyer, regardless of the Party liable for such obligations under applicable Law or the Party making payment to the applicable Governmental Authority or other third party. The applicable Parties shall cooperate in filing such forms, declarations, affidavits, Tax Returns, and documents as may be necessary, including to permit any such Transfer Tax to be assessed and paid on or prior to the Closing Date in accordance with any available presale filing procedure, and to obtain any exemption or refund of any such Transfer Tax.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Cooperation on Tax Matters</u>. Seller and Buyer shall cooperate, as and to the extent reasonably requested by any other Party, in connection with the filing of Tax Returns, and any audit, litigation or other proceeding with respect to Taxes. Such cooperation shall include the retention and (upon the other party's request) the provision of records and information which are reasonably relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Responsibility for Filing Tax Returns</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seller shall prepare and timely file, or shall cause to be prepared and timely filed, all Tax Returns in respect of the Company that are required by Law to be filed on or before the Closing Date, and shall timely pay, or cause to be timely paid, all Taxes of due thereof. Further, Seller shall include the income and activities of the Company for the Tax period ending on the Closing Date in Seller's consolidated federal income Tax Return (the "<u>Federal Consolidated Income Tax Return</u>") and timely pay all Taxes due thereon. At least thirty (30) days prior to the date on which the Federal Consolidated Income Tax Return is due, Seller shall submit the portions of the Federal Consolidated Income Tax Return relating to the Company (including all relevant work papers and other items required to understand such Federal Consolidated Income Tax Return or other items as reasonably requested by Buyer) to Buyer for review and comment, and Seller shall incorporate all reasonable comments received no less than five (5) days prior to the due date thereof. For the avoidance of doubt, in the event Buyer makes the Section 338(h)(10) Election, Seller shall timely pay and include any and all Taxes attributable thereto in the Federal Consolidated Income Tax Return. After the Closing, Seller shall not file any amended or original federal income or other material Tax Return (other than the Federal Consolidated Income Tax Return) if such Tax Return would cause the Company to incur or pay any Taxes unless (A) such Taxes are fully paid by Seller with such filing and (B) Buyer consents to such filing (such consent not to be unreasonably withheld or delayed).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp; Other than the Federal Consolidated Tax Return, Buyer, at its expense, shall prepare and timely file, or cause the Company to prepare and timely file, all Tax Returns of the Company required to be filed after the Closing Date (taking into account extensions) with respect to any Pre-Closing Tax Period or Straddle Period ("<u>Pre-Closing Tax Returns</u>"). Such Pre-Closing Tax Returns shall be prepared on a basis consistent with existing procedures, practices and accounting methods of the Company, unless otherwise required by applicable Law and all Transaction Tax Deductions will be treated as properly allocable to the Pre-Closing Tax Period to the maximum extent permitted by applicable Law (at a "more likely than not" (or higher) level of comfort). At least thirty (30) days prior to the date on which each such Pre-Closing Tax Return is due or any amendment is to be made to a Pre-Closing Tax Return, Buyer shall submit such Pre-Closing Tax Return (and all relevant work papers and other items required to understand such Pre-Closing Tax Return or other items as reasonably requested by Seller) to Seller for review and comment, and Buyer shall incorporate all reasonable comments received no less than five (5) days prior to the due date thereof. Buyer shall remit, or cause to be remitted, to the appropriate Governmental Authority all Taxes reflected on such Pre-Closing Tax Returns; *provided*, *however*, that Sellers shall within five (5) days of Buyer's remittance reimburse Buyer for any and all such Taxes that are allocable to the Pre-Closing Tax Period (and, in case of a Straddle Period, determined in accordance with <u>Section 6.2(c)(iii)</u>).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp; In the case of any Straddle Period, the amount of any Taxes (and any refunds of Taxes) based on or measured by income, receipts, sales, use or payroll of the Company for the Pre-Closing Tax Period shall be determined based on an interim closing of the books as of the close of business on the Closing Date and the amount of other Taxes (and any refunds of other Taxes) of the Company for a Straddle Period that relates to the Pre-Closing Tax Period shall be deemed to be the amount of such Tax for the entire taxable period multiplied by a fraction the numerator of which is the number of days in the taxable period ending on and including the Closing Date and the denominator of which is the number of days in such Straddle Period.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>338(h)(10) Election</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At Buyer's option, the Company and Seller shall join with Buyer in making a timely election under Section 338(h)(10) of the Code (and any election corresponding to Section 338(h)(10) or Section 338(g) of the Code under state, local, and foreign Law) with respect to the purchase and sale of the shares of the Company hereunder (collectively, a "<u>Section 338(h)(10) Election</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp; If a Section 338(h)(10) Election is made, Seller and Buyer agree that the Purchase Price and the liabilities of the Company (plus other relevant items) shall be allocated among the assets of the Company for all purposes (including Tax and financial accounting) as shown on the allocation schedule prepared in accordance with Code Sections 338 and 1060 (the "<u>Allocation Schedule</u>"). A draft of the Allocation Schedule shall be prepared by Seller and delivered to Buyer within thirty (30) days following the Closing Date for its approval. If Buyer notifies Seller in writing that Buyer objects to one or more items reflected in the Allocation Schedule, Buyer and Seller shall negotiate in good faith to resolve such dispute; *provided*, *however*, that if Buyer and Seller are unable to resolve any dispute with respect to the Allocation Schedule within sixty (60) days following the Closing Date, such dispute shall be resolved by the Independent Accountant. The fees and expenses of the Independent Accountant shall be borne equally by Seller and Buyer. Buyer, the Company and Seller shall file all Tax Returns (including amended returns and claims for refund) and information reports in a manner consistent with the Allocation Schedule.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp; Buyer and Seller shall cooperate in the preparation of all forms, attachments and schedules necessary to effectuate the Section 338(h)(10) Election, including IRS Forms 8023 and 8883 and any similar forms under applicable state and local income Tax Laws (collectively, the "<u>Section 338(h)(10) Forms</u>") in a manner consistent with the Allocation Schedule. Buyer and Seller shall, or shall cause their relevant Affiliates to, timely file such Section 338(h)(10) Forms with each applicable Taxing Authority. Seller and Buyer agree that neither of them shall, or shall permit any of their Affiliates to, revoke the Section 338(h)(10) Election following the filing of the Section 338(h)(10) Forms without the prior written consent of Seller or Buyer, as applicable. Seller and Buyer shall and shall cause their Affiliates to (i) file all Tax Returns in a manner consistent with the Section 338(h)(10) Election, the Section 338(h)(10) Forms and the Allocation Schedule and (ii) take no position contrary thereto in connection with any Action or otherwise, in each case, except to the extent required otherwise pursuant to applicable Law. Each of Buyer and Seller shall deliver to the other party at the Closing one or more duly executed IRS Forms 8023 that reflect the Section 338(h)(10) Election.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Employee and Related Matters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Buyer shall, and shall cause its Affiliates to, credit each Company Employee with all service credited to such Company Employee by the Company as of the Closing Date for all purposes under Buyer's Benefit Programs and shall provide that Company Employees may commence participation under employee benefit plans, programs, policies, agreements, or arrangements offered by Buyer or its Affiliates ("<u>Buyer's Benefit Programs</u>") immediately upon the Closing Date. Buyer shall waive, or shall use commercially reasonable efforts to cause to be waived, all pre-existing condition exclusions, evidence of insurability requirements, actively at work requirements, waiting periods, and similar requirements for participation and coverage applicable under Buyer's Benefit Programs with respect to Company Employees and their dependents. Buyer shall use commercially reasonable efforts to credit, or shall cause to be credited, Company Employees with all amounts paid prior to the Closing Date with respect to each Company Benefit Program that is a welfare benefit plan for purposes of satisfying all applicable deductible, coinsurance, and out-of-pocket requirements for the plan year that includes the Closing Date under each applicable Buyer's Benefit Plan as if such amounts had been paid with respect to such Buyer's Benefit Program.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Buyer shall, and shall cause its Affiliates to, honor, recognize and permit each Company Employee to use and/or have available to use all accrued but unused vacation and paid time off as of the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regardless of anything else contained herein, this <u>Section 6.3</u> shall not be construed to amend any Company Benefit Plans or any other plans, policies, programs, agreements, or arrangements or create any rights or obligations except between the parties to this Agreement. No Company Employee or other Person not a party to this Agreement shall be entitled to assert any claim hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Florida Performance Bond</u>. As soon as practicable following the Closing Date and in any event before October 31, 2023, Buyer shall, and shall cause its Encompay, Inc. affiliate to, (a) negotiate in good faith and use commercially reasonable efforts to cause Continental Heritage Insurance Company, as surety (the "<u>Florida Surety</u>"), to terminate the General Indemnity Agreement, dated October 27, 2022, by and between the Florida Surety and each of Company, Seller and Parent with respect to the General Performance Bond made as of October 31, 2022 in favor of the State of Florida Department of Health (the "<u>Florida Performance Bond</u>") as it relates to each of Seller and Parent; and (b) enter into a successor General Indemnity Agreement with the Florida Surety (or a successor surety) with respect to the Florida Performance Bond in order to enable Seller and Parent to be relieved of such obligations as soon as practicable following the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Further Assurances</u>. Each of the Parties covenants and agrees to use its reasonable best efforts to effectuate the Transactions and to do all acts and things as may be required to carry out their obligations hereunder, including executing, sealing and delivering all such other instruments and other documents, and taking all such other actions, as may be required to carry out the provisions of the Transaction Agreements and consummate and make effective the Transactions.

#### SECTION 7

#### CLOSING DELIVERABLES
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Company and Seller Deliveries</u>. At the Closing, the Company and Seller shall have delivered, or caused to be delivered to Buyer:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Secretary's Certificate</u>. A certificate of the Secretary of the Company, dated as of the Closing Date, certifying as to (i) the incumbency of officers of the Company executing documents executed and delivered in connection herewith; (ii) the copies of the Certificate of Incorporation and Bylaws, each as in effect as of the Closing and (iii) a copy of the resolutions of the sole director of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Resignation of Company Sole Director and Officers</u>. The resignations of the officers of the Company and the sole director of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Payoff Letters</u>. The Company shall have obtained from each Person who, on or following the Closing Date, holds any Indebtedness for borrowed money of the Company, a payoff letter in form and substance reasonably satisfactory to Buyer and such other evidence as Buyer may reasonably request to the effect that all such Indebtedness of the Company has been paid in full and any and all Liens with regard to such Indebtedness have been fully and finally released.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Good Standing Certificates</u>. The Company shall have delivered a good standing certificate for the Company from the Secretary of State of the State of Florida, dated as of a date not earlier than ten (10) Business Days prior to the Closing.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp; <u>FIRPTA Certificate</u>. A certificate, under penalties of perjury, stating that the Company is not and has not been a United States real property holding corporation, dated as of the Closing Date and in form and substance required under Sections 1.1445-2(c)(3) and 1.897-2(h) of the Treasury Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Stock Certificates</u>. A stock certificate or affidavit of lost stock certificate representing all shares of Company Common Stock owned by such Seller in form and substance reasonably acceptable to Buyer, together with stock transfer powers for the shares of Company Common Stock in the form attached hereto as Exhibit B, duly executed by such Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Interim Services Agreement</u>. The Interim Services Agreement, duly executed by Seller and Parent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>License Agreement</u>. The License Agreement, duly executed by Seller and Parent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Security Agreement</u>. The Security Agreement, duly executed by Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp; <u>Pledge Agreement</u>. The Pledge Agreement, duly executed by Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Guaranty Agreements</u>. The Guaranty Agreements, duly executed by Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Indemnification Letter Agreement</u>. The Indemnification Letter Agreement, duly executed by Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Transaction Approval</u>. Copies of the resolutions or written consent duly adopted by the sole director of the Company authorizing the execution, delivery and performance of the Transaction Agreements and the consummation of the Transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Buyer Closing Deliveries</u>. At the Closing, Buyer shall have delivered, or caused to be delivered, to the Seller:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Transaction Approval</u>. Copies of the resolutions or written consent duly adopted by the board of directors of Buyer authorizing the execution, delivery and performance of the Transaction Agreements and the consummation of the Transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Interim Services Agreement</u>. The Interim Services Agreement, duly executed by Buyer and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>License Agreement</u><u>. The License Agreement, duly executed by Buyer and the Company.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Security Agreement</u><u>. The Security Agreement, duly executed by Buyer.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Pledge Agreement</u>. The Pledge Agreement, duly executed by Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp; <u>UCC-1 Financing Statements</u>. The UCC-1 Financing Statements, duly executed by Buyer.(g)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Guaranty Agreements</u>. The Guaranty Agreements, duly executed by the Company and each of the guarantors party thereto, respectively.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp; <u>Indemnification Letter Agreement</u>. The Indemnification Letter Agreement, duly executed by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp; <u>R&W Insurance Policy</u>. Evidence of the purchase by Buyer of the R&W Insurance Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Frustration of Closing Conditions</u>. Neither Buyer, on the one hand, nor Seller, on the other hand, may rely on the failure of any condition set forth in this <u>Section 7</u> to be satisfied if such failure was caused by such Party's or its respective Affiliates' failure to act in good faith or to comply with its agreements set forth herein.

#### SECTION 8

#### R&W INSURANCE; SURVIVAL AND PARTIAL RELEASE
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1&nbsp;&nbsp;&nbsp;&nbsp; <u>R&W Insurance</u>. Buyer shall obtain the R&W Insurance Policy issued in the name of Buyer or any of its Affiliates in connection with this Agreement and the Transactions and Seller shall be responsible for paying fifty percent (50%) of (i) the premiums, fees, costs and expenses associated with procuring the R&W Insurance Policy (up to a maximum of $150,000) and (ii) the retention for such R&W Insurance Policy (up to a maximum of $150,000). Buyer will cause the R&W Insurance Policy to expressly provide that the insurer thereunder will not pursue any subrogation rights or any other claims against the Company or Seller in connection with any claim made by a policyholder (including Buyer) thereunder, except for customary subrogation rights with respect to Fraud by the Company or the Seller in connection with the Transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Survival and Partial Release</u>. Except with respect to (i) Seller's Fraud and (ii) the representations and warranties of Seller in <u>Section 3.2</u>, which shall survive closing and shall remain in full force and effect until the date that is three (3) months after the lapse or expiration of the applicable limitations period for claims associated with such representations and warranties (the "<u>Non-Released Claims</u>"), (a) the representations, warranties and covenants of the Company and Seller contained in this Agreement shall terminate on the Closing Date and there shall be no remedies available to Buyer or its assigns, creditors, representatives, agents (including the insurer under the R&W Insurance Policy) or Affiliates (including the Company) (collective, the "<u>Buyer Parties</u>") or any Person after the Closing against Seller or any past, present or future director, officer, employee, incorporator, member, partner, manager, stockholder, Affiliate, agent, attorney, representative or assignee of, and any financial advisor, insurer or lender to Seller, or any past, present or future director, officer, employee, incorporator, member, partner, manager, stockholder, Affiliate, agent, attorney, representative or assignee of, and any financial advisor, insurer or lender to, any of the foregoing (collectively, "<u>Non-Party Affiliates</u>"), with respect to any breach of the representations, warranties, or covenants of Seller, except for covenants required to be performed by their terms in whole or in part after the Closing (collectively, the "<u>Released Claims</u>") and (b) Buyer, on behalf of itself and the Buyer Parties, hereby fully, finally and irrevocably releases, acquits and forever discharges (i) Seller from any Liability with respect to any Released Claims and (ii) each Non-Party Affiliate from any Liability with respect to Released Claims and Non-Released Claims. For the avoidance of doubt, Seller shall have no Liability in connection with the Transactions except in respect of the Non-Released Claims and Non-Party Affiliates shall have no Liability whatsoever in connection with the Transactions, including in respect of Non-Released Claims and Released Claims. Buyer, on behalf of itself and the Buyer Parties, hereby irrevocably covenants to refrain from, directly or indirectly, asserting any cause of action, or commencing, instituting or causing to be commenced, or continuing with any claim, action or proceeding therefor, against Seller (except with respect to any Non-Released Claim) or any Non-Party Affiliate, and this Agreement may be raised by Seller or any Non-Party Affiliate as an estoppel to any such claims, actions or proceedings. In no event shall Seller's Liability under this Agreement exceed the Purchase Price.

------

#### SECTION 9

#### MISCELLANEOUS
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>RESERVED</u>].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Amendment</u>. This Agreement may not be amended or modified except (a) by an instrument in writing signed by or on behalf of Buyer, Seller and the Company or (b) by a waiver in accordance with <u>Section</u> <u>9.3</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Waiver</u>. Any Party to this Agreement may waive compliance or performance of any provision of this Agreement that is intended for the benefit of such waiving Party. Any such extension or waiver shall be valid only if set forth in a writing executed by the Party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or waiver of the same term or condition or as a waiver of any other term or condition of this Agreement. The failure of any Party to assert any of its rights under this <u>Section</u> <u>9.3</u> shall not constitute a waiver of any of such rights. No course of dealing between or among any persons having any interest in this Agreement shall be deemed effective to modify, amend or discharge any part of this Agreement or any rights or obligations of any Party under or by reason of this Agreement. Except as otherwise provided herein, all rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4&nbsp;&nbsp;&nbsp;&nbsp; <u>Specific Performance</u>. Each Party agrees and acknowledges that in the event of a breach of its covenants that survive the Closing Date, money damages may be inadequate and the non-breaching Parties may have no adequate remedy at law. Accordingly, each Party agrees that each Party shall have the right, in addition to any other rights and remedies existing in its favor, to enforce its rights and the other Party's obligations hereunder not only by an action or actions for damages but also by an action or actions for equitable relief, including injunction and specific performance. If any such action is brought by a Party to enforce the covenants that survive the Closing Date, the other Party hereby waives the defense that there is an adequate remedy at law or the requirement for the posting of any bond or similar security.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Expenses</u>. Except as otherwise expressly provided herein, each of the Parties hereto shall pay all of its own fees, costs and expenses (including fees, costs and expenses of legal counsel, investment bankers, brokers or other representatives and consultants and appraisal fees, costs and expenses) incurred in connection with the negotiation of the Transaction Agreements and the consummation of the Transactions. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of this Agreement, the prevailing Party shall be entitled to reasonable attorneys' fees, costs and necessary disbursements in addition to any other relief to which such Party may be entitled.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6<u>Notices</u>. All notices, claims, demands and other communications given or delivered under this Agreement shall be in writing and shall be deemed to have been duly made or given when personally delivered, mailed by first class mail, return receipt requested, or delivered by express courier service or via facsimile or electronic mail (with original copy to follow) to the respective Parties at the following addresses (or such other address for a Party as shall be specified in a notice given in accordance with this Section 9.6); *provided*, that with respect to any notices deliverable to Seller, such notices shall be delivered solely via email or facsimile:

---

| | |
|:---|:---|
| If to Seller or the Company (prior to the Closing Date:<br>Helix Technologies, Inc.<br> c/o Forian Inc.<br> 41 University Drive, Suite 400<br> Newtown, PA 18940<br> Attention: Chief Executive Officer<br> Email: [\*\*\*\*\*] | with a copy (which shall not constitute notice) to:<br>Duane Morris LLP<br> 30 South 17th Street<br> Philadelphia, PA 19103<br> Attention: Darrick M. Mix<br> E-mail: [\*\*\*\*\*]<br> *and*<br> [\*\*\*\*\*] |

---

------

---

| | |
|:---|:---|
| If to Buyer:<br>BT Assets Group, Inc.<br> 21550 Biscayne Blvd, Suite 400<br> Aventura, FL 33180<br> Email: [\*\*\*\*\*]<br> Attention: Chief Financial Officer | with a copy (which shall not constitute notice) to:<br>PremierCounsel, LLP<br> 201 Spear Street, Suite 1100<br> San Francisco, CA 94104<br> Attention: William Kushner<br> Email: [\*\*\*\*\*] |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Binding Agreement; Assignment</u>. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns; *provided*, that neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by operation of law or otherwise without the prior written consent of Buyer and Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.8&nbsp;&nbsp;&nbsp;&nbsp; <u>Severability</u>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law or public policy, such provision shall be ineffective only to the extent of such prohibition or invalidity, and all other terms of this Agreement shall remain in full force and effect for so long as the economic or legal substance of the Transactions are not affected in any manner materially adverse to any Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Construction</u>. The Parties have participated jointly in the negotiation and drafting of this Agreement and the other agreements, documents and instruments executed and delivered in connection herewith with sophisticated counsel. In the event an ambiguity or question of intent or interpretation arises, this Agreement and the agreements, documents and instruments executed and delivered in connection herewith shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement and the agreements, documents and instruments executed and delivered in connection herewith. The Parties intend that each representation, warranty and covenant contained herein shall have independent significance. Unless the context of the Agreement otherwise requires: (a) the word "including" shall mean "including without limitation" regardless of whether such words are included in some contexts but not others; (b) words of any gender include each other gender and neutral forms of such words; (c) words using the singular or plural number also include the plural or singular number, respectively; (d) the terms "hereof," "herein," "hereto," "hereunder" and derivative or similar words refer to this entire Agreement; (e) references to clauses without a cross-reference to a Section or subsection are references to clauses within the same Section or, if more specific, subsection; (f) the word "or" is disjunctive but not necessarily exclusive; (g) the words "writing", "written" and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form; (h) references from or through any date mean, unless otherwise specified, from and including or through and including, respectively; (i) the words "dollar", "USD" or "$" shall mean U.S. dollars; and (j) the word "day" means calendar day unless Business Day is expressly specified.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.10&nbsp;&nbsp;&nbsp;&nbsp; <u>Captions</u>. The captions used in this Agreement are for convenience of reference only and do not constitute a part of this Agreement and shall not be deemed to limit, characterize or in any way affect any provision of this Agreement, and all provisions of this Agreement shall be enforced and construed as if no caption had been used in this Agreement.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.11&nbsp;&nbsp;&nbsp;&nbsp; <u>Entire Agreement</u>. This Agreement and the Disclosure Schedule identified in this Agreement and the other documents referred to herein contain the entire agreement between the Parties and supersede any prior understandings, agreements or representations by or between the Parties, written or oral, which may have related to the subject matter hereof in any way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.12&nbsp;&nbsp;&nbsp;&nbsp; <u>Counterparts</u>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument. The execution and delivery of a facsimile or other electronic transmission of a signature to this Agreement shall constitute delivery of an executed original and shall be binding upon the person whose signature appears on the transmitted copy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.13&nbsp;&nbsp;&nbsp;&nbsp; <u>Choice of Law; Consent to Jurisdiction</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The law of the State of Delaware shall govern this Agreement, the interpretation and enforcement of its terms and any claim or cause of action (in law or equity), controversy or dispute arising out of or related to it or its negotiation, execution or performance, whether based on contract, tort, statutory or other law, in each case without giving effect to any conflicts-of-law or other principle requiring the application of the law of any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each of the Parties hereof hereby irrevocably and unconditionally consents to submit to the sole and exclusive jurisdiction of the courts of the State of Delaware and of the United States District Court for the District of Delaware, in each case, located in the State of Delaware (the "<u>Chosen Courts</u>") for any litigation arising out of or relating to the Transaction Agreements, or the negotiation, validity or performance thereof, or the Transactions (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Chosen Courts and agrees not to plead or claim in any Chosen Court that such litigation brought therein has been brought in any inconvenient forum. Each of the Parties hereto agrees that service of process may also be made on such Party by prepaid certified mail with a proof of mailing receipt validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to the preceding sentence above shall have the same legal force and effect as if served upon such Party personally within the Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.14&nbsp;&nbsp;&nbsp;&nbsp; <u>WAIVER OF JURY TRIAL</u>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AND ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.15&nbsp;&nbsp;&nbsp;&nbsp; <u>Parties in Interest</u>. Nothing in this Agreement, express or implied, is intended to confer on any person other than the Parties and their respective successors and assigns any rights or remedies under or by virtue of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.16&nbsp;&nbsp;&nbsp;&nbsp; <u>Press Releases and Announcements; Confidentiality</u>. None of the Parties nor any of their respective representatives shall issue any press releases or make any public announcements with respect to this Agreement or the underlying Transactions without the prior written consent of Buyer or Seller, as the case may be. Notwithstanding the foregoing, any such press release or public announcement may be made if required by applicable Law or a securities exchange rule; *provided*, that the Party required to make such press release or public announcement shall, to the extent possible, confer with the other Parties concerning the timing and content of such press release or public announcement before the same is made.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.17&nbsp;&nbsp;&nbsp;&nbsp; <u>No Representations Regarding Projections or Forecasts; Acknowledgment</u>. None of the Company nor any other Person has made, and Buyer acknowledges and agrees that it has not relied upon, any representation or warranty, express or implied as to, and none of the Company nor any other Person shall have any Liability to Buyer or any other Person with respect to any financial projections, forecasts, estimates, plans or budgets relating to the Company or its operations or other forward-looking statements of the Company (except, in each case, to the extent expressly addressed in a representation or warranty in <u>Section 3</u>).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.18&nbsp;&nbsp;&nbsp;&nbsp; <u>Disclosure Schedule</u>. Nothing in the Disclosure Schedule is intended to broaden the scope of any representation or warranty contained in this Agreement or to create any covenant unless clearly specified to the contrary herein or therein. Inclusion of any item on any Disclosure Schedule (a) does not represent a determination that such item is material nor shall it be deemed to establish a standard of materiality; (b) does not represent a determination that such item did not arise in the Ordinary Course of Business and (c) shall not constitute, or be deemed to be, an admission to any third party concerning such item. The Disclosure Schedule includes descriptions of instruments or brief summaries of certain aspects of the Company and its business and operations. The descriptions and brief summaries are not necessarily complete and are provided in the Disclosure Schedule to identify documents or other materials previously delivered or made available.

\* \* \* \*

------

IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement as of the day and year first above written.

---

| | |
|:---|:---|
| **COMPANY:** | **COMPANY:** |
| **BIO-TECH MEDICAL SOFTWARE, INC.** | **BIO-TECH MEDICAL SOFTWARE, INC.** |
| By: | /s/ Edward Spaniel Jr. |
| Name: Edward Spaniel Jr. | Name: Edward Spaniel Jr. |
| Title: Vice President and Secretary | Title: Vice President and Secretary |
| **SELLER:** | **SELLER:** |
| **HELIX TECHNOLOGIES, INC.** | **HELIX TECHNOLOGIES, INC.** |
| By: | /s/ Edward Spaniel Jr. |
| Name: Edward Spaniel Jr. | Name: Edward Spaniel Jr. |
| Title: Vice President and Secretary | Title: Vice President and Secretary |
| **BUYER:** | **BUYER:** |
| **BT ASSETS GROUP, INC.** | **BT ASSETS GROUP, INC.** |
| By: | /s/ Justin Soulen |
| Name: Justin Soulen | Name: Justin Soulen |
| Title: Authorized Representative | Title: Authorized Representative |

---

*[Signature Page to Stock Purchase Agreement]*

** 

<br> ** 

<br> *44*

## Exhibit 10.1

------

<u>Exhibit 10.1</u>

#### LICENSE AGREEMENT
THIS LICENSE AGREEMENT (this "<u>Agreement</u>"), dated as of February 10, 2023 (the "<u>Effective Date</u>"), is made and entered into by and among Forian Inc., a Delaware corporation ("<u>Forian</u>") and Helix Technologies, Inc., a Delaware Corporation ("<u>Seller</u>" and together with Forian, the "<u>Licensees</u>"), each for itself and for the benefit of their respective Affiliates, collectively as licensees, on the one hand, and each of BT Assets Group, Inc., a Delaware corporation ("<u>Buyer</u>"), and Bio-Tech Medical Software, Inc., a Florida corporation (the "<u>Company</u>"), each for itself and on behalf of their respective Affiliates, collectively as licensors, on the other hand. Buyer and the Company are referred to in this Agreement each as a "<u>Licensor</u>" and collectively as the "<u>Licensors</u>". Forian, Seller, Buyer and the Company are collectively referred to in this Agreement each as a "<u>Party</u>" and collectively as the "<u>Parties</u>."

WHEREAS, the Seller, Buyer and the Company have entered into that certain Stock Purchase Agreement dated as of the Effective Date (the "<u>Purchase Agreement</u>") and certain documents and agreements ancillary thereto; and

WHEREAS, as provided in the Purchase Agreement, the Parties are entering into this Agreement in order to modify the existing license arrangement between the Company and Forian to provide for, among other things, Licensors' provision to Forian of a royalty-free license to certain de-identified transactional data with respect to the cannabis and cannabidiol ("<u>CBD</u>") industry and attendant services on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual representations, warranties, covenants and promises contained in this Agreement, the adequacy and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Definitions</u>. Capitalized terms which are used but not defined in this
 Agreement shall have the meanings ascribed to such terms in the Purchase Agreement.

<br> 1.1 "<u>Existing Company Software</u>" means the Company's point of sale software solutions (as such solutions are owned, licensed, or operated by the Company on the Closing Date of the Transactions).

---

| | |
|:---|:---|
| 1.2 | "<u>Licensed Data</u>" means all transactional data with respect to the cannabis and CBD industry that are generated from customers based in the United States and its territories and Processed by Licensors or any of their Affiliates through Existing Company Software or Successor Company Software, including the data elements identified in the specification attached hereto as <u>Schedule A</u> ("<u>Specification</u>"); *provided*, that the Licensed Data shall exclude all such transactional data that results from customers of Buyer that are acquired through Buyer's acquisition of a software solution after the Closing Date of the Transactions ("<u>Excluded Transactional Data</u>"). |

---

---

| | |
|:---|:---|
| 1.3 | "<u>Process</u>" means any operation or set of operations which is performed on data or on sets of data, whether or not by automated means, such as collection, recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction. |

---

<br> 1.4 "<u>Successor Company Software</u>" means any point of sale software solution owned, licensed or operated by Licensors or any of their Affiliates that Processes transactions previously Processed through the Existing Company Software.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>License</u>.

---

| | |
|:---|:---|
| 2.1 | <u>Grant</u>. Subject to the terms and conditions of this <u>Section 2</u>, Licensors hereby grant to Forian and its Affiliates a perpetual (subject to <u>Section 2.4</u>), world-wide, exclusive (subject to <u>Section 2.2</u>), royalty-free, transferable and sublicensable license to access, use, copy, distribute (publicly and otherwise), display (publicly and otherwise), perform (publicly and otherwise), transmit, store, maintain, make derivative works of and commercialize the Licensed Data (the "<u>License</u>"). |

---

---

| | |
|:---|:---|
| 2.2 | <u>Non-Exclusivity</u>. The License shall be non-exclusive with respect to all Licensed Data Processed by customers of Buyer that were not customers of the Company as of the Closing of the Transactions ("<u>Non-exclusive License</u>"). |

---

<br> 2.3 <u>Negotiation of Additional and Alternative Licenses</u>.

<br> (a) Upon Forian's request, Buyer shall negotiate with Forian in good faith regarding additional or alternative license terms (including license fees) with respect to the Non-exclusive License or with respect to the Excluded Transactional Data.

(b) In the event that an independent third party solicits a license or other arrangement from Licensors or their Affiliates: (i) that is similar to the Non-exclusive License with respect to any of the Licensed Data or (ii) for the Excluded Transactional Data, Licensors shall provide written notice to Forian at least thirty (30) days prior to consummating such license or arrangement and engage with Forian in good faith to allow Forian the opportunity to propose to Licensors an alternative license.

---

| | |
|:---|:---|
| 2.4 | <u>Termination</u>. Upon the consummation of a Qualified Transaction (as defined below), the License shall transition from a perpetual term to a term expiring on the later to occur of (a) the five (5) year anniversary of the consummation of such Qualified Transaction and (b) the seven (7) year anniversary of the Effective Date of this Agreement; *provided,* that, prior to closing such Qualified Transaction, Buyer has used good faith efforts to negotiate the continuation of the License, which shall include the obligation to engage with Forian in good faith for a period of at least ten (10) business days to allow Forian to negotiate reasonably and in good faith (including with the buyer in such Qualified Transaction) concerning the terms of such continued license. A "<u>Qualified Transaction</u>" means a transaction pursuant to which Buyer sells or transfers (including a change of control transaction) greater than 80% of the assets that generate the Licensed Data to an independent third party in which, prior to such transaction, none of Buyer or its Affiliates has any ownership interest in, nor has provided any prior financing to, directly or indirectly (it being understood that a third party in which Buyer or its Affiliates obtains an ownership interest no greater than 20% in connection with such transaction or a transaction in which the purchase price is partially financed through a seller note shall constitute an independent third party transaction). |

---

---

| | |
|:---|:---|
| 2.5 | <u>Rights of Affiliates</u>. For the avoidance of doubt, all rights and licenses granted to Forian in this <u>Section 2</u> shall extend to and may be fully exercised by Forian's Affiliates (whether existing on or after the Effective Date); *provided*, that each such Affiliate complies with this Agreement to the same extent as Forian; and *provided, further*, that Forian (or its legal successor in interest) is and remains primarily responsible for the performance of this Agreement and fully liable for any act or omission of any such Affiliate or any party obtaining or accessing the Licensed Data by or through such Affiliate or Forian, as if such were the acts or omissions of Forian directly. |

---

&nbsp;&nbsp;&nbsp; 2 of 11<br>

------

---

| | |
|:---|:---|
| 2.6 | <u>No Implied Rights</u>. Except for the limited rights and licenses expressly granted under this Agreement, nothing in this Agreement grants, by implication, waiver, estoppel or otherwise, to Forian or any third party any intellectual property rights or other right, title, or interest in or to any data or technology owned or controlled by Licensors. |

---

---

| | |
|:---|:---|
| 2.7 | <u>Buyer Restrictions</u>. For the five (5) year period following the Closing Date of the Transactions, none of Buyer or its Affiliates shall sell, license or otherwise provide information, business intelligence or analytics products or services that use the Licensed Data for use by customers within the healthcare and life sciences industries (which for purposes of this <u>Section 2.7</u> shall exclude the cannabis and CBD industry). |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Delivery and Integration</u>. As soon as
 practicable following the Effective Date in accordance with the Specification and consistent with each party's obligations hereunder and under that certain Interim Services Agreement by and among the Parties entered into as of the
 Effective Date (the " <u>Interim Services Agreement</u> "), Licensors shall support Forian's adoption, integration and implementation of the Licensed Data into the Forian enterprise for
 Forian's exercise of the License (" <u>Integration</u> ") on a time and materials basis: (a) in the case of work as provided in the Specification (the " <u>Initial Integration Services</u> "), at an hourly rate of US$100, and (b) in the case of Integration-related services that are beyond the scope of Licensors' obligations under Specification (the " <u>Subsequent Integration Services</u> "), at an hourly rate of US$200 pursuant to commercially reasonable statements of work under this Agreement as mutually agreed by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Representations; Warranties and Covenants</u>. Licensors represent, warrant
 and covenant the following to Forian:

<br> 4.1 <u>Specification</u>. The Licensed Data shall include at least the data elements identified in the Specification except for limitations as may be required by the Legal Requirements (as defined below).

---

| | |
|:---|:---|
| 4.2 | <u>Use Rights</u>. Licensors shall provide written notice to Forian of any and all limitations on the use rights that Licensors and their Affiliates have with respect to the Licensed Data ("<u>Licensor Use Rights</u>") and shall use commercially reasonable efforts to obtain and maintain Licensor Use Rights sufficient to enable the License granted hereunder without any material limitations. Notwithstanding the foregoing sentence, Forian acknowledges that (a)(1) certain clients of the Company as of the Effective Date restrict Licensor Use Rights (the "<u>Restricted Accounts</u>", and the data produced in relation to such Restricted Accounts, the "<u>Restricted Account Data</u>"); and (2) such Restricted Account Data is not included in the Licensed Data; and (b) it and not Licensors shall be solely responsible at and as of the Effective Date and from time to time during the term of this Agreement to not use and to delete from its records all Restricted Account Data and other data that Licensors advise pursuant to Section 4.4 below is restricted due to Legal Requirements. |

---

---

| | |
|:---|:---|
| 4.3 | <u>Performance</u>. All services provided by or on behalf of Licensors to Forian and its Affiliates, including in connection with the Integration of Licensed Data, shall be performed by skilled personnel, in a workmanlike and professional manner, and in accordance with standards utilized within the Licensors generally. |

---

---

| | |
|:---|:---|
| 4.4 | <u>Compliance with Laws</u>. Licensors shall (a) promptly inform Licensees from time to time of any Law that it determines in its sole and reasonable discretion upon advice of counsel precludes, limits or conditions the Licensees' receipt or ongoing use of the Licensed Data (collectively, the "<u>Legal Requirements</u>") and (b) take such commercially reasonable actions upon advice of counsel and in consultation with Licensees in good faith as are necessary to comply with such Legal Requirements (including the actions specified in Section 1.0(d) of the Specification). |

---

&nbsp;&nbsp;&nbsp; 3 of 11<br>

------

<br> 4.5 <u>Ownership or Necessary Rights</u>. Other than as identified in <u>Section 4.2</u> above, the Licensors own or have all necessary rights in the Licensed Data in order to grant the License provided under this Agreement.

---

| | |
|:---|:---|
| 4.6 | <u>Malicious Code</u>. Except as is resident in the Existing Company Software, the Licensed Data and all software and systems used by Licensors and their Affiliates to provide or make available the Licensed Data to Forian and its Affiliates shall not contain any "time bomb," "Trojan horse," "back door," "worm," virus, malware, spyware, or other device or code ("<u>Malicious Code</u>") designed or intended to, or that would reasonably be expected to, (a) disrupt, disable, harm or otherwise impair in any material respect the normal and authorized operation of, or provide unauthorized access to, any computer system, hardware, firmware, network or device on which any such software is installed, stored or used, or (b) damage, destroy or prevent the access to or use of any data or file without the user's consent. |

---

---

| | |
|:---|:---|
| 4.7 | <u>Open Source</u>. Except as is resident in the Existing Company Software, the Licensors shall not use any Open Source Technology in a manner that requires, or would reasonably be expected to require, the (a) disclosure or distribution of any software or technology owned or controlled by Licensors or Forian ("<u>Proprietary Software and Technology</u>") in source code form, (b) license or other provision of any Proprietary Software and Technology on a royalty-free basis, or (c) grant of any license, non-assertion covenant or other rights or immunities under any Proprietary Software and Technology or rights to modify, make derivative works based on, decompile, disassemble or reverse engineer any Proprietary Software and Technology, including any "copyleft" license. The Licensors shall be in compliance with all material notice, attribution, and other requirements of each license applicable to the Open Source Technology. "<u>Open Source Technology</u>" means any software or other technology that is distributed as or that contains, or is derived in any manner (in whole or in part) from, any software or other technology that is distributed as free software, open source or similar licensing or distribution models, or requires as a condition of use, modification or distribution that any technology (1) be disclosed or distributed in source code form, (2) be licensed for the purpose of making derivative works, (3) be redistributable at no charge, or (4) grants to any third party any license, non-assertion covenant or other rights or immunities to or under any technology. Open Source Technology includes technology licensed or distributed under any of the following licenses or distribution models, or licenses or distribution models similar to any of the following: Apache License, MIT License, BSD 3-Clause "New" or "Revised" License or BSD 2-Clause "Simplified" or "FreeBSD" License, GNU's General Public License (GPL), Lesser/Library GPL (LGPL), or Affero GPL, Mozilla Public License, Common Development and Distribution License (CDDL), Eclipse Public License, Artistic License, Netscape Public License, Sun Community Source License (SCSL), Sun Industry Standards License (SISL), the Common Public License, Creative Commons License, or any license or distribution agreement or arrangement listed on www.opensource.org/licenses/index.php or any successor website thereof or that is considered "free" or "open source" by the Open Source Foundation or the Free Software Foundation. |

---

<br> 4.8 <u>Exceptions</u>. Notwithstanding any provisions to the contrary in this Agreement, the representations and warranties set forth in this <u>Section 4</u> do not apply to:

<br> (a) the Licensed Data Processed through the Existing Company Software prior to the Effective Date;

<br> (b) the Restricted Accounts and the Restricted Account Data;

&nbsp;&nbsp;&nbsp; 4 of 11<br>

------

<br> (c) modifications of the Licensed Data, including combination or supplementation of the Licensed Data with other data, by Forian;

<br> (d) Forian's or any third party's negligence, abuse, misapplication or misuse of the Licensed Data; or

<br> (e) the operation of, or access to, Forian's or a third party's system or network.

---

| | |
|:---|:---|
| 4.9 | <u>Disclaimer of Warranties</u>. EXCEPT FOR THE EXPRESS LIMITED WARRANTIES CONTAINED IN <u>SECTION 4</u>, LICENSORS HEREBY DISCLAIM ALL OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE LICENSED DATA. IN PARTICULAR, ANY AND ALL WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT ARE EXPRESSLY EXCLUDED. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Indemnification</u>.

---

| | |
|:---|:---|
| 5.1 | <u>Mutual Indemnity</u>. Each Party ("<u>Indemnitor</u>") shall defend, indemnify and hold harmless the other Party and its Affiliates and each of their respective officers, directors, shareholders, members, partners, principals, owners, employees, agents, successors, and assigns (each, an "<u>Indemnitee</u>") from and against all claims, demands, causes of action, suits, investigations, inquiries, or proceedings by a third party (each, a "<u>Third-Party Claim</u>") to the extent arising out of any breach of this Agreement by the Indemnitor and Indemnitor shall pay any and all damages, judgments, awards, settlements, fines, penalties, costs and expenses (including, without limitation, reasonable attorneys' fees), liabilities, and losses of any and every kind that are finally awarded or assessed as a result of, or agreed to as a settlement of, such a Third-Party Claim; *provided*, that the Indemnitor's obligation to indemnify, defend and hold harmless an Indemnitee shall not apply to the extent such Third-Party Claims arise or result from the Indemnitee's gross negligence, recklessness, or willful misconduct. |

---

---

| | |
|:---|:---|
| 5.2 | <u>Notice and Procedure</u>. An indemnified party shall provide an indemnifying party prompt written notice of any such Third-Party Claim; *provided*, that any failure or delay in providing such notice shall not relieve the indemnifying party of its indemnity obligations under this Agreement except to the extent the indemnifying party is actually prejudiced by such failure or delay. The indemnifying party shall have right to control the defense and settlement of such Third-Party Claim; *provided*, that (a) the indemnifying party shall not settle any such Third-Party Claim without the prior written consent of the indemnified party, which consent will not be unreasonably withheld or delayed and (b) the indemnified party may, at its option and expense, participate in connection with the defense and settlement of any such Third-Party Claim. The indemnified party shall provide, at the indemnifying party's request and expense, reasonable cooperation in defending or settling any such Third-Party Claim. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Limitation of Liability</u>. NEITHER PARTY
 SHALL BE LIABLE TO THE OTHER PARTY OR ANY OTHER PARTY FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND (INCLUDING LOST PROFITS) REGARDLESS OF THE FORM OF ACTION WHETHER IN CONTRACT, TORT (INCLUDING
 NEGLIGENCE), STRICT PRODUCT LIABILITY, LAW, EQUITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

&nbsp;&nbsp;&nbsp; 5 of 11<br>

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Confidentiality</u>.

<br> 7.1 <u>Confidential Information</u>.

(a) As used herein, the term "<u>Confidential Information</u>" means information in the possession or under the control of a Party relating to a Party's or its licensors' technical, marketing, pricing and payment terms, product and business affairs, or other categories of proprietary information, including customers, prospects, price, licensors, data sources and other proprietary and trade secret information, whether oral, graphic, written, electronic or in machine readable form, and includes all computer programs (and source code therefor), all proposals, plans, programs, analyses, compilations, forecasts, studies or other documents prepared by a Party or by them jointly relating to any subject matter of this Agreement, including the existence of and terms of this Agreement. Confidential Information does not include information which: (i) is or becomes available to the public other than as the consequence of a breach of this Agreement; (ii) is actually known to or in the possession of the receiving Party without any limitation on use or disclosure prior to receipt from the disclosing Party; (iii) is rightfully received from a third party in possession of such information who is not under obligation to the disclosing Party not to disclose the information; or (iv) is independently developed by the receiving Party without use of or reference to the disclosing Party's Confidential Information.

(b) The receiving Party may use Confidential Information of the disclosing Party only for the purposes of exercising the receiving Party's rights and fulfilling the receiving Party's obligations under this Agreement. The receiving Party shall use the same degree of care, but no less than a reasonable degree of care, to protect against the unauthorized disclosure or use of the disclosing Party's Confidential Information as it uses to protect its own confidential information of a similar type. The receiving Party shall disclose Confidential Information of the disclosing Party only to its employees or independent contractors who have a need to know and who are bound by obligations no less restrictive than the terms of this Agreement. Each Party shall promptly (but no later than within two (2) business days) notify the other Party in writing in the event it becomes aware of any unauthorized disclosure of Confidential Information. Any duplication, use, disclosure, or other act or omission by any person or entity that obtains access to or possession of Confidential Information through the receiving Party that would be a breach of this Agreement if committed by the receiving Party is deemed a breach of this Agreement by the receiving Party for which the receiving Party shall be responsible. The receiving Party shall not remove any confidentiality or proprietary notices from the disclosing Party's Confidential Information. In the event that Confidential Information is required to be disclosed pursuant to subpoena, court order, government authority or Law, the receiving Party shall, to the extent legally permissible, provide prompt written notice to the disclosing Party prior to such disclosure, so that the disclosing Party may seek a protective order or other available relief. In the event that a protective order or relief is not obtained, the receiving Party agrees to disclose only that portion of the Confidential Information which is required.

&nbsp;&nbsp;&nbsp; 6 of 11<br>

------

(c) None of the Parties or any of their respective representatives shall issue any press releases or make any public announcements with respect to this Agreement without the prior written consent of the other Parties. Notwithstanding the foregoing, any such press release or public announcement may be made if required by applicable Law or a securities exchange rule; *provided*, that the Party required to make such press release or public announcement shall, to the extent possible, confer with the other Parties concerning the timing and content of such press release or public announcement before the same is made. Licensors acknowledge that Forian may need to publicly disclose this Agreement and the subject matter hereof to comply with the rules and regulations of the U.S. Securities and Exchange Commission and the Nasdaq Capital Market, and Licensors consent to such disclosure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <u>Amendment</u>. This Agreement may not be amended or
 modified except (a) by an instrument in writing signed by or on behalf of the Parties or (b) by a waiver in accordance with <u>Section 8.2</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <u>Waiver</u>. Any Party to this Agreement may waive
 compliance or performance of any provision of this Agreement that is intended for the benefit of such waiving Party. Any such waiver shall be valid only if set forth in a writing executed by the Party to be bound thereby. Any waiver of
 any term or condition shall not be construed as a waiver of any subsequent breach or waiver of the same term or condition or as a waiver of any other term or condition of this Agreement. The failure of any Party to assert any of its
 rights under this <u>Section 8.2</u> shall not constitute a waiver of any of such rights. No course of dealing between or among any persons having any interest in this Agreement
 shall be deemed effective to modify, amend or discharge any part of this Agreement or any rights or obligations of any Party under or by reason of this Agreement. Except as otherwise provided herein, all rights and remedies existing
 under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <u>Specific Performance</u>. Each Party agrees and
 acknowledges that in the event of its breach of <u>Section 7</u> of this Agreement, money damages may be inadequate and the non-breaching Parties may have no adequate remedy at Law.
 Accordingly, each Party agrees that each Party shall have the right, in addition to any other rights and remedies existing in its favor, to enforce its rights and the other Party's obligations hereunder not only by an action or actions
 for damages but also by an action or actions for equitable relief, including injunction and specific performance. If any such action is brought by a Party, the other Party hereby waives the defense that there is an adequate remedy at
 Law or the requirement for the posting of any bond or similar security.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <u>Expenses</u>. Except as otherwise expressly provided
 herein, each of the Parties hereto shall pay all of its own fees, costs and expenses (including fees, costs and expenses of legal counsel, investment bankers, brokers or other representatives and consultants and appraisal fees, costs
 and expenses) incurred in connection with the negotiation of this Agreement. If any action at Law or in equity (including arbitration) is necessary to enforce or interpret the terms of this Agreement, the prevailing Party shall be
 entitled to reasonable attorneys' fees, costs and necessary disbursements in addition to any other relief to which such Party may be entitled, and, if the
 adjudicating body determines a Party to be the prevailing Party under circumstances where the prevailing party won on some but not all of the claims and counterclaims, the adjudicating body may award the prevailing Party an appropriate percentage of the costs and attorneys' fees reasonably incurred by the
 prevailing Party in connection with the adjudication and the enforcement of its rights under this Agreement . This <u>Section 8.4</u> shall survive the termination of this Agreement.

&nbsp;&nbsp;&nbsp; 7 of 11<br>

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5 <u>Notices</u>. All notices, claims, demands and other
 communications given or delivered under this Agreement shall be in writing and shall be deemed to have been duly made or given when personally delivered, mailed by first class mail, return receipt requested, or delivered by express
 courier service or via electronic mail (with original copy to follow) to the respective Parties at the following addresses (or such other address for a Party as shall be specified in a notice given in accordance with this Section); *provided*, that with respect to any notices deliverable to Forian, such notices shall be delivered solely via email:

---

| | |
|:---|:---|
| Forian Inc. | with a copy (which shall not constitute notice) to: |
| If to Forian: | Duane Morris LLP |
| 41 University Drive, Suite 400 | 30 South 17th Street |
| Newtown, PA 18940 | Philadelphia, PA 19103 |
| Attention: Chief Executive Officer | Attention: Darrick M. Mix |
| Email: [\*\*\*\*\*] | E-mail: [\*\*\*\*\*] |
|  | *and* |
|  | [\*\*\*\*\*] |
| If to Licensors: | with a copy (which shall not constitute notice) to: |
| BT Assets Group, Inc. | PremierCounsel, LLP |
| 21550 Biscayne Blvd, Suite 400 | 201 Spear Street, Suite 1100 |
| Aventura, FL 33180 | San Francisco, CA 94104 |
| Email: [\*\*\*\*\*] | Attention: William Kushner |
| Attention: Chief Financial Officer | Email: [\*\*\*\*\*] |

---

 

<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.6 <u>Binding Agreement; Assignment</u>. This Agreement and
 all of the provisions hereof shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by
 the Parties without the prior written consent of the non-assigning Party(ies) (which consent shall not be unreasonably withheld, conditioned or delayed) unless such assignment is in connection with an acquisition or merger transaction
 pursuant to which substantially all of the business of the assigning Party is assigned.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7 <u>Severability</u>. Whenever possible, each provision
 of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law or public policy, such provision
 shall be ineffective only to the extent of such prohibition or invalidity, and all other terms of this Agreement shall remain in full force and effect for so long as the economic or legal substance of the Transactions are not affected
 in any manner materially adverse to any Party.

&nbsp;&nbsp;&nbsp; 8 of 11<br>

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8 <u>Construction</u>. The Parties have participated
 jointly in the negotiation and drafting of this Agreement and the other agreements, documents and instruments executed and delivered in connection herewith with sophisticated counsel. In the event an ambiguity or question of intent or
 interpretation arises, this Agreement and the agreements, documents and instruments executed and delivered in connection herewith shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise
 favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement and the agreements, documents and instruments executed and delivered in connection herewith. The Parties intend that each representation,
 warranty and covenant contained herein shall have independent significance. Unless the context of the Agreement otherwise requires: (a) the word "including" shall mean "including without limitation" regardless of whether such words are
 included in some contexts but not others; (b) words of any gender include each other gender and neutral forms of such words; (c) words using the singular or plural number also include the plural or singular number, respectively; (d) the
 terms "hereof," "herein," "hereto," "hereunder" and derivative or similar words refer to this entire Agreement; (e) references to clauses without a cross-reference to a Section or subsection are references to clauses within the same
 Section or, if more specific, subsection; (f) the word "or" is disjunctive but not necessarily exclusive; (g) the words "writing", "written" and comparable terms refer to printing, typing and other means of reproducing words (including
 electronic media) in a visible form; (h) references from or through any date mean, unless otherwise specified, from and including or through and including, respectively; (i) the words "dollar", "USD" or "$" shall mean U.S. dollars; and
 (j) the word "day" means calendar day unless Business Day is expressly specified.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.9 <u>Captions</u>. The captions used in this Agreement are
 for convenience of reference only and do not constitute a part of this Agreement and shall not be deemed to limit, characterize or in any way affect any provision of this Agreement, and all provisions of this Agreement shall be enforced
 and construed as if no caption had been used in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.10 <u>Entire Agreement</u>. This Agreement (including its
 Schedules) and the Purchase Agreement, and the other documents referred to herein and therein, contain the entire agreement between the Parties and supersede any prior understandings, agreements or representations by or between the
 Parties, written or oral, which may have related to the subject matter hereof in any way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.11 <u>Counterparts</u>. This Agreement may be executed in
 two or more counterparts, each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument. The execution and delivery of a facsimile or other electronic transmission of a signature
 to this Agreement shall constitute delivery of an executed original and shall be binding upon the person whose signature appears on the transmitted copy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.12 <u>Choice of Law; Consent to Jurisdiction</u>.

(a) The Law of the State of Delaware shall govern this Agreement, the interpretation and enforcement of its terms and any claim or cause of action (in Law or equity), controversy or dispute arising out of or related to it or its negotiation, execution or performance, whether based on contract, tort, statutory or other Law, in each case without giving effect to any conflicts-of-Law or other principle requiring the application of the Law of any other jurisdiction.

(b) Each of the Parties hereof hereby irrevocably and unconditionally consents to submit to the sole and exclusive jurisdiction of the courts of the State of Delaware and of the United States District Court for the District of Delaware, in each case, located in the State of Delaware (the "<u>Chosen Courts</u>") for any litigation arising out of or relating to this Agreement, or the negotiation, validity or performance thereof (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Chosen Courts and agrees not to plead or claim in any Chosen Court that such litigation brought therein has been brought in any inconvenient forum. Each of the Parties hereto agrees that service of process may also be made on such Party by prepaid certified mail to the applicable address described in <u>Section 8.5</u> with a proof of mailing receipt validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to the preceding sentence above shall have the same legal force and effect as if served upon such Party personally within the State of Delaware.

&nbsp;&nbsp;&nbsp; 9 of 11<br>

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.13 <u>WAIVER OF JURY TRIAL</u>. EACH OF THE PARTIES HERETO
 HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AND ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN
 NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.14 <u>Parties in Interest</u>. Nothing in this Agreement,
 express or implied, is intended to confer on any person other than the Parties and their respective successors and assigns any rights or remedies under or by virtue of this Agreement.

---

| | |
|:---|:---|
| 8.15 | <u>Bankruptcy Code</u>. All rights and licenses granted hereunder are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, 11 U.S.C. Section 101, et seq. (the "<u>Bankruptcy Code</u>"), licenses of rights to "intellectual property" as defined under Section 101(56) of the Bankruptcy Code. The Parties agree that the licensees of such rights and licenses shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. |

---

\* \* \* \*

&nbsp;&nbsp;&nbsp; 10 of 11<br>

------

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.

---

| | |
|:---|:---|
| **Forian Inc.** | **Forian Inc.** |
| By: | /s/ Max C. Wygod |
|  | Name: Max C. Wygod |
|  | Title: Executive Chairman |
| **Helix Technologies, Inc.** | **Helix Technologies, Inc.** |
| By: | /s/ Edward Spaniel Jr  |
|  | Name: Edward Spaniel Jr  |
|  | Title: Vice President and Secretary  |
| **BT Assets Group, Inc.** | **BT Assets Group, Inc.** |
| By: | /s/ Justin Soulen |
|  | Name: Justin Soulen |
|  | Title: Authorized Representative |
| **Bio-Tech Medical Software, Inc.** | **Bio-Tech Medical Software, Inc.** |
| By: | /s/ Justin Soulen |
|  | Name: Justin Soulen |
|  | Title: Authorized Representative |

---

&nbsp;&nbsp;&nbsp;&nbsp; 11 of 11<br>

------

## Exhibit 10.2

------

<u>Exhibit 10.2</u>

---

| | | |
|:---|:---|:---|
| ![](image01.jpg) | ![](image02.jpg) | Forian Inc. |
| ![](image01.jpg) | ![](image02.jpg) | 41University Drive |
| ![](image01.jpg) | ![](image02.jpg) | Suite 400 <br>|
| ![](image01.jpg) | ![](image02.jpg) | Newtown, PA 18940 |

---

February 10, 2023

<u>Via Email</u>

Daniel Barton

[\*\*\*\*\*]

[\*\*\*\*\*]

#### Re: Separation and Release Agreement
Dear Dan:

With our sincere thanks for your service to Forian Inc. (together with its subsidiary and affiliated companies, collectively the "***Company***"), this letter agreement (the "***Agreement***") sets forth the terms and conditions of our mutual agreement regarding the separation of your employment as the Chief Executive Officer and President of the Company consistent with your rights and obligations as set forth in that certain Employment Agreement, dated as of October 16, 2019, by and between you and the Company (through its subsidiary, Medical Outcomes Research Analytics, LLC)(the "***Employment Agreement***"). Capitalized terms used and not defined herein shall have the meanings given to such terms in that certain Employment Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Separation Date**. Your last day of employment with the Company will be February 10, 2023 (the "***Separation Date***"). After the Separation Date, you will no longer serve as an employee, officer or director of the Company nor will you have any authority to act on the Company's behalf or otherwise bind the Company and you shall not give any third person the appearance that you have any such authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Accrued Base Salary and Vacation Time**. The Company will pay you your regular Base Salary through and including the Separation Date, which will be paid in accordance with the Company's regular payroll practices, subject to standard payroll deductions and withholdings. As a result of the Company's policy of unlimited vacation policy, no vacation time will be paid out in connection with the separation of your employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Employee Benefits**. The Company will provide you your regular employee benefits through the Separation Date, except that any medical, vision and dental coverage will continue through the last day of the month in which your Separation Date occurs. Thereafter, you will be eligible to continue your group health insurance benefits pursuant to COBRA, in accordance Section 4(c) below, applicable law and the terms of the plan. Additional information regarding COBRA and any other benefit continuation or conversion rights will be provided to you separately following the Separation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Existing Severance Benefits**. If you sign, date, and return this Agreement to the Company prior to the Expiration Date (as defined below), and you do not revoke it, and you comply fully with your obligations hereunder, the Company shall provide you with the following severance benefits (the "***Existing Severance Benefits***") in accordance with Section 4(b)(ii) of the Employment Agreement (and subject to Section 4(f) thereof):

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Continuation of Base Salary</u>. You shall receive the continuation of your Base Salary for a period of twelve (12) months following the Separation Date, payable in accordance with the Company's regular payroll schedule, subject to applicable tax withholdings. The severance payments will start (the ***"Starting Date"***) on the first payroll date following the Effective Date, with the first payment of severance to include amounts that would have been paid from the Separation Date to the Starting Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Annual Bonus</u>. You shall receive your Annual Bonus for the fiscal year ended December 31, 2022 in the amount of $87,500, payable in accordance with the Company's regular payroll schedule for annual bonus payments (no later than March 15, 2023), subject to applicable tax withholdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp; <u>Continuation of Health Benefits</u>. If you timely and properly elect to continue participation in any group medical, dental, vision and/or prescription drug plan benefits to which you or your eligible dependents would be entitled under COBRA following the Separation Date, you shall be entitled to continuation of group health plan benefits, with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the Separation Date until the earliest of (i) the expiration of the twelve (12) month period following the Separation Date; (ii) the expiration of your continuation coverage under COBRA; and (iii) the date on which you are eligible for comparable benefits as a result of new employment or self-employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Additional Severance Benefit**. If you sign, date, and return this Agreement to the Company prior to the Expiration Date (as defined below), and you do not revoke it, and you comply fully with your obligations hereunder, in addition to the Existing Severance Benefits, the Company shall provide you accelerated vesting, as of the Effective Date, of all unvested shares of restricted common stock of Forian Inc. awarded to you pursuant to that certain Equity Contribution Agreement, dated as of March 2, 2021 (with all vesting restrictions set forth on the signature page thereto terminating as of the Separation Date) (the "***Additional Severance Benefit***" and, together with the Existing Severance Benefits, the "***Severance Benefits***"), which acceleration will be subject to applicable tax withholdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Expense Reimbursements**. You hereby confirm that prior to the Separation Date you have submitted and been reimbursed for any business expenses you incurred through the Separation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **No Other Compensation or Benefits**. You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation or benefits, including any base salary, wages, overtime, incentive compensation, commissions, bonuses, retention bonuses, equity, notice pay, severance, time off (paid or unpaid) or benefits after the Separation Date. In addition, you acknowledge that you have no known workplace injuries or occupational diseases and have been provided and/or have not been denied any leave under the Family and Medical Leave Act, the Families First Coronavirus Response Act, or similar laws, and have been provided and/or have not been denied any reasonable accommodations under the Americans with Disabilities Act or similar laws.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.**&nbsp;&nbsp;&nbsp;&nbsp; **Release and Waiver; Acknowledgement**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Release and Waiver</u>. You (for yourself and your dependents, heirs, executors, administrators, legal representatives, assigns and/or any others who have or may have a claim by or through you) hereby irrevocably release and discharge the Company and its current and former parent, subsidiary and affiliated companies, and their respective directors, officers, employees, shareholders, agents, advisors, attorneys and plan administrators (in both their official and personal capacities), and each of their predecessors, successors and assigns (collectively, the "***Released Parties***") from any and all legally waivable suits, causes of action, claims, demands, charges, complaints, arbitrations, obligations and/or actions of any sort whatsoever, whether in law or equity, direct or indirect, which you ever had, now have, or hereinafter can or may have against the Released Parties, up to and including the Effective Date of this Agreement, including any and all claims relating to or in any way arising out of any aspect of your employment relationship and/or your separation from employment with the Company, including under the Employment Agreement.

This release specifically includes any and all claims for wrongful discharge, constructive discharge, breach of contract (whether express or implied), claims for compensation (including wages, overtime, salary, incentive compensation, commissions, bonuses, retention bonuses), equity, severance, notice pay, employee benefits, in each case except as provided herein, and any and all forms of employment discrimination in violation of any federal, state or local statute, ordinance, executive order, or common law doctrine (including claims for discrimination or harassment on the basis of race, color, religion, sex, national origin, age and/or mental or physical disability or any other protected characteristic, whether asserted under the Civil Rights Act of 1991, Title VII of the Civil Rights Act of 1964, 42 U.S.C. section 2000e et seq., the Civil Rights Act of 1870, 42 U.S.C. section 1981, the Age Discrimination in Employment Act of 1967, 29 U.S.C. section 621 et seq., the Older Workers Benefit Protection Act, 29 U.S.C. section 621 et seq., the Rehabilitation Act of 1972, 29 U.S.C. section 701, et seq., the Equal Pay Act, 29 U.S.C. section 206(d) et seq., the Employee Retirement Income Security Act, 29 U.S.C. 1001 et seq., the Americans with Disabilities Act, 42 U.S.C. section 12101, et seq., the Family and Medical Leave Act, 29 U.S.C. section 2601 et seq., the Pennsylvania Human Relations Act, the Pennsylvania Equal Pay Law, the Pennsylvania Whistleblower Law, the Pennsylvania Workers' Compensation Law retaliation provisions, and the Pennsylvania labor laws, all as amended, and/or under any other applicable federal, state or local antidiscrimination or antiharassment law), any and all suits in tort (including any claims for misrepresentation, defamation, wrongful termination, interference with contract or with prospective economic advantage, tortious infliction of emotional distress and/or negligence), any and all claims for retaliation, as well as any and all claims for additional compensation or damages of whatsoever kind arising in connection with your employment relationship and/or separation from employment with the Company.

This release includes your waiver of all forms of relief and benefits, no matter how denominated, including physical and mental injury, pain and suffering, reinstatement, back pay, front pay, interest, compensatory damages, and punitive damages. In addition, this release specifically includes all claims for costs and/or attorney's fees, if any, incurred by you in connection with any aspect of your employment relationship and/or your separation from employment with the Company. In waiving and releasing any and all claims, whether or not now known to you, you understand that this means that if you later discover facts different from or in addition to those facts currently known by you, or believed by you to be true, the waivers and releases of this Agreement will remain effective in all respects, despite such different or additional facts and your later discovery of such facts, even if you would not have agreed to this Agreement if you had prior knowledge of such facts.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Claims Not Being Released</u>. The only claims that are not being waived and released by you are claims you may have for (i) unemployment, state disability and/or paid family leave insurance benefits pursuant to the terms of applicable state law; (ii) any benefit entitlements that are vested as of your Separation Date pursuant to the terms of a Company-sponsored benefit plan; (iii) violation of any federal, state or local statutory and/or public policy right or entitlement that, by applicable law, is not waivable; (iv) claims under the Indemnification Agreement (as defined below) and (iv) any claims for breach of this Agreement by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Acknowledgement of Voluntariness and Time to Review</u>. You acknowledge that: (i) you have read this Agreement and understand it; (ii) this Agreement has not been offered to you in connection with a claim of discrimination or harassment (sexual or otherwise) by you; (iii) you are signing this Agreement voluntarily in order to release any claims you may have against the Released Parties in exchange for the Severance Benefits, which payment is greater than what you would otherwise have received; (iv) you have been given at least twenty-one (21) days from your receipt of this Agreement (the "***Expiration Date***") to consider whether to sign this Agreement, which you agree is a reasonable period of time; (v) you are advised to consult with an attorney of your choosing prior to signing this Agreement; (vi) you know that you can revoke this Agreement within seven (7) days after signing it (the "***Revocation Period***") and that the Agreement does not become effective until the day following the expiration of Revocation Period (such date being the "***Effective Date***" of this Agreement); and (vii) you agree that changes to this Agreement before its execution, whether material or immaterial, do not restart your time to review the Agreement. To be effective, any revocation by you must be in writing and received by the Company prior to the expiration of the Revocation Period. Written notice of revocation should be sent via email to the attention of each of Rebecca Adams, VP of Human Resources, at [\*\*\*\*\*] and Edward Spaniel, Jr., EVP and General Counsel, at [\*\*\*\*\*].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.**&nbsp;&nbsp;&nbsp;&nbsp; **Reports to Government Entities**. Nothing in this Agreement, including Sections 11 and 12 and the Release and Waiver set forth in Section 8, restricts or prohibits you from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General (collectively, the "***Regulators***"), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. However, to the maximum extent permitted by law, you are waiving your right to receive any individual monetary relief from the Company or any others covered by the Release and Waiver resulting from such claims or conduct, regardless of whether you or another party has filed them, and in the event you obtain such monetary relief the Company will be entitled to an offset for the payments made pursuant to this Agreement. This Agreement does not limit your right to receive an award from any Regulator that provides awards for providing information relating to a potential violation of law. You do not need the prior authorization of the Company to engage in conduct protected by this paragraph, and do not need to notify the Company that you have engaged in such conduct.

Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose a trade secret to their attorney, a court, or a government official in certain, confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.**&nbsp;&nbsp;&nbsp;&nbsp; **No Prior Claims**. You represent and agree that you have not filed any notices, reports, complaints, charges, applications, arbitrations, or lawsuits of any kind whatsoever against the Released Parties with any court or abitral forum with respect to any matter related to the Company or arising out of your employment with and/or termination from employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11.**&nbsp;&nbsp;&nbsp;&nbsp; **Covenant Not to Sue**. You covenant and agree that neither you, nor any of your dependents, heirs, executors, administrators, legal representatives, assigns and/or any others who have or may have a claim by or through you, will commence, prosecute or cause to be commenced or prosecuted against the Company or any other Released Party, any action, arbitration or other proceeding based upon any claims, demands, causes of action, obligations, damages or liabilities which are being released by this Agreement, nor will you seek to challenge the validity of this Agreement, except that this covenant not to sue does not affect your future right to appropriately (i) enforce the terms of this Agreement or (ii) challenge the validity of this Agreement under the Older Workers Benefit Protection Act with respect to claims under the Age Discrimination in Employment Act. In addition, nothing in this Agreement prevents or prohibits you from (i) filing a claim with a Regulator that is responsible for enforcing a law or (ii) cooperating, participating or assisting in any Regulator investigation or proceeding. If you breach your promise and file a lawsuit, arbitration or any other action or proceeding regarding claims that you have released, you agree to pay for all costs incurred by the Released Parties, including reasonable attorneys' fees, in defending against such claims, to the fullest extent permitted by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Additional Covenants of Employee**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Existing Covenants</u>. You acknowledge and agree that your covenants and related provisions contained in the Employment Agreement that expressly survive termination (including Sections 5, 6 and 7 thereof) are incorporated herein by this reference and shall continue to apply in accordance with their terms even though your employment is ending (the "***Existing Covenants***"). The Company's willingness to enter into this Agreement is conditioned upon your continuing to honor the Existing Covenants in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Return of Company Property</u>. You represent and agree that as of the Separation Date (i) you have returned (or will promptly return within ten (10) days of the Separation Date) to the Company all of its property, including all documents and equipment, including all records, manuals, guides, notebooks, files, correspondences, reports, memoranda, computer, printer, cellular telephone, computer discs, external hard drives or similar devices, software, usernames, passwords, keys, credit cards, reference materials, forms, reports, customer lists, price lists and documents of whatsoever kind, and all copies of any such documents (whether or not containing confidential information), and (ii) to the extent you have retained any company information or documents in electronic format (*e.g*., on your home computer(s), personal email account(s), external hard drive(s), mobile device(s), etc.), you have destroyed (or will promptly destroy within ten (10) days of the Separation Date) these materials, subject to any legal notification received previously to retain such materials.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u> </u><u>Cooperation</u>. You covenant and agree to cooperate with and make yourself readily available to the Company, as the Company may reasonably request, to assist the Company in any matter, including by providing information for compliance, litigation or other purposes, giving truthful testimony in any litigation or potential litigation which you may have knowledge, information or expertise, answering questions relating to the work you did for the Company, and signing routine documents for administrative purposes. You will be reimbursed for your reasonable expenses incurred in connection with such cooperation.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp; <u>Nondisparagement</u>. You agree not to disparage, defame, or discredit the Company or its officers, directors, employees, agents, products or services or engage in any activity that would have the effect of disparaging, defaming or discrediting the Company or its officers, directors, employees, agents, products or services. This restriction applies to all formats and platforms now known or hereafter developed, whether written, printed, oral or electronic (including emails, blogs, internet and social media sites, chat or newsrooms, podcasts, webcasts, or any online forum). The Company agrees to instruct its executive officers and members of its Board of Directors not to disparage, defame or discredit you. Notwithstanding the foregoing, nothing herein prevents any person from responding accurately and fully to any question, inquiry or request for information from a Regulator or when required by legal process*.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Exceptions</u>. You and the Company agree that nothing in this Agreement, including this Section 12, prevents or prohibits you from (i) making any disclosure of relevant and necessary information or documents in connection with any charge, action, investigation, or proceeding relating to this Agreement, or as required by law or legal process; (ii) participating, cooperating, or testifying in any charge, action, investigation, or proceeding with, or providing information to, any Regulator; or (iii) filing, testifying, participating in or otherwise assisting in a proceeding relating to an alleged violation of any federal, state or municipal law relating to fraud, or any rule or regulation of any self-regulatory organization. To the extent permitted by law, upon receipt of any subpoena, court order or other legal process compelling the disclosure of any such information or documents, you agree to give prompt written notice to the Company to the attention of the General Counsel so as to permit the Company to protect its interests in confidentiality to the fullest extent possible, unless such notice to the Company is prohibited by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Equitable Relief</u>. You acknowledge that any breach of the covenants contained in this Section 12 may irreparably harm the Company, that the damages suffered as a result of such breach will be difficult to ascertain, and that the Company may not have an adequate remedy at law for such breach. Therefore, you agree and consent that in the event of a breach of this Section 12, the Company shall be entitled, without posting a bond, in addition to all other rights and remedies to which it may be entitled (including recovery of all payments made hereunder), to have a decree of specific performance or an injunction issued in a court of competent jurisdiction requiring any such violation to be cured and enjoining you from continuing the violation. The existence of any claim or cause of action that you may have against the Company shall not constitute a defense or bar the enforcement of this Section 12. You acknowledge and agree that the provisions of this Section 12 are reasonable and necessary to protect the legitimate business interests of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13.**&nbsp;&nbsp;&nbsp;&nbsp; **No Admissions**. You acknowledge and agree that this Agreement is not and shall not be construed to be an admission by the Company or any other Released Party of any violation of any federal, state or local statute or regulation, or of any duty owed by the Company to you. Likewise, the Company acknowledges that this Agreement shall not be construed as an admission by you of any violation of any federal, state or local statute or regulation, or of any duty owed by you to the Company.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14.**&nbsp;&nbsp;&nbsp;&nbsp; **Entire Agreement; No Modification; Assignment; Governing Law; Severability**. Upon becoming effective, this Agreement shall set forth the entire agreement between the parties and supersede all prior proposals, agreements and representations related to the subject matter hereof and any and all prior arrangements or agreements between you and the Company, in each case, whether written or oral; *provided, however*, that (i) the Existing Covenants are incorporated herein and shall remain in full force and effect in accordance with their terms; (ii) the WAIVER OF JURY TRIAL as set forth in Section 20 of the Employment Agreement shall be incorporated herein and apply to the terms of this Agreement, and (iii) the Indemnification Agreement between you and the Company, dated March 2, 2021 (the "***Indemnification Agreement***"), shall survive and remain in full force and effect consistent with its terms. Neither this Agreement nor any term hereof may be orally changed, waived, or terminated, except by a written agreement between the parties hereto. All terms and provisions of this Agreement shall be binding upon, inure to the benefit of and be enforceable by the legal representatives, successors and assigns of the parties. This Agreement shall be governed by the laws of the Commonwealth of Pennsylvania, without regard to conflicts of law principles. If any provision of this Agreement is found to be invalid or unenforceable, the remaining provisions shall remain in full force and effect, and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law; provided that if the Release and Waiver in Section 8 is declared invalid or unenforceable and cannot be modified to be enforceable, then the entire Agreement will be null and void, including the Company's obligations to provide the Severance Benefits (or if already made, shall be repaid to the Company upon demand), although your employment will still end on the Separation Date. When used herein, the words "includes" and "including" and their syntactical variations shall be deemed followed by the words "without limitation." This Agreement may be executed in any number of counterparts, including by electronic signature, each of which, when executed and delivered, shall be deemed to be an original and all of which taken together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15.**&nbsp;&nbsp;&nbsp;&nbsp; **Section 409A.** It is intended that any amounts payable to you under this Agreement will either be exempt from Section 409A of the Internal Revenue Code (including Treasury regulations and other published guidance related thereto) ("***Section 409A***") or will otherwise comply with Section 409A so as not to subject you to payment of any additional tax, penalty or interest imposed under Section 409A. The provision of this Agreement will be construed and interpreted to avoid the imputation of any such additional tax, penalty or interest under Section 409A yet preserve (to the nearest extent reasonably possible) the intended benefit payable to you. The termination of your employment with the Company is intended to be a "separation from service" and an "involuntary termination" for purposes of Section 409A. If an amount is to be paid in installments, then each installment shall be treated as a separate payment for purposes of Section 409A. Notwithstanding the foregoing, the Company makes no representation or warranty and will have no liability to you or to any other person if any of the provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A, but that do not satisfy an exemption from, or the conditions of, that section. Notwithstanding any provision to the contrary in this Agreement, if as of the Separation Date you are a "specified employee" within the meaning of Section 409A, any Severance Benefits payable to you under this Agreement during the first six months and one day following the Separation Date that constitute nonqualified deferred compensation within the meaning of Section 409A shall not be paid until the date that is six (6) months and one day following the Separation Date to the extent necessary to avoid adverse tax consequences under Section 409A, and, if such payments are required to be so deferred, the first payment shall be in an equal amount to the total amount to which you would otherwise have been entitled to during the period following the Separation Date if such deferral had not been required.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16.**&nbsp;&nbsp;&nbsp;&nbsp; **Acknowledgements**. You hereby certify that (i) you have read the terms of this Agreement; (ii) you have been informed by this document that you may discuss this Agreement with an attorney of you own choice, and the Company advises you to do so; (iii) you understand this Agreement's terms and effects, and further that they are in addition to any agreement between you and the Company that includes obligations you have to the Company that expressly survive your separation of employment, such as the Existing Covenants; (iv) you have the intention of releasing all claims recited herein in exchange for the consideration described herein, which you acknowledge as adequate and satisfactory; (v) neither the Company nor any of its agents, representatives or attorneys have made any representations to you concerning the terms or effects of this Agreement other than those contained herein; and (vi) you have been given twenty-one (21) days to review this Agreement and seven (7) days after signing it to decide if you want to revoke it.

*[Signatures on Following Page]*

------

I hereby AFFIRM AND ACKNOWLEDGE that I have read the foregoing Separation and General Release Agreement, that I have had sufficient time and opportunity to review and discuss it with the attorney of my choice, that I have had any questions about the Agreement answered to my satisfaction, that I fully understand and appreciate the meaning of each of its terms, and that I am voluntarily signing the Agreement on the date indicated below, intending to be fully and legally bound by its terms.

ACKNOWLEDGED AND AGREED:

---

| | | |
|:---|:---|:---|
| /s/ Daniel Barton | /s/ Daniel Barton | February 10, 2023 |
| Daniel Barton | Daniel Barton | Date: |
| FORIAN INC. | FORIAN INC. |  |
| By: | /s/ Max C. Wygod | February 10, 2023 |
|  | Max C. Wygod | Date: |
|  | Executive Chairman |  |

---

------

## Exhibit 99.1

------

<u>Exhibit 99.1</u>

#### Forian Announces the Sale of BioTrack to Alleaves

Newtown, PA and Deerfield Beach, FL, February 13, 2023 (GLOBAL NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a provider of technology, analytics and data science driven solutions, today announced the sale of Forian's cannabis software subsidiary, Bio-Tech Medical Software, Inc. (d/b/a BioTrack), to Alleaves, Inc., a provider of ERP software solutions to the cannabis industry, effective February 10, 2023, for a total purchase price of $30 million in cash, comprised of $20 million paid at closing and $10 million paid in twelve required equal monthly installments, subject to any working capital adjustments. Forian will retain a license to certain cannabinoid-based data to enhance its healthcare information offerings. As a result of the transaction, Forian will focus on its healthcare information business and will no longer provide software solutions to the cannabis industry.

"This transaction allows us to focus our efforts on our healthcare information business, which has been the key driver of our growth to date and will further accelerate our path to positive Adjusted EBITDA," said Max Wygod, Executive Chairman of Forian.

The acquisition by Alleaves adds industry leading point of sale and traceability platforms within the cannabis industry, including BioTrack<sup>™</sup> and Cannalytics<sup>®</sup>, to the Alleaves<sup>™</sup> offering suite.

*"*The addition of BioTrack and Cannalytics will accelerate our mission to provide top-of-the-line ERP solutions to the cannabis industry," said Mike Beedles, Founder of Alleaves. "I'm especially encouraged for our current and future clients who will benefit from having access to two leading cannabis software organizations, both of which are dedicated to our customers' need for improved control, cohesion, clarity and compliance in this vast and evolving industry."

Simultaneous with the transaction, Daniel Barton stepped down as Chief Executive Officer and President of Forian effective February 10, 2023. Max Wygod, Forian's co-founder and Executive Chairman, has been appointed Interim Chief Executive Officer and President. "On behalf of the Board, I want to thank Dan for his dedication to and leadership of Forian," commented Max Wygod.

#### About Forian
Forian Inc. provides a unique suite of data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments. For more information, please visit the Forian's website at <u>www.forian.com</u>.

#### About Alleaves
Alleaves was founded with a knowledge of cannabis cultivation, manufacturing, and sale embedded in the company's culture. Its ultimate goal is to optimize the unique complexity of the cannabis journey affecting its operator customers, with a top-of-the-line ERP platform, focusing on the flexibility for customers to choose elements of its cohesive system designed to improve cannabis operator business operations. For more information, please visit Alleaves' website at <u>www.alleaves.com</u>.

------

#### Cautionary Statements Regarding Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond the control of Forian, and are not guarantees of future results, such as statements about the anticipated benefits of the transaction announced, future financial and operating results, company strategy and intended product offerings and market positioning. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Forian's business, operations, strategy and goals; Forian's ability to execute on its strategy; the timing of the introduction of new product offerings; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Forian's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 31, 2022, and elsewhere in Forian's filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof, and Forian undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Forian Media and Investor Contact:

forian.com/investors

<u>ir@forian.com</u>

267-225-6263<u> </u>

Alleaves Media Contact:

Michael Alfonso

<u>michael.a@alleaves.com</u>

321-987-9018

------

## Exhibit 99.2

------

<u>Exhibit 99.2</u>

#### UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

#### Sale of BioTrack

On February 10, 2023, Helix Technologies, Inc., a Delaware corporation ("Helix") and a wholly owned subsidiary of Forian Inc. (the "Company"), completed the sale of 100% of the outstanding capital stock of its wholly owned subsidiary, Bio-Tech Medical Software, Inc., a Florida corporation ("BioTrack"), to BT Assets Group Inc., a Delaware corporation ("Buyer") and a wholly owned subsidiary of Alleaves Inc., a Delaware corporation ("Alleaves"), pursuant to that certain Stock Purchase Agreement (the "Purchase Agreement"), dated February 10, 2023, by and among Helix, BioTrack and the Buyer (the "Transaction").

The total consideration paid by the Buyer under the Purchase Agreement is $30 million in cash, subject to any working capital adjustments. The Buyer paid $20 million in cash at closing and is required to make twelve equal monthly cash payments totaling $10 million commencing March 2023, which subsequent payments are guaranteed by certain affiliates of the Buyer.

#### Unaudited Pro Forma Condensed Consolidated Financial Statements

The Transaction constitutes a significant disposition for the Company for purposes of Item 2.01 of Current Report on Form 8-K. As a result, the following unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2022 and for the year ended December 31, 2021 are presented as if the Transaction had occurred immediately prior to January 1, 2021. The following unaudited pro forma condensed consolidated balance sheet as of September 30, 2022 is presented as if the Transaction had occurred on September 30, 2022. The unaudited condensed consolidated pro forma financial statements are based on the historical financial statements prepared in accordance with U.S. generally accepted accounting principles and are presented based on information currently available. They are intended for informational purposes only and are not intended to represent the Company's financial position or results of operations had the Transaction and related events occurred on the dates indicated, or to project the Company's financial performance for any future period.

The following unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Regulation S-X Article 11, Pro Forma Financial Information, as amended by the final rule, Amendments to Financial Disclosures About Acquired and Disposed Businesses, as adopted by the U.S. Securities and Exchange Commission on May 20, 2020, and should be read in conjunction with the following: (i) the accompanying notes to the unaudited pro forma condensed consolidated financial information; (ii) the audited consolidated financial statements and accompanying notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021; and (iii) the unaudited condensed consolidated financial statements and accompanying notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2022.

The unaudited pro forma condensed consolidated financial information is presented based on assumptions, adjustments and currently available information described in the accompanying notes and is intended for informational purposes only. The unaudited pro forma condensed consolidated financial information is not necessarily indicative of what the Company's results of operations or financial condition would have been had the divestiture been completed on the dates assumed. In addition, it is not necessarily indicative of the Company's future results of operations or financial condition

------

#### FORIAN INC.

#### UNAUDITED CONSOLIDATED CONDENSED BALANCE SHEET

#### AS OF SEPTEMBER 30, 2022

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Historical** | **Balances** <br> **Attributable to** <br> **BioTrack (a)** | **Pro Forma Adjustments** | **Pro-Forma Condensed** |
| **ASSETS** | | | | |
|  Current assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $1585594 | $(865610) | $19702000<br> (b) | $20421984 |
| &nbsp;&nbsp;&nbsp; Marketable securities | 19046961 |  |  | 19046961 |
| &nbsp;&nbsp;&nbsp; Accounts receivable, net | 3553323 | (571987) |  | 2981336 |
| &nbsp;&nbsp;&nbsp; Contract assets | 1978181 |  |  | 1978181 |
| &nbsp;&nbsp;&nbsp; Prepaid expenses | 1205630 | (175492) |  | 1030138 |
| &nbsp;&nbsp;&nbsp; Proceeds receivable from sale of BioTrack |  |  | 9590000<br> (c) | 9590000 |
| &nbsp;&nbsp;&nbsp; Other assets | 436101 | (7471) |  | 428630 |
| &nbsp;&nbsp;&nbsp; Total current assets | 27805790 | (1620560) | 29292000 | 55477230 |
| &nbsp;&nbsp;&nbsp; Property and equipment, net | 2870667 | (2731259) |  | 139408 |
| &nbsp;&nbsp;&nbsp; Intangible assets, net | 7344677 | (7344677) |  |  |
| &nbsp;&nbsp;&nbsp; Goodwill | 9099372 | (9099372) |  | 0 |
| &nbsp;&nbsp;&nbsp; Right of use assets, net | 706272 | (668615) |  | 37657 |
| &nbsp;&nbsp;&nbsp; Deposits and other assets | 274532 |  |  | 274532 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $48101310 | $(21464483) | $29292000 | $55928827 |
|  **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |  |  |
|  Current liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Accounts payable | 896916 | (210123) |  | 686793 |
| &nbsp;&nbsp;&nbsp; Accrued expenses | 4557385 | (479278) | 2678697<br> (f) | 6756804 |
| &nbsp;&nbsp;&nbsp; Short-term operating lease liabilities | 265474 | (244365) |  | 21109 |
| &nbsp;&nbsp;&nbsp; Warrant liability | 26079 |  |  | 26079 |
| &nbsp;&nbsp;&nbsp; Deferred revenues | 2685027 | (537825) |  | 2147202 |
| &nbsp;&nbsp;&nbsp; Total current liabilities | 8430881 | (1471591) | 2678697 | 9637987 |
| &nbsp;&nbsp;&nbsp; Long-term liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Long-term operating lease liabilities | 444996 | (428448) |  | 16548 |
| &nbsp;&nbsp;&nbsp; Convertible notes payable, net of debt issuance costs ($6,000,000 in principal is held by a related party.) | 24893488 |  |  | 24893488 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total long-term liabilities | 25338484 | (428448) |  | 24910036 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 33769365 | (1900039) | 2678697 | 34548023 |
|  Commitments and contingencies |  |  |  |  |
|  Stockholders' equity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Parent Investment in Subsidiary |  | (19564444) | 19564444 |  |
| &nbsp;&nbsp;&nbsp; Preferred Stock; par value $0.001; 5,000,000 Shares authorized; 0 issued and outstanding as of September 30, 2022 and December 31, 2021 |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Common Stock; par value $0.001; 95,000,000 Shares authorized; 32,138,000 issued and outstanding as of September 30, 2022 and 31,773,154 issued and outstanding as of December 31, 2021 | 32138 |  |  | 32138 |
| &nbsp;&nbsp;&nbsp; Additional paid-in capital | 69535194 |  |  | 69535194 |
| &nbsp;&nbsp;&nbsp; Accumulated deficit | (55235387) |  | 7048859 | (48186528) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity | 14331945 | (19564444) | 26613303 | 21380804 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $48101310 | $(21464483) | $29292000 | $55928827 |

---

------

#### FORIAN INC.

#### UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

#### FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

---

| | | | |
|:---|:---|:---|:---|
|  | **Historical** | **Proforma** <br> **adjustments** <br> **attributable to** <br> **BioTrack (a)** | **Pro Forma** |
|  **Revenues:** | | | |
|  Information and Software | $18674213 | $(7225745) | $11448468 |
|  Services | 1168034 | (1168034) |  |
|  Other | 259618 | - | 259618 |
|  Total revenues | 20101865 | (8393779) | 11708086 |
|  **Costs and Expenses:** |  |  |  |
|  Cost of revenues | 5154353 | (4246138) | 908215 |
|  Operating Expenses | 29943274 | (6985189) | 22958085 |
|  Separation expenses | 5611857 |  | 5611857 |
|  Gain on sale of businesses | (202159) |  | (202159) |
|  Depreciation and amortization | 2052729 | (1992561) | 60168 |
|  Transaction related expenses |  |  |  |
|  Total costs and expenses | 42560054 | (13223888) | 29336166 |
|  **Loss From Operations** | (22458189) | 4830109 | (17628080) |
|  **Other Income (Expense):** |  |  |  |
|  Change in fair value of warrant liability | 343155 |  | 343155 |
|  Interest and investment income | 112602 | (916) | 111686 |
|  Interest expense | (659425) |  | (659425) |
|  Foreign currency related gains (losses) | 266600 |  | 266600 |
|  Total other income (expense), net | 62932 | (916) | 62016 |
|  Net loss before income taxes | (22395257) | 4829194 | (17566063) |
|  Income tax expense | (20000) |  | (20000) |
|  **Net Loss** | $(22415257) | $4829194 | $(17586063) |
| &nbsp;&nbsp;&nbsp; Basic and diluted net loss per common share | $(0.70) | $0.15 | $(0.55) |
|  Weighted-average shares outstanding: | 31978719 | 31978719 | 31978719 |

---

------

#### FORIAN INC.

#### UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

#### FOR THE YEAR ENDED DECEMBER 31, 2021

#### <br>

---

| | | | |
|:---|:---|:---|:---|
|  | **Historical** | **Proforma** <br> **adjustments** <br> **attributable to** <br> **BioTrack (a)** | **Pro Forma** |
|  **Revenues:** | | | |
|  Information and Software | $14952247 | $(7813337) | $7138910 |
|  Services | 1122528 | (1122528) |  |
|  Other | 804940 | - | 804940 |
|  Total revenues | 16879715 | (8935865) | 7943850 |
|  **Costs and Expenses:** |  |  |  |
|  Cost of revenues | 4717175 | (3777817) | 939358 |
|  Operating Expenses | 36582202 | (5783838) | 30798364 |
|  Separation expenses |  |  |  |
|  Gain on sale of businesses |  |  |  |
|  Depreciation and amortization | 1986816 | (1918547) | 68269 |
|  Transaction related expenses | 1210279 |  | 1210279 |
|  Total costs and expenses | 44496472 | (11480202) | 33016270 |
|  **Loss From Operations** | (27616757) | 2544336 | (25072421) |
|  **Other Income (Expense):** |  |  |  |
|  Change in fair value of warrant liability | 878481 |  | 878481 |
|  Interest and investment income | 6809 | (487) | 6322 |
|  Interest expense | (322379) |  | (322379) |
|  Foreign currency related gains (losses) | 525252 |  | 525252 |
|  Total other income (expense), net | 1088163 | (487) | 1087676 |
|  Net loss before income taxes | (26528594) | 2543849 | (23984745) |
|  Income tax expense | (22511) |  | (22511) |
|  **Net Loss** | $(26551105) | $2543849 | $(24007256) |
| &nbsp;&nbsp;&nbsp; Basic and diluted net loss per common share | $(0.90) | $0.09 | $(0.81) |
|  Weighted-average shares outstanding: | 29527608 | 29527609 | 29527609 |

---

------

#### FORIAN INC.

#### NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL INFORMATION
**1.** **Basis of Presentation**

The pro forma condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the "SEC"). The unaudited pro forma condensed consolidated financial information has been derived from the historical consolidated financial statements and accounting records of the Company. The unaudited pro forma condensed consolidated balance sheet at September 30, 2022 was prepared as if the sale of Bio-Tech Medical Software, Inc. ("BioTrack") had occurred on September 30, 2022. The unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2022 and for the year ended December 31, 2021 were prepared as if the sale of BioTrack had occurred on immediately prior to January 1, 2021. The unaudited pro forma condensed consolidated financial statements and underlying pro forma adjustments are based upon currently available information and include certain estimates and assumptions made by management; accordingly, actual results could differ materially from the pro forma information. Management believes the assumptions provide a reasonable and reliably determinable basis for presenting the significant effects of the sale of BioTrack. These unaudited pro forma condensed consolidated financial statements are provided for illustrative purposes only and may or may not provide an indication of results in the future.

**2.** **Unaudited Pro Forma Condensed Consolidated Balance Sheet and Statement of Operations Adjustments**

Pro Forma Adjustments Balance Sheet unaudited pro forma condensed combined financial information is prepared in accordance with Article 11 of SEC Regulation S-X. The historical financial information has been adjusted in the accompanying unaudited pro forma condensed combined financial information to give effect to unaudited pro forma events that are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Represents amounts related to BioTrack for the periods presented.

---

| | |
|:---|:---|
| (b)-(f) | Represents the impacts of the sale of BioTrack as if it occurred on September 30, 2022 as shown in the table below. Income Taxes reflects the estimated tax liability attributable to the sale of BioTrack after the expected utilization of estimated available 2022 net operating losses and 2021 net operating loss carryforwards for federal and state tax purposes. |

---

------

---

| | |
|:---|:---|
| **Pro Forma Gain on sale of BioTrack as if Transaction occurred on September 30, 2022** | |
| Closing Payment | $20000000<br> (b) |
| Deferred Payments, net of estimated discount of $410,000 | 9590000<br> (c) |
| Total Purchase Price | 29590000 |
| Estimated Transaction Expenses | (298000) (b) |
| Net Book Value | (19564444) (d) |
| Pre Tax Gain | 9727556<br> (e) |
| Income Taxes after utilization of net operating loss carryforwards | (2678697) (f) |
| Net Gain on Sale of BioTrack | $7048859 |

---

------